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Cancer is still a global challenge worldwide with a high impact not only on human health, causing
morbidity and mortality, but also on economics. Although significant advances have been obtained
in early diagnosis and in the development of new drugs, there is still a need of new molecules that
contribute to span and improve the actual therapeutic strategies.
Natural compounds from animal, microbial, vegetal, or fungi origin represent countless sources
of new compounds that can be used as anticancer drugs if their activity, bioavailability, and toxicity are
adequate. There are some general [1] and specific [2] reviews covering this topic, however, the use of
natural compounds is not always supported by scientific evidence. This special issue tries to solve this
problem, incorporating original manuscripts with new evidence on the use of natural compounds in
cancer research and covering the actual state of the art with several reviews.
In this special issue original research manuscripts including both pure compounds and whole
natural extracts have been included. Chiang et al. [3] have used sulforaphane, natural molecules
previously characterized as promising for fighting cancer [4], to challenge melanoma in combination
with the epigenetic drug 5-aza-2′-deoxycytidine (DAC). In this manuscript, the authors have observed
that the combination between DAC and sulforaphane reduces melanoma cell growth by changing gene
expression profiles but without altering epigenetics. This manuscript is relevant as it demonstrates
that the ingestion of some natural compounds can improve the outcome of some cancer treatments.
In this sense, this relationship between diet and drugs is not new [5]. There is a long list of interactions
between foods and drugs, but these results must be taken in mind carefully as the interactions will not
always be beneficious and every case must be studied individually and in the context of a complete
and balanced diet. In addition, studies about natural compounds’ bioavailability must also be done to
ensure that the dose of the natural compounds that can influence drug treatments is achieved.
This special issue also contains data on the use of whole extracts and complex mixtures.
Araki et al. [6] present their results about the use of royal jelly from honey bees on a randomized,
double-blind, placebo-controlled trial. Royal jelly is a well-known functional food with relevant
health-promoting properties [7]. In their manuscript, Araki et al. focus on patients with renal cell
carcinoma under tyrosine kinase inhibitors treatment and observed that those who were supplemented
with royal jelly presented lower side effect levels in terms of fatigue and anorexia. This clinical trial does
not pretend to introduce royal jelly as an anticancer treatment, but suggests its use as a complementary
treatment that could be useful to treat side effects of tyrosine kinase inhibitors treatment. However,
further studies increasing the obtained evidence would be interesting before recommending its use in
cancer patients, especially those focused on the putative interference between the compounds and the
pharmacological treatments.
The last original manuscript of this special issue also studies a complex mixture of natural
compounds. Le et al. studied the anticancer potential of a whole natural extract obtained from
Momordica cochinensis seeds [8]. They performed different extraction procedures and studied the
correlation between main compound families and antioxidant, and anticancer activities using different
statistical approaches. This is a preliminary study that can be a first step for the future use of these
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extracts for melanoma treatment research, but before that, a whole extract characterization must be
done in order to ensure which compounds are present qualitatively and quantitatively. In addition,
expanding the research to other cancer types would be also recommendable.
Reviews are also included in this special issue covering different topics with significant relevance
regarding cancer research. Two of these reviews are focused on the pure compound resveratrol.
Resveratrol is a stilbene with a long list of biological activities [9], including cardiovascular disease
prevention [10], UV protection [11], antiobesity [12], and anticancer properties [13,14]. The first review
about resveratrol resumes the actual evidence on the epigenetic changes induced by resveratrol in the
context of cancer [15]. It underlines the evidence about the epigenetic action of resveratrol on different
types of cancer, including breast, lung, cervical, colon, leukemia, lymphoma, and prostate cancers,
providing interesting comments about the existing evidence on each case. The second review about
resveratrol is more specific, as it focuses on the role of resveratrol in the expression of the miR-663
microRNA and the relationships between this expression, inflammation, and cancer [16].
Green tea polyphenols have been also reviewed in this special issue. Miyata et al. [17] present
in their review an extensive study of the anticancer effects of these polyphenols against bladder
cancer. They cover not only in vitro studies using bladder cancer cell lines and in vivo studies using
animal models but also new treatment strategies for patients with bladder cancer, based on green
tea consumption.
Probiotics are also included in this special issue. Hendler et al. [18] update the previously published
evidence on the relationship between probiotics and colon cancer [19,20]. They have written their
review with a special interest on animal and human studies. They conclude that the use of probiotics
can be recommended to reduce the colon cancer risk by influencing the microbiome composition.
However, a more ambitious study, like a metanalysis must be done to reinforce this conclusion.
A global perspective on the use of natural compounds in cancer treatment is taken by Herranz et al.
in their review [21]. In this manuscript, the authors provide an interesting point of view about the
relevance of multitargeting and synergy when studying natural compounds. The molecular promiscuity
of natural compounds has also been discussed by the same authors [22], but in this manuscript they
focus on cancer, providing advice on experiment design and presenting the advantages and drawbacks
when using complex mixtures of natural compounds as extracts. This last point is especially relevant,
as there are still some points that must be improved in natural compounds research if we aspire to be
considered as seriously as other disciplines are. As mentioned in this review, correct identification of
the compounds, extract reproducibility, and bioavailability studies are the main but not the only weal
points of natural product research. Better designs for in vivo trials, the use of non-tumor cell lines as
controls of in vitro experiments, and synergy studies with other natural and non-natural compounds,
especially clinically used drugs, will be welcome.
Finally, this special issue has met its original objective, contributing to increase the scientific
evidence on the use of natural compounds in cancer research and treatment. However, there is a long
way ahead, and new studies and evidence must be obtained in the future. Nature is a limitless source
of new drugs, but these new drugs must always be supported by strong scientific evidence.
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Abstract: Background: UV exposure-induced oxidative stress is implicated as a driving mechanism
for melanoma. Increased oxidative stress results in DNA damage and epigenetic dysregulation.
Accordingly, we explored whether a low dose of the antioxidant sulforaphane (SFN) in combination
with the epigenetic drug 5-aza-2’-deoxycytidine (DAC) could slow melanoma cell growth. SFN is
a natural bioactivated product of the cruciferous family, while DAC is a DNA methyltransferase
inhibitor. Methods: Melanoma cell growth characteristics, gene transcription profiles, and histone
epigenetic modifications were measured after single and combination treatments with SFN and
DAC. Results: We detected melanoma cell growth inhibition and specific changes in gene expression
profiles upon combinational treatments with SFN and DAC, while no significant alterations in histone
epigenetic modifications were observed. Dysregulated gene transcription of a key immunoregulator
cytokine—C-C motif ligand 5 (CCL-5)—was validated. Conclusions: These results indicate a potential
combinatorial effect of a dietary antioxidant and an FDA-approved epigenetic drug in controlling
melanoma cell growth.
Keywords: sulforaphane; epigenetic; 5-aza-2’-deoxycytine; melanoma
1. Introduction
While the incidence of certain cancer types has declined, the number of diagnosed melanoma
cases has increased sharply over the past three decades [1,2]. Ultraviolet (UV) exposure is one of
the most apparent risk factors for melanoma [3]. There are many types of photosensitizers, such
as DNA, melanin, and tryptophan, that can receive UV energy and result in direct DNA damage
and ROS accumulation [4–6]. UVB affects DNA by forming cyclobutane pyrimidine dimers (CPDs),
which lead to DNA mutation [7]. UVA directly induces oxidative stress through the accumulation of
8-oxo-7,8-dihydroguanine (8-oxo-G) and other photoproducts [4]. UV also induces melanin synthesis [8].
There are two types of melanin, eumelanin, and pheomelanin. The ratio of the two types of melanin
is dependent on the polymorphism of the melanocortin-1 receptor (MC1R) gene and results in
differential pigmentation [6,9]. Synthesis of eumelanin leads to scavenges of reactive oxygen species
(ROS) while the synthesis of pheomelanin leads to depletion of antioxidants and results in ROS
accumulation [10–12]. This is in concert with the determination that people with pale skin and red hair
have low eumelanin and high pheomelanin and are known to have a higher risk of melanoma [13].
Medicines 2019, 6, 71; doi:10.3390/medicines6030071 www.mdpi.com/journal/medicines4
Medicines 2019, 6, 71
Many studies have identified another photosensitizer, tryptophan, which utilizes the energy from
UVA and UVB to form a tryptophan photoproduct, 6-formylindolo(3,2-b) carbazole (FICZ) [14,15].
FICZ has a high affinity to the aryl hydrocarbon receptor (AhR) and activates AhR response genes,
including cyclooxygenase-2 (Cox2), a melanoma prognostic marker gene [16], and cytochrome
P4501A1, which increases ROS accumulation [17]. It has been shown that UVB activates AhR
responses that decrease the tumor suppressor gene p27 and impairs nucleotide excision repair
(NER) resulting in DNA mutation [18]. In addition to UV exposure, other environmental factors
such as cigarette smoking, environmental dioxin 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and
arsenic exposure also induce melanogenesis [3,19–22]. Accumulated ROS from UVA and UVB via
different photosensitizers, as well as environmental exposures, have many impacts on cell growth
and defense. These impacts include inhibition of p27, cell cycle regulation, increased cytokines,
decreased antioxidant glutathione s-transferase, increased 8-oxoG, activation of mitogen-activated
protein kinase/extracellular signal-regulated kinases1/2 (MAPK/ERK1/2), increased cell proliferation
and decreased tumor suppressor gene p16 [5]. These findings support the fact that melanoma patients
have a higher level of oxidative stress and that this stress is associated with the progression of the
disease [23].
Studies have shown that environmental exposure-induced DNA damage and oxidative stress
can also result in epigenetic changes [24–27]. Elevated ROS is associated with DNA methylation and
histone post-translational modifications (PTMs) [25–27]. DNA hypermethylation at promoter CpG
sites, especially at tumor suppressor gene promoters, is associated with silencing gene expression in a
variety of cancers, including melanoma [28,29]. Many tumor suppressor genes related to cell cycle
progression, DNA repair, and apoptosis are methylated in different stages of melanoma [5,24,30–33].
Whole genome DNA methylation profiles from advanced melanoma patients have uncovered a
differential methylation pattern that is correlated with survival rates [34]. In addition to aberrant DNA
methylation, histone PTMs play critical roles in cancer development independently, in combination
with other histone PTMs, and interactively with DNA methylation [24]. Our lab identified the elevation
of trimethylation of lysine 27 on histone H3 (H3K27me3) in metastatic melanoma relative to primary
melanoma [35]. H3K27me3 is catalyzed by the protein Enhancer of Zeste 2 (EZH2), a member of the
Polycomb-group (PcG) family. EZH2 can recruit DNA methyltransferase (DNMT1) to chromatin to
form a multisubunit protein complex that suppresses gene expression [36].
Epigenetic therapy using 5-aza-2’-deoxycytidine (DAC), an FDA-approved DNA demethylation
agent, has been successfully used to treat myelodysplastic syndromes (MDSs) either alone or in
combination with other drugs [37–39]. DAC is a deoxycytidine analog with the replacement of nitrogen
at position 5 of the pyrimidine ring [40]. DAC interferes with normal DNA methylation by forming an
irreversible covalent bond with DNMT1 [41]. The subsequent DNA-DNMT adducts play a role in
controlling cancer cells depending on the dose of DAC. At high doses, DAC induces cytotoxicity by
accumulated DNA–DNMT1 adduct-induced apoptosis and DNA synthesis arrest. At low doses, DNA
synthesis is continued, while DNA–DNMT1 adduct bonds are being degraded and repaired, resulting
in systematically hypomethylated DNA [41,42]. Studies show that DAC has effects on melanoma via
decreasing cell growth and invasion [43] as well as alerting gene expression, includes tumor suppressor
genes [44].
Regulating oxidative stress via the consumption of antioxidant-rich cruciferous vegetables
(e.g., broccoli and Brussels sprouts) has been well-studied in cancer prevention [45–47]. One of the
common compounds from cruciferous vegetables with cancer prevention characteristics is glucosinolate.
Glucosinolate is not bioactivated until the enzyme myrosinase is released from the plant cell, by chewing
or through denaturing by cooking, to catalyze a hydrolytic reaction to form isothiocyanates (ITCs) [48].
Sulforaphane (SFN) is one of the promising anticancer ITCs and can induce biphasic biological impact
via generating different level of ROS depending on their doses [48,49]. At a dietary dose, SFN-derived
ROS stimulate antioxidant protein expression to balance the ROS level induced from UV exposure.
SFN activates nuclear erythroid 2-related factor 2 (Nrf2) to bind to the antioxidant response element
5
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at the promoter region of Nrf2-regulated genes. Those genes are phase-II detoxification enzymes
(e.g., glutathione S-transferase, quinone reductase, and glucuronosyltransferase). By doing this,
SFN increases antioxidant capacity. Furthermore, phase-I enzymes such as P450s, which activate
toxic chemical compounds, are reduced by SFN at dietary doses [50–52]. In this way, SFN delivers
chemopreventive effects through strengthening cell defense systems by increasing antioxidant enzymes
and reducing carcinogen toxicity. Studies have shown that SFN acts as a cell-killing agent at high
doses. At a high concentration of SFN, elevated amounts of SFN-derived ROS accumulate in the cells,
mitochondrial function is disrupted [49], cell proliferation is blocked, cell cycle G2/M is arrested, and
caspase-mediated apoptosis is induced [48,52–55]. High concentrations of SFN also induce epigenetic
modification. Studies show that high doses of SFN enhance global histone acetylation by inhibiting
histone deacetylase (HDAC) activity and reducing cell growth in prostate cancer [56,57]. The dual roles
of SFN in cytoprotection and slowed tumor growth, as well as the low toxicity, are cell-specific [48].
Where and how the ROS is formed by SFN and the impact of surrounding molecular environments
has gained great interest in research either with SFN alone or in combination with other chemotherapy
drugs in many cancers [58–60].
The research reported here seeks to determine whether combining DAC and SFN can synergistically
slow melanoma cell growth. We aimed to utilize a dietary dose of SFN as a natural antioxidant, while
at the same time suppressing gene transcription with a low dose of the clinically approved epigenetic
modifier DAC. We rationalized that with lower oxidative stress, the low dose of DAC could deliver its
epigenetic effect without inducing cytotoxicity. This study is the first step in testing the combined effect
of DAC and SFN in a mouse melanoma cell line. Cell growth characteristics, gene expression profiles,
and histone PTMs are compared between single and combination treatments of DAC and SFN using
mouse melanoma cells. Our data show cell growth inhibition, dysregulation of gene transcription,
and increased cytokine production with combination treatment compared to individual treatments.
Histone PTMs were identified but did not show differences following treatment. This in-vitro data
provides a path to investigate the role of target gene sets and the potential role of the dietary antioxidant
SFN in melanoma treatment and prevention.
2. Materials and Methods
2.1. Cell Culture and Treatment
Mouse melanoma B16F10 cells were obtained from ATCC and maintained in Dulbecco’s
Modified Eagle Medium (DMEM) (ThermoFisher, Waltham, MA, USA) supplemented with 10%
FBS (ThermoFisher, Waltham, MA, USA) and 1% penicillin/streptomycin (ThermoFisher, Waltham, MA,
USA). Cells were checked for mycoplasma contamination by MycoAler PLUS Mycoplasma Detection
Kit (Lonza Walkersville, Walkersville, MD, USA) before experiments.
IC50s for both drugs were determined by using CellTiter 96 AQueous One Solution Cell Proliferation
Kit (Promega, Madison, WI, USA), following the manufacturer’s protocols. In brief, cells were seeded
at 1500 cells/well in a 96-well plate for 24 h. Cells were then treated with 5-aza-2′-deoxycytidine
(DAC) (Sigma Aldrich, St. Louis, MO, USA) dissolved in dimethyl sulfoxide (DMSO) at concentrations
ranging from 25 μM to 6.1 nM (4-fold dilutions from 25 μM, 6.25 μM, 1.56 μM, 390 nM, 97.7 nM,
24.4 nM, to 6.1 nM) for 72 h; and sulforaphane (LKT labs, St Paul, MN, USA) dissolved in water at
concentrations ranging from 352 μM to 86 nM (4-fold dilutions ranging from 352 μM, 88.1 μM, 22 μM,
5.5 μM, 1.37 μM, 344 nM, to 86 nM) for 48 h. Dimethyl sulfoxide (DMSO) (Sigma Aldrich, St. Louis,
MO, USA) was used as a control in the DMSO wells, at 0.00025%, equivalent to the highest amount of
DMSO in the highest dose of treatment (10 mM DAC in DMSO was freshly diluted 400,000 times to
25 nM in culture medium).
Preliminary tests with different doses and duration were performed, based on the results from
IC50 measurements, in 6-well plates. The optimal doses and duration of treatments were chosen
based on the number of viable cells with greater than 50% of cell survival at single treatment for
6
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DAC and SFN, with fewer cells surviving with combination treatment. SFN at 5 μM and DAC 25 nM
were determined to be an optimal dose in the preliminary tests. Cells were seeded in 6-well plates
at 4 × 104 cells/well and were allowed to attach for 24 h. For combinatorial drug treatment, cells
were treated with DAC at 25 nM for 24 h, the medium was removed, and fresh medium with 25 nM
DAC and 5 μM SFN was added. Cells were then incubated for another 48 h. For DAC or SFN single
treatment, cells were treated with only DAC or SFN following the same operations as a combination
treatment. All treatment groups were harvested at the same time for different target analysis, which
included cell number counting and measurements of apoptosis, cell cycle, and gene transcription.
Three independent biological repeats were performed.
For cytokine analysis, cells were seeded in 10 cm dishes at 3 × 105 cells/dish and were treated with
SFN and DAC as described above in 10% serum-containing medium. Culture medium was replaced
from 10% to 1% serum-containing medium with the same dosing scheme at the last 24 h of treatment.
The purpose is to reduce potential background. Also, the final culture medium was reduced from
10 mL to 5 mL to increase the concentration of cytokine in the supernatant. The supernatant of each
dish was collected for cytokines array analysis. The cell number is calculated to adjust the final amount
of supernatant to be loaded from even amount of cells for cytokine analysis.
For CCL5 enzyme-linked immunosorbent assay (ELISA) analysis, cells were grown and treated as
described for cytokine array analysis, except the initial cell density is at 2 × 105 cells per10 cm dish,
and the final culture medium was reduced from 10 mL to 5 mL.
For histone analysis, cells were seeded in 10 cm dishes at 2 × 105 cells/dish and were treated
with SFN and DAC as described above. Additionally, EZH2 inhibitor EPZ6438 (Med Chem Express,
Monmouth Junction, NJ, USA), was used at 5 μM to treat cells for 48 h for analysis of histone epigenetic
post-translational modifications. The dose of EPZ6438 was selected for optimal inhibition of the
catalytic output of EZH2, histone H3K27me3, and was used as a positive control for histone analysis.
DMSO at 0.05%, equivalent to the highest amount of DMSO in the treatment (10 mM EPZ6438 in
DMSO was freshly diluted 2000 time to 5 μM in culture medium) was used in the control plates. Three
independent biological repeats were performed.
2.2. Assays for Characteristics of Cell Growth
2.2.1. Viable Cell Count
Cell number was counted with Trypan blue solution (0.4%) using a hemocytometer. The number
of the cell count was controlled to within 20–50 cells/square via dilution of cells before mixing with
trypan blue.
2.2.2. Cell Cycle Arrest Analysis
Cells cycle was analyzed by fixing cells in 70% ethanol overnight and staining with propidium
iodide (PI)/RNase Staining Buffer (BD Biosciences, San Jose, CA, USA). The stained DNA was analyzed
at the University of Arkansas for Medical Sciences (UAMS) flow cytometry core with an LSRFortessa
Flow cytometer (BD Biosciences, San Jose, CA, USA). Flow cytometry data were analyzed with Flow Jo
(Ashland, OR, USA) and Dean-Jett Fox (DJF) model (BD, Franklin Lakes, NJ, USA).
2.2.3. Apoptotic Analysis
Apoptosis was measured by Annexin V and 4′,6-diamidino-2-phenylindole (DAPI) staining
using the annexin V-FITC apoptosis detection kit (BD Pharmigen, San Jose, CA, USA), following the
manufacturer’s protocol. Cells were analyzed at the UAMS flow cytometry core with an LSRFortessa
Flow cytometer (BD Biosciences, San Jose, CA, USA). Flow cytometry data were analyzed with Flow Jo
(Ashland, OR, USA).
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2.3. RNA-Seq Analysis
2.3.1. RNA Extraction and Targeted Gene Expression Analysis
RNA was extracted with the RNeasy Mini Kit (Qiagen, Germantown, MD, USA) following the
manufacturer’s protocols and eluted in water. RNA was reversed transcribed into cDNA with the One
Step iScript kit (BioRad, Hercules, CA, USA) following the manufacturer’s protocol.
Targeted genes of interest were amplified with 20 ng of cDNA, SYBR green Supermix (Bio-Rad,
Hercules, CA, USA) and primers (final concentration at 750 nM). The PCR cyclic conditions used were
95 ◦C for 3 min, followed by 39 cycles of 98 ◦C for 15 s and 57 ◦C for 30 s. The following primer pairs










Ccl5: (C-C motif) ligand 5 (Gene ID:20304); IL33: interleukin 33 (Gene ID:77125); Dusp15: dual specificity
phosphatase-like 15 (Gene ID:252864); UBC: Ubiquitin C (Gene ID: 22190).
2.3.2. RNA-Seq Sample Preparation
cDNA libraries were constructed using Illumina’s TruSeq stranded mRNA sample preparation
kit according to the manufacturer’s protocol. Briefly, 500 ng of total RNA was polyA selected,
chemically fragmented, and converted to single-stranded cDNA using random hexamer-primed
reverse transcription. Second strand synthesis was then performed to generate double-stranded cDNA,
followed by fragment end repair and the addition of a single A base to each end of the cDNA. Adapters,
including a 3’ adapter and a 5’ adapter containing 1 of 48 unique indexes, were then ligated to the
fragment ends to enable attachment to the sequencing flow cell and sample pooling. Next, library
DNA was PCR amplified and validated for fragment size and quantity using an Advanced Analytical
Fragment Analyzer (AATI) and Qubit fluorometer (Life Technologies), respectively. Equal amounts
(5 μL of 4 nM dilutions) of each library were pooled and 5 μL of the pool was denatured for 5 min
by the addition of 5 μL of 0.2 N NaOH, incubated at room temperature for 5 min, neutralized by the
addition of 5 μL 200 mM Tris pH 7.0, and diluted to a loading concentration of 1.8 pM; 1.3 mL of the
denatured, diluted library was added to a NextSeq reagent cartridge V2.0 for sequencing on a NextSeq
500 platform using a high output flow cell to generate approximately 25 million 75-base reads per
sample. All sequencing was conducted by the Center for Translational Pediatric Research Genomics
Core Lab at Arkansas Children’s Research Institute (Little Rock, AR, USA).
2.3.3. RNA-Seq Data Analysis
RNA reads were checked for quality of sequencing using FastQC v.0.11.7 (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/). The adaptors and low-quality bases (Q < 20) were
trimmed to a minimum of 36 base pairs using Trimmomatic v0.38 [61]. Reads that passed quality control
were aligned to the mouse (mm10) (GCA_000001305.2) reference genome using TopHat v2.1.1 [62].
Sample alignment files (.bam) were then imported into Blast2GO v5.1.13, and gene level expression
counts quantified using htseq [63,64]. Only reads uniquely aligned to known genes were retained
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and counted. Multimapped reads were discarded. Genes with low counts were then removed before
downstream analysis. To retain the maximum number of interesting features genes with a minimum
of 1 counts-per-million (CPM) values in at least 3 libraries were retained for further investigation.
The filtered dataset was then normalized for compositional bias using a trimmed mean of M values
(TMM) and log2 transformed [65]. For each comparison, edgeR quasi-likelihood method (glmQLFTest)
correcting for batch effect was used to identify differentially expressed genes between experimental
groups [2]. Genes with multiple tests corrected (FDR) p-values of 0.05 [66] and a fold change > 2 were
selected for further comparisons between treatments and analyzed by Ingenuity Pathway Analysis
(IPA) for biological involvement.
2.4. Chemokines Analysis
The supernatant of control and combination treated groups was spun at 10,000 g for 5 min to
remove the cell debris. The supernatant was added to the membrane of Proteome Profiler mouse XL
Cytokine array kit (R&D system Inc, Minneapolis, MN, USA). The manufactural protocol was followed
with modification at the final film developing. Western Lightning Plus-ECL (PerkinElmer, Waltham,
MA, USA) was applied at the end of film developing to have clear signals.
For ELISA, the supernatant was spun at 10,000 g for 5 min to remove the cell debris and further
diluted 10 times in 1 × PBS. Duplicate diluted supernatant from each group and the serially diluted
standards (ranging from 7.8 pg/mL to 500 pg/mL) were tested for the level of CCL5 according to the
manufacturer’s instructions (R&D Systems Inc., Minneapolis, MN, USA). The cell number is also
calculated and applied in data analysis to reflect the level of CCL5 in the supernatant is from the same
amount of cells.
2.5. Histone PTM Mass Spectrometry
Histones were purified from approximately 5 million cells by acid extraction, as described by
Taverna, SD et al. [67]. The amount of protein was quantified by BCA Protein Assay Kit (ThermoFisher,
Waltham, MA, USA). Extracted histones (5 μg), were resolved on a 4–20% gradient SDS-PAGE gel.
Histone bands were visualized by staining with GelCode Blue (Thermo). Histones were excised from
the gel, destained, and treated with 20 μL/band of 30% d6-acetic anhydride in 50 mM ammonium
bicarbonate. Histones were then digested in-gel with 125 ng/band sequencing-grade trypsin at 37 ◦C
overnight. Acidified tryptic peptides were separated using a 2.5 μm Waters XSelect CSH resin on a
150 mm × 0.075 mm column using a nanoAcquity UPLC system (Waters, Milford, MA, USA). Peptides
were separated using a 60-min chromatography gradient, with a 40-min linear separation gradient from
97% buffer A (0.1% formic acid in water (v/v)), 3% buffer B (0.1% formic acid (v/v), 99.9% acetonitrile
(v/v)), to 80% of buffer A, 20% buffer B. Eluted peptides were ionized by electrospray (2150 V) and
analyzed on an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher, Waltham, MA, USA) using
data-dependent acquisition. A full-scan MS was acquired in profile mode at 120,000 resolution from
375 to 1500 m/z (AGC target 5 × 105, max injection time 100 ms), followed by data-dependent MS/MS
analysis with a 3 second duty cycle time. Peptides with a determined monoisotopic peak, intensity
threshold greater than 2 × 104 counts, and charge state of 2–7 were selected for HCD fragmentation at
30% collision energy, AGC target of 1 × 104, maximum injection time 35 milliseconds, and analyzed in
the ion trap with scan speed set to rapid.
Raw data files were analyzed using Mascot (Matrix Science, London, UK) using a custom Uniprot
database which included only mouse histones (Table 2). Files were searched with a precursor tolerance
of 3 ppm and fragment ion tolerance of 0.5 Da. Fixed modifications included carbamidomethylation of
cysteine. Variable modifications to lysine included monomethylation, dimethylation, trimethylation,
acetylation, deuterated acetylation, and methylation and deuterated acetylation. Variable modifications
to arginine included monomethylation and dimethylation. Variable modifications to serine and
threonine were phosphorylation. Up to four missed trypsin cleavages were permitted. Mascot search
results were loaded into Scaffold, and filtered for a protein FDR of 1%, a peptide score probability of
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80%, and a minimum of 5 peptides per protein. Spectral count data was exported in tabular format
and analyzed using R [68].
Table 2. List of mouse histones used for analysis.
Mouse Histones
H10 H1FOO H2A2B H2AX H2B1H H2B3B
H11 H1T H2A2C H2AY H2B1K H31
H12 H2A1 H2A3 H2AZ H2B1M H32
H13 H2A1F H2AB1 H2B1A H2B1P H33
H14 H2A1H H2AJ H2B1B H2B2B H3C
H15 H2A1K H2AV H2B1C H2B2E H4
H1FNT H2A2A H2AW H2B1F H2B3A
3. Results
3.1. SFN and DAC Single and Combination Treatment Result in Growth Inhibition
The IC50 for SFN was calculated to be approximately 22 μM for SFN and 44 nM for DAC
(Figure 1A). For cell growth inhibition, a dose of 5 μM of SFN and 25 nM of DAC were chosen based
on cell viability assays with more than 50% cells surviving from a single treatment of SFN and DAC
respectively. Viable cell counts were calculated in the single and combination treatment of DAC and
SFN compared to control (Figure 1B). There was 58% ± 4% and 56% ± 7% viable cells compared to
control for the single treatment with DAC and SFN, respectively and only 33% ± 5% of viable cells
in SFN and DAC combination treatment. The combination treatment induced significant growth
inhibition compared to any single treatment ( p < 0.03, Student’s t-test).
3.2. SFN and DAC Single and Combination Treatment Result in Minimal Apoptosis
Apoptosis analysis showed that most of the cells were noted as alive by negative stain for annexin
V and DAPI in all treatments and control (Figure 1C,D). The percentage of viable cells not in apoptosis
with DAC and SFN single treatments, was 99% ± 0.2% (p < 0.01) and 97% ± 1%( p < 0.01), respectively,
compared to control. Combination treatment of DAC and SFN results in 95% ± 1% (p < 0.004) of viable
cells compared to control. The percentage of viable cells not in apoptosis with combination treatments
was slightly lower than any single treatment of SFN (p < 0.03) and DAC (p < 0.01).
3.3. SFN and DAC Single and Combination Treatment Result in No Cell Cycle Arrest
Cell cycle analysis indicated that all treated and control cells were in normal distributions for
different cell cycles with G1 as dominant, followed by S phase and G2 phase, as shown in representative
figures (Figure 1E). There was no significant difference between treatments in the G2/M phase
(Figure 1F).
10
Medicines 2019, 6, 71
Figure 1. Impact of SFN and DAC single and combination treatment on the growth of B16 melanoma.
(A) The IC50 of SFN and DAC single treatment is approximately 22 μM and 44 nM, respectively. Cell
viability was determined using the CellTiter 96 AQueous One Solution Cell Proliferation kit. The data
were analyzed by nonlinear regression to determine the IC50. (B) Growth inhibition induced from
single and combination treatment of SFN and DAC. Viable cells were measured by trypan blue staining
and analyzed by Student’s t-test. (C) Representative apoptosis analysis (AnnexinV/DAPI) by flow
cytometry from control, SFN, and DAC single treatment. (D) The percentage of viable cells with DAC
and SFN single and combination treatments were compared to control. (E) Representative cell cycle
analysis from control and SFN and DAC single treatment. Data were analyzed with Flow Jo /Dean-Jett
Fox (DJF) model. (F) The percent G2/M phase in DAC and SFN single and combination treatments
were compared to control with Student’s t-test. * Significantly different from control, # Single treatment
is significantly different from combinational treatment (Student’s t-test).
3.4. SFN Induced Dysregulated Gene Transcription
RNAseq data analysis revealed a differential gene expression profile by SFN single treatment
compared to control. There were 126 genes with greater than 2-fold change compared to control.
The data have been deposited in NCBI’s Gene Expression Omnibus [69]. The top genes with greater
than 2.5-fold change (p < 0.001) are shown in the heatmap (Figure 2A). The biological roles of genes
responding to SFN single treatment with greater than 2-fold change were analyzed with IPA. The top
canonical pathways analysis, with a negative log p-value greater than 2, indicated many important
biological pathways dysregulated in response to SFN single treatment (Figure 2B).
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Figure 2. Differential gene expression induced by SFN single treatment and the related biological
pathways. (A) Differentially expressed genes from SFN single treatment compared to control. Genes
with greater than 2.5 fold changes (p < 0.001) were analyzed with unsupervised clustering (Z score
shown in the color key). (B) Top canonical pathways from SFN single treatment. Genes greater than
two-fold change relative to control were analyzed with Ingenuity Pathway Analysis (IPA) for their
biological significance. The top eight pathways are shown here.
3.5. SFN and DAC Uniquely Induced Dysregulated Gene Transcription
DAC single treatment induced 19 genes to greater than 2-fold change compared to control
(p < 0.05), and this number is too low for canonical pathway analysis by IPA. However, SFN and DAC
combination treatment induced more genes than any single treatment. There were 261 genes with
greater than a 2-fold change from the combination treatment of SFN and DAC compared to control
(p < 0.05). The data from DAC single and SFN and DAC combination treatment have been deposited
in NCBI’s Gene Expression Omnibus [69] as described above for SFN single treatment with the same
accession number GSE12752. The top genes with greater than 3-fold change (p < 0.001) induced from
SFN and DAC combination treatment are shown in the heatmap (Figure 3A). The biological roles of
genes responded to SFN and DAC combination treatment compared to control with greater than 2-fold
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change were analyzed with IPA. The top canonical pathways analysis, with a negative log p-value
greater than 3.5, showed many biological pathways involvement (Figure 3B). The role of vitamin
D receptor/retinoid X receptor (VDR/RXR) activation and aryl hydrocarbon receptor signaling were
listed as the top two canonical pathways from SFN and DAC combination treatment with a negative
log p-value greater than 5.5. These two pathways were also detected in SFN single treatment with a
negative log p-value approximately 3.0 (Figure 2B).
 
Figure 3. Differential gene expression induced by SFN and DAC combination treatment and the
involved biological pathways. (A) Differentially expressed genes from the combination treatment of
SFN and DAC compared to control treatments. Genes with greater than 3-fold change (p < 0.001)
were analyzed with unsupervised clustering (Z score shown in the color key). (B) Top canonical
pathways from the combination treatment of SFN and DAC. Genes greater than 2-fold change than the
control with the combination treatment of SFN and DAC were analyzed with IPA for their biological
significance. The top nine pathways are shown here.
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3.6. Validation of Dysregulated Gene Transcription Induced by SFN and DAC Combination Treatment
There were 261 genes with greater than 2-fold change (p< 0.05) of gene expression (either increased
or decreased) with DAC plus SFN combination treatments compared to control. The number of genes
with expression changes greater than 2-fold (p < 0.05), compared to control, from the single treatment
were 19 and 126 genes for DAC and SFN, respectively (Figure 4A). Furthermore, there were 150 unique
genes from combination treatment compared to control (Figure 4B).
We selected genes for further validation from the SFN and DAC combination treatment with
greater than 2-fold change compared to control. The preliminary selection criteria from RNA-seq data
were genes with the highest differential expression compared to control or involved in multiple top
biological pathways (Figure 4C). Three genes, CCL5, DUSP15, and IL33, were validated by reverse
transcription PCR (RT-PCR) (Figure 4D). These genes were selected for validation on the criteria
that they showed differential expression between single treatment and control as well as between
combination treatment and single treatment. CCL5 increased 2 ± 0.1 (p < 2.4 × 10−6) and 3 ± 0.2 (p < 1.5
× 10−5) times with single treatment of DAC and SFN, respectively, and increased 5 ± 0.2 (p < 1.3 × 10−7,
Student’s t-test) with combination treatment compared to control. DUSP15 increased 1.7 ± 0.2 (p < 6.2
× 10−3) and 1.9 ± 0.1 (p < 8.7 × 10−6) times with single treatment of DAC and SFN, respectively, and
increased 3.6 ± 0.3 (p < 1.7 × 10−5, Student’s t-test) with combination treatment compared to control.
IL33 increased 1.6± 0.3 (p < 4.2 × 10−2) and 2.2 ± 0.2 (p < 2.0 × 10−4) times with single treatment of
DAC and SFN, respectively, and increased 3.0 ± 0.3 (p < 2.1 × 10−4, Student’s t-test) with combination
treatment compared to control.
The level of secreted cytokines CCL5 and IL33, as well as other 111 cytokines, were measured in
the supernatant using a mouse XL cytokines array (Figure 4E). Out of the 111 mouse cytokines probes
on the membrane, CCL5 was detected with greater than two times increased signal in combination
treatment compared to the control group. IL33 was not present at detectable levels. Other cytokines,
such as CXCL10 (Gene ID 15945), angiopoietin-2 (Gene ID 11601), CD105 (Gene ID 13805), VEGF
(Gene ID 22339), and CCN4 (Gene ID 22402), were detected with an increased level of expression in
combination treatment than control.
Specific CCL5 ELISA further confirmed the increase in CCL 5 in DAC/SFN combination treatment,
as indicated in Figure 4F. The level of CCL5 in control is about 55 +/− 22.3 pg/mL and is increased to
348 +/− 92.2 pg/mL in SFN/DAC combination treatment from two independent biological runs.
14
Medicines 2019, 6, 71
 
Figure 4. Validation of combination effects from SFN and DAC. (A) The number of differentially
expressed genes induced by different treatments. (B) The number of unique genes responding to single
and combination treatment. All genes were selected from greater than 2-fold change compared to
control with p < 0.05. (C) A heatmap and list of top selected genes from SFN and DAC combination
treatments (Z score shows in the color key). (D) Relative gene expression validation by rtPCR of Ccl5,
Dusp15, and IL33 between treatments. * Significantly different from control, p < 0.05, # Single treatment
is significantly different from combinational treatment, p < 0.05 (Student’s t-test). (E) Expression of
cytokines detected by cytokine array. Ref indicates reference spots. Neg: negative control. Arrays were
performed in duplicate. (F) Specific CCL5 ELISA further confirmed the increase in CCL 5 in DAC/SFN
combination treatment. The left side indicated the standard curve of CCL5, ranged from 7.8 pg/mL to
500 pg/mL. The right side indicates the concentration of CCL5 in the supernatant is increased from
55pg/mL in control to 348 pg/mL in DAC/SFN combination treated group. All data were from two
independent biological runs.
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3.7. Analysis of Histone Epigenetic Post-Translational Modifications (PTMs)
Post-translational modifications were identified and subsequently quantified on histones H3 and
H4. EPZ treatment is known to decrease H3K27me3, and was consequently used as a positive control.
We treated cells with EPZ6438 for 48 hrs along with SFN and DAC combination treatments as described
in the methods section. Histone PTMs were analyzed using lysine derivatization and a bottom-up
proteomic workflow. Aside from positive control, no significant differences in histone PTMs were
detected (Supplementary Figure S1).
4. Discussion
For the current study, we explored the possibility of controlling melanoma cell growth by
combining the antioxidant SFN and the epigenetic drug DAC. The rationale behind this work was to
control the level of ROS while altering the epigenetic status with a relatively low dose of each drug.
The aim is to lay the first step for our long term goal in using a dietary dose of an antioxidant to help
epigenetic drugs in controlling melanoma. Therefore, we aimed to use a low dose of each drug to allow
the future application of a dietary dose of SFN and a low dose of DAC to reduce side effects. We chose
5 μM of SFN and 25 nM of DAC, which are equal to or lower than half of the respective IC50 from
our test (Figure 1A). These doses of the drugs induce significant growth inhibition with combination
treatment compared to control and either single treatment (Figure 1B). We did not find apoptosis or cell
cycle arrest in any treatments (Figure 1C–F). This finding is different from other studies using a higher
dose of each drug (6–25 μM of SFN [70,71] and 200 nM–0.5 μM of DAC [72,73]). These higher-dose
studies all demonstrate apoptosis and cell arrest effects. At the low doses used in this study, the two
drugs induced different mechanisms as compared to studies using relatively high doses of SFN or
DAC. Our findings suggest that the growth inhibition may be involved in mechanisms other than
apoptosis and cell cycle arrest. A combination treatment of low-dose SFN and DAC reduced the cell
growth without initiating cell cycle arrest or apoptosis. These data indicate that attenuating ROS with
the antioxidant SFN may enhance the utility of the epigenetic drug DAC in controlling cell growth,
with less impact on the host.
We investigated the impact of this drug combination at the transcriptional level by RNAseq
(Figures 2 and 3). There was a significant increase in the total number of genes with greater than
2-fold (p < 0.05) expression change in cells that received the combination treatment as compared
to those that received either single treatment and as compared to control (Figure 4A). The absolute
number of genes altered by 25 nM of DAC is very low at 19, and those altered by SFN alone is higher
at 126. This may be attributed to the low dose treatment with limited impact. Interestingly, the
number of altered genes increased to 261 when SFN and DAC combination treatment was applied.
The top differentially-expressed genes and canonical pathways showed different distributions between
single SFN and combination SFN and DAC treatment (Figures 2 and 3). VDR/RXR activation and
aryl hydrocarbon receptor signaling (AhR receptor) are two top-listed pathways from combination
treatments. Both pathways are known to be associated with UV exposure [5,15,74–76]. We validated
select genes involved in more than one canonical pathway or listed as top differentially-expressed genes
(Figure 4C). The transcription level of the three genes (CCL5, IL33, and DUSP15) were significantly
higher in the combination treatment than either of the single treatments (Figure 4D). Two (CCL5 and
IL33) of the three genes are secreted proteins. We further validated secreted proteins with cytokine
arrays and ELISA on CCL5 (Figure 4E,F). CCL5 was validated to have increased levels, both in
transcription level and detected extracellularly after combination treatment as compared to control.
CCL5 is also known as RANTES (regulated on activation, normal T cell expressed and secreted). It is
one of the cytokines which functions as a chemoattractant for natural killer (NK) cells [77], which do not
efficiently infiltrate solid tumors such as melanoma [78]. CCL5 is the main factor in inhibiting melanoma
growth by bringing NK cells to the tumor site, while autophagy is suppressed [79]. Activated NK cells
could stimulate the immune checkpoint programmed cell death protein 1 (PD-1) [80] and cytotoxic T
lymphocytes (CTL)-associated antigen 4 (CTLA4) [81] to deliver immunoregulatory effects. Increased
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expression of CCL5 involves the phosphorylation of the MAPK8/JNK-JUN/c-Jun signaling pathway,
which is initiated by decreased expression of protein phosphatase 2 A (PP2A), while autophagy is
suppressed [82,83]. Clinically, a high level of CCL5 is positively associated with the NK cell marker
NKp46 as well as with melanoma patients’ survival [79,84].
We also investigated whether low dose treatments of SFN and DAC have an impact on histone
PTMs. There was no differential PTMs detected when control and combination of SNF and DAC
treated cells were analyzed (Supplementary Figure S1). This suggests that under the conditions of
our treatments, the differential gene expression and cell inhibition may not be associated with histone
epigenetic reprogramming, but rather the direct effects of SFN and DAC.
In summary, our data suggest that attenuating ROS through the use of the antioxidant SFN can
help the epigenetic drug DAC control cell growth. This control is not via direct cell killing with
apoptosis, cell cycle arrest or histone modifications, but, more directly, by changing gene transcription
and cytokine production, which may increase the immune defense system by recruiting natural
killer cells.
5. Conclusions
Melanoma patients not only have high oxidative stress [23], but also have a high frequency of
recurrence of the disease [85,86]. It is apparent that melanoma patients are susceptible to daily UV-
and environmental exposure-induced ROS [5]. Managing the level of ROS via natural antioxidants has
demonstrated beneficial effects in controlling melanoma [5], but does not eliminate the tumor. Our
study aimed to attenuate ROS by a low dose of the antioxidant SFN and allow the epigenetic drug
DAC to control melanoma at a lower dose. The current study clearly demonstrates that SFN could
have combinational effects with the commonly used, FDA-approved demethylation agent DAC in
significantly inhibiting melanoma cell growth. The next goal is to apply our findings to animal studies.
The long term goal is for the clinical application of controlling melanoma with a dietary dose of SFN
and target drugs (e.g., epigenetic and immunotherapeutic drugs) at lower doses that may have fewer
side effects for patients.
Supplementary Materials: The following are available online at http://www.mdpi.com/2305-6320/6/3/71/s1,
Figure S1: Histone post-translational modifications on Histone H3 (A) and H4 (B) were detected upon EPZ6438
treatment as well as SFN and DAC combination treatment. As anticipated for the positive control, H3K27me3 was
significantly lower following EPZ treatment.
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Abstract: Background: Although tyrosine kinase inhibitors (TKIs) are still recommended as the
standard therapy in renal cell carcinoma (RCC), the high frequency of adverse events is a weakness
of this therapy. Because royal jelly (RJ) possesses anti-inflammatory and antioxidant properties,
we assessed its protective effects on TKI-induced toxicities in RCC patients. Methods: We enrolled
33 patients with advanced RCC who were assigned to start TKI therapy in combination with a
randomized, double-blinded, placebo-controlled RJ trial consisting of a placebo group with 17 subjects
and an RJ group with 16 subjects. Results: Fatigue and anorexia frequencies in the RJ group were
significantly lower than in the placebo group (p = 0.003 and 0.015, respectively). A statistically
significant correlation between RJ and fatigue or anorexia was detected in sunitinib-treated patients.
The dose reduction- or discontinuation-free periods were significantly longer (p = 0.013) in the RJ
group than in the placebo group. Furthermore, similar observations were made in sunitinib-treated
patients (p = 0.016). Conclusions: Our clinical trial showed that RJ exerted protective effects against
TKI-induced fatigue and anorexia and lowered TKI dose reduction or discontinuation. Hence, RJ is
beneficial for maintaining the quality of life and medication compliance in TKI-treated RCC patients.
Keywords: royal jelly; adverse events; tyrosine kinase inhibitors; renal cell carcinoma; double-blinded;
randomized clinical trial
1. Introduction
Renal cell carcinoma (RCC) is one of the most common urological cancers, and its incidence has
continuously increased over the past few decades [1]. Although a nephrectomy is usually performed
for organ-confined RCC, additional systematic therapy is the standard treatment strategy in patients
with metastatic RCC. Currently, new treatment options including immune check-point inhibitors are
being developed; however, a molecularly targeted therapy using tyrosine kinase inhibitors (TKIs) is
still the recommended standard therapy for these patients [2–4]. In addition, molecularly targeted
therapies are often used as neoadjuvant therapy for cytoreductive nephrectomy [5], and clinical trials
of combination therapies including molecularly targeted therapeutics and other anticancer agents are
currently in progress [6–8]. On the other hand, a major limitation of molecularly targeted therapies is
the relatively high frequency of adverse events (AEs) with occasionally severe effects [9,10]. Therefore,
the management of drug-induced AEs is critical for maintaining the quality of life during treatment
and continuous therapy in these patients.
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Sunitinib and pazopanib are approved as first-line therapy for patients with RCC, especially in
favorable- or intermediate-risk clear cell RCC [2]. In addition, these TKIs are often used in real-world
patients with non-clear cell RCC [11]. On the other hand, axitinib and sorafenib are also used
in some patients with metastatic RCC [12,13]. Typical AEs linked to these TKIs include various
symptoms such as oral mucositis, hand–foot syndrome, hypertension, fatigue, and gastrointestinal
events [14–18]. In addition, functional disorders of the kidneys, liver, and thyroid are often associated
with TKIs [14,15,17]. The occurrence and progression of these AEs are suggested to be mediated by
complex mechanisms that involve inflammation, oxidative stress, and the immune system [19–21].
Based on these findings, we hypothesized that controlling these biological factors may suppress
TKI-induced adverse events.
Royal jelly (RJ) is secreted by the hypopharyngeal and mandibular glands of worker honeybees
of Apis mellifera, and is the exclusive food for the queen honeybee and larvae. The most important
biological effects of RJ are its anti-inflammatory and antioxidative activities, and its ability to exert some
control over the immune system [22–24]. These RJ-related activities are predicted to be beneficial in the
protection against anticancer agent-induced adverse events involving inflammation, oxidative stress,
and immune system dysfunction [25,26]. In fact, the protective efficacy of RJ against anticancer therapy
associated toxic effects, such as oral mucositis, intestinal damage, and nephro- and hepato-toxicities,
has been demonstrated in animal models with malignancies [27–30].
Thus, in recent decades, several studies have examined the biological effects of RJ on cancer cell
lines and corresponding animal models. However, despite several clinical trials, not many studies
have reported the clinical benefits and limitations of RJ administration in cancer patients [31–35].
Specifically, there are no reports about the effects of RJ on the adverse events caused by molecularly
targeted therapies in RCC patients. Therefore, the aim of this study was to assess the protective efficacy
of RJ against TKI-induced toxicities in patients with RCC.
2. Methods
2.1. Patients
This study protocol was approved by the Human Ethics Review Committee of Nagasaki
University Hospital (Nagasaki, Japan; No. 15102604-2), and it was registered as UMIN000020152.
In addition, this trial was conducted according to the Declaration of Helsinki. Patients provided
written informed consent to participate in all aspects of the study. Patients with RCC who had been
assigned to start TKIs were enrolled by the Nagasaki University Hospital. Eligibility criteria of this
trial were age >20 years, Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1,
and no honey allergy.
2.2. Study Design
This is a randomized, double-blinded, placebo-controlled clinical trial. Patients were assigned to
two groups, namely the placebo and RJ groups, at a ratio of 1:1 using computer-generated random
numbers. The patient selection process was performed by independent non-medical staff at our
hospital who had no information on the aim of this trial, and the process was also hidden from the
patients and urologists who provided treatment until the end of all analyses.
RJ and the placebo were provided by the Yamada Agriculture Center Inc (Okayama, Japan).
RJ and the placebo were prepared as capsules containing 900 mg RJ and starch, respectively, that share
the same taste, smell, size, shape, and color. Capsules were orally administered four times per day for
three months.
2.3. Protocol
All subjects received medical examinations and were checked for clinical symptoms every two
weeks. Blood samples were collected simultaneously every two weeks and subjected to laboratory
23
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analysis routinely performed in patients treated with TKIs. The initial starting dose of sunitinib,
pazopanib, axitinib, and sunitinib was 50 mg/day, 800 mg/day, 10 mg/day, and 800 mg/day,
respectively, but if an intolerable AE was observed, the dose was decreased to 37.5 mg/day,
400–600 mg/day, 5 mg/day, and 400 mg/day, respectively. In addition, for the sunitinib regimen,
if the dose reduction was necessary, all affected patients were treated with an alternative every other
day [36]. Furthermore, TKI administration was stopped if intolerable AEs persisted or high-grade
abnormalities in the blood analysis were observed. The primary outcome was the frequency and
severity of AEs caused by TKIs in patients with RCC, and the secondary outcome was the sustained
period of the initial TKI regimen.
Toxicities were graded according to the National Cancer Institute Common Terminology Criteria
for Adverse Events, version 5.0. In this study, toxicities classified as grade 3 and 4, or identified as the
cause for discontinued TKI administration, were judged as severe AEs.
2.4. Statistical Analyses
Results are expressed as the mean and standard deviation (SD) for normally distributed data
and the median and interquartile range (IQR) for non-normally distributed data. The Student’s t-test
or Mann–Whitney U test was used to compare continuous variables and Scheffé’s method was used
for multiple comparisons. The sustained periods of initial dosage were derived from Kaplan–Meier
curves, and statistical significance was analyzed using the log-rank test. Values with p < 0.05 were
considered statistically significant. Statistical analyses were carried out using StatView for Windows
v.5.0 software (Abacus Concept, Berkeley, CA, USA).
3. Results
All subjects of the placebo and RJ group consumed the respective capsules for three months or
until disease progression. In addition, we confirmed that the compliance rate was >95% in both groups
and no patient experienced any side effects including allergy due to the trial capsules.
3.1. Patient Background
Thirty-three patients with RCC were enrolled in this study. The pathological features and basic
characteristics of our study population at baseline are presented in Table 1.
Table 1. Clinicopathological features and basic characteristics.
Variables Entire (n = 33) Placebo (n = 17) Royal Jelly (n = 16) p Value
Age 0.101
Mean ± SD, years 67.6 ± 6.6 65.8 ± 8.8 69.6 ± 5.9
Gender; n (%) 0.909
Male/Female 23/10 (30.3) 12/5 (29.4) 11/5 (31.3)
Performance Status 0.598
0/1 16/17 (51.5) 9/8 (47.1) 7/9 (56.3)
Pathological Type 0.446
Conventional 29 (87.9) 16 (94.1) 13 (81.3)
Fuhrman Grade 0.425
1 or 2/3 or 4 6/27 (81.8) 2/15 (88.2) 4/12 (75.0)
pT stage 0.201
1 or 2/3 or 4 9/24 (72.7) 3/14 (82.4) 6/10 (62.5)
Lymph Node Metastasis 0.881
Presence 19 (57.6) 10 (58.8) 9 (56.3)
Distant Metastasis 0.325
Presence 27 (81.8) 15 (88.2) 12 (75.0)
Neo-Adjuvant Setting 0.965
Yes 2 (6.1) 1 (5.9) 1 (6.3)
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Table 1. Cont.
Variables Entire (n = 33) Placebo (n = 17) Royal Jelly (n = 16) p Value
Past Therapy Used TKI 0.948
Presence 4 (12.1) 2 (11.8) 2 (12.5)
TKIs 0.539
Sunitinib 21 (63.6) 11 (64.7) 10 (62.5)
Pazopanib 7 (21.2) 3 (17.6) 4 (25.0)
Axitinib 4 (12.1) 3 (17.6) 1 (6.3)
Sorafenib 1 (3.0) 0 (0.0) 1 (6.3)
TKIs = tyrosine kinase inhibitors. SD = standard deviation.
The statistical analysis indicated that the baseline parameters did not significantly differ between
the placebo and the RJ groups. As shown in Table 1, among the 33 patients, 21, 8, and 3 patients were
treated with sunitinib, pazopanib, and axitinib, respectively, whereas only one patient was treated
with sorafenib. The patients were further divided into two subgroups, namely the sunitinib and the
other TKI group, because 63.5% of the patients were treated with sunitinib. The clinicopathological
features and basic characteristics of each subgroup are listed in Table 2.
Table 2. Clinicopathological features and basic characteristics according to used agents.
Variables Placebo Royal Jelly p Value
Sunitinib n = 11 n =10
Age (mean ± SD), years 66.5 ± 8.3 67.8 ± 5.8 0.673
Gender; Male/Female, n (%) 6/5 (45.5) 8/2 (20.0) 0.217
Performance Status; 0/1 7/4 (36.4) 6/4 (40.0) 0.864
Pathological Type; Conventional 11 (100.0) 8 (80.0) 0.297
Fuhrman grade; 2/3+4 1/10 (90.9) 2/8 (80.0) 0.476
pT stage; 1+2/3+4 2/9 (81.8) 3/7 (70.0) 0.525
Lymph Node Metastasis; Presence 7 (63.6) 6 (60.0) 0.864
Distant Metastasis; Presence 9 (81.8) 8 (80.0) 0.916
Neo-Adjuvant Setting; Yes 1 (9.1) 0 (0.0) 0.329
Past Therapy Used TKI; Presence 1 (9.1) 0 (0.0) 0.329
Others n = 6 n = 6
Age (mean ± SD); years 64.5 ± 3.8 72.5 ± 5.3 0.013
Gender; Male / Female 6/0 (0.0) 3/3 (50.0) 0.182
Performance Status; 0/1 2/4 (66.7) 1/5 (83.3) 0.505
Pathological Type; Conventional 5 (83.3) 5 (83.3) 0.999
Fuhrman grade; 2/3+4 1/5 (83.3) 3/3 (50.0) 0.221
pT Stage; 1+2/3+4 1/5 (83.3) 2/4 (66.7) 0.501
LN Metastasis; Presence 3 (50.0) 3 (50.0) 0.999
Distant Metastasis; Presence 6 (100.0) 4 (66.7) 0.121
Neo-Adjuvant Setting; Yes 0 (0.0) 1 (16.7) 0.296
Past Therapy Used TKI; Presence 1 (16.7) 2 (33.3) 0.505
In the other TKI group, the mean age of the RJ group was significantly higher (p = 0.013) compared
to that of the RJ group. However, the remaining parameters did not significantly vary between these
two groups.
3.2. Adverse Events
In the study population (n = 33), the most common AE was hypertension (n = 23; 69.7%) followed
by fatigue (n = 20; 60.6%), and anorexia (n = 18; 60.0%) and hand–foot syndrome (n = 18; 60.0%).
Furthermore, anorexia (n = 4; 12.1%) was the most common severe adverse event.
As shown in Table 3, the frequencies and severities of fatigue and anorexia were significantly
lower in the RJ group than those in the placebo group (p = 0.003 and 0.015, respectively). The digestive
symptoms varied similarly, but the difference between the RJ and placebo group was not statistically
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significant (p = 0.077). In addition, none of the other symptoms varied significantly, including
hypertension. However, when the same analysis was performed separately on the subgroups of
patients treated with either sunitinib or other TKIs, such significant differences in fatigue and anorexia
differed significantly between the RJ and placebo groups in patients treated with sunitinib (p = 0.040
and 0.038, respectively), but not in those treated with other TKIs (p = 0.065 and 0.343, respectively).
The frequencies of the remaining symptoms were similar between the two groups regardless of the
TKI regimen.
Table 3. Relationships between royal jelly intake and clinical symptoms.
Adverse Events
Entire Sunitinib Others
Placebo (n = 17) RJ (n = 16) Placebo (n = 11) RJ (n = 10) Placebo (n = 6) RJ (n = 6)
Hypertension
Nothing 6 (35.3) 4 (25.0) 5 (45.5) 3 (30.0) 1 (16.7) 1 (16.7)
Mild 10 (58.8) 12 (75.0) 6 (54.5) 7 (70.0) 4 (66.7) 5 (83.3)
Severe 1 (5.9) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0)
p value 0.460 0.466 0.574
Fatigue
Nothing 2 (11.8) 11 (68.8) 1 (9.1) 6 (60.0) 1 (16.7) 5 (83.3)
Mild 13 (76.5) 5 (31.3) 9 (81.8) 4 (40.0) 4 (66.7) 1 (16.7)
Severe 2 (11.8) 0 (0.0) 1 (9.1) 0 (0.0) 1 (16.7) 0 (0.0)
p value 0.003 0.040 0.065
Anorexia
Nothing 4 (23.5) 11 (68.8) 3 (27.3) 8 (80.0) 1 (16.7) 3 (50.0)
Mild 9 (52.9) 5 (31.3) 5 (45.5) 2 (20.0) 4 (66.7) 3 (50.0)
Severe 4 (23.5) 0 (0.0) 3 (27.3) 0 (0.0) 1 (16.7) 0 (0.0)
p value 0.015 0.038 0.343
Digestive Symptoms
Nothing 6 (35.3) 11 (68.8) 3 (27.3) 7 (70.0) 3 (50.0) 4 (66.7)
Mild 8 (47.1) 5 (31.3) 6 (54.5) 3 (30.0) 2 (33.3) 2 (33.3)
Severe 3 (17.6) 0 (0.0) 2 (18.2) 0 (0.0) 1 (16.7) 0 (0.0)
p value 0.077 0.102 0.565
Dysgeusia
Nothing 7 (41.2) 9 (56.3) 5 (45.5) 5 (50.0) 2 (33.3) 4 (66.7)
Mild 9 (52.9) 7 (43.8) 5 (45.5) 5 (50.0) 4 (66.7) 2 (33.3)
Severe 1 (5.9) 0 (0.0) 1 (9.1) 0 (0.0) 0 (0.0) 0 (0.0)
p value 0.479 0.621 0.248
Hand–Foot Syndrome
Nothing 7 (41.2) 8 (50.0) 3 (27.3) 4 (40.0) 4 (66.7) 4 (66.7)
Mild 9 (52.9) 8 (50.0) 8 (72.7)) 6 (60.0) 1 (16.7) 2 (33.3)
Severe 1 (5.9) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0)
p value 0.578 0.537 0.513
Oral Mucositis
Nothing 9 (52.9) 11 (68.8) 7 (63.6) 7 (70.0) 2 (33.3) 4 (66.7)
Mild 8 (47.1) 5 (31.3) 4 (36.4) 3 (30.0) 4 (66.7) 2 (33.3)
Severe 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
p value 0.353 0.757 0.248
RJ = royal jelly.
Table 4 shows the laboratory blood test results in relation to the trial capsule treatment groups.
The frequency of patients with normal anemia values was higher in the RJ group (87.5%) than in the
placebo group (58.8%); however, the difference was not statistically significant (p = 0.162). When the
same analysis was performed with the data of the sunitinib-treated patients, no significant difference
was detected (p = 0.117). Overall, none of the laboratory blood test results varied significantly between
the placebo and the RJ group (Table 4).
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Table 4. Relationships between royal jelly intake and results of blood examinations.
Adverse Events
Entire Sunitinib Others
Placebo (n = 17) RJ (n = 16) Placebo (n = 11) RJ (n = 10) Placebo (n = 6) RJ (n = 6)
Leukopenia
Nothing 11 (35.3) 11 (25.0) 5 (45.5) 6 (60.0) 6 (100.0) 5 (83.3)
Low 5 (58.8) 5 (75.0) 5 (45.5) 4 (40.0) 0 (0.0) 1 (16.7)
High 1 (5.9) 0 (0.0) 1 (9.1) 0 (0.0) 0 (0.0) 0 (0.0)
p value 0.616 0.561 0.296
Anemia
Nothing 10 (58.8) 14 (87.5) 4 (36.4) 8 (80.0) 6 (100.0) 6 (100.0)
Mild 6 (35.3) 2 (12.5) 4 (36.4) 2 (20.0) 0 (0.0) 0 (0.0)
Severe 1 (5.9) 0 (0.0) 1 (9.1) 0 (0.0) 0 (0.0) 0 (0.0)
p value 0.162 0.117 > 0.999
Platelets
Nothing 5 (29.4) 9 (56.3) 2 (18.2) 5 (50.0) 3 (50.0) 4 (66.7)
Mild 8 (47.1) 4 (25.0) 6 (54.5) 3 (30.0) 2 (33.3) 1 (16.7)
Severe 4 (23.5) 3 (18.8) 3 (27.3) 2 (20.0) 1 (16.7) 1 (16.7)
p value 0.274 0.295 0.788
Renal Dysfunction
Nothing 8 (47.1) 10 (62.5) 5 (45.5) 6 (60.0) 3 (50.0) 4 (66.7)
Mild 9 (52.9) 6 (37.5) 6 (54.5) 4 (40.0) 3 (50.0) 2 (33.3)
Severe 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
p value 0.373 0.505 0.558
Liver Dysfunction
Nothing 12 (70.6) 14 (87.5) 7 (63.6) 9 (90.0) 5 (83.3) 5 (83.3)
Mild 4 (23.5) 1 (6.3) 4 (36.4) 1 (10.0) 0 (0.0) 0 (0.0)
Severe 1 (5.9) 1 (6.3) 0 (0.0) 0 (0.0) 1 (16.7) 1 (16.7)
p value 0.382 0.621 0.999
Thyroid Abnormality
Nothing 9 (52.9) 10 (62.5) 7 (63.6) 7 (70.0) 2 (33.3) 3 (50.0)
Mild 7 (41.2) 6 (37.5) 4 (36.4) 3 (30.0) 3 (50.0) 3 (50.0)
Severe 1 (5.9) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0)
P value 0.577 0.757 0.549
3.3. Dose Reduction or Discontinuation of Tyrosine Kinase Inhibitors
In our study population, 23 of the 33 patients (69.7%) required a dose reduction or discontinuation
of the TKI regimen due to severe AEs and disease progression within three months of TKI treatment
initiation. The frequency of dose reduction or discontinuation was significantly lower (p = 0.017) in
the RJ group (5/16 = 50.0%) than in the placebo group (15/17 = 88.2%). The Kaplan–Meier survival
curves for dose-reduction- or discontinuation-free survival rates in the placebo and RJ group are
shown in Figure 1A. The free-periods were significantly longer (p = 0.013) in the RJ group than in the
placebo group. Furthermore, a similar result was observed in patients treated with sunitinib (p = 0.016;
Figure 1B). However, although the dose-reduction- or discontinuation-free survival rates appeared
to be better in the RJ group than in the placebo group among patients treated with TKIs other than
sunitinib, the difference between these subgroups was not significant (p = 0.296; Figure 1C).
Figure 1. Kaplan–Meier survival curves of the dose-reduction- or discontinuation-free survival rate in
the placebo and RJ groups. Dose-reduction- or discontinuation-free survival was better in the RJ group
than in the placebo group for patients treated with any TKI (A) and sunitinib (B) (p = 0.127 and 0.016,
respectively). However, this difference was not observed in patients treated with other TKIs (C).
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4. Discussion
In this study, we investigated the preventive effects of prophylactic RJ consumption on
AEs associated with TKI-induced toxicities because the appropriate management of these AEs
is critical for maintaining quality of life in RCC patients treated with TKIs. Various harmful
symptoms and abnormal observations are known as adverse events of TKIs [12,14–18]. Among these
chemotherapy-induced symptoms, such as oral mucositis, anorexia, digestive symptoms, fatigue,
and damage of the kidneys and liver, few have been shown to be suppressed by RJ administration
in animal experiments and clinical trials [27–34,37]. In addition, it is known that RJ improves
protection against hypertension, hand–foot syndrome, and bone marrow suppression, which are
representative adverse events associated with TKIs [38,39]. However, we found that among these
harmful symptoms, RJ administration was not significantly associated with the frequency and
severity of hypertension, hand–foot syndrome, oral mucositis, dysgeusia, and kidney or liver damage.
Importantly, we demonstrated that fatigue and anorexia in the RJ group were significantly mild
compared to that in the placebo group. Interestingly, RJ has been shown to exert anti-fatigue
effects in an animal experiment that investigated fatigue-related parameters such as serum lactate,
serum ammonia, and muscle glycogen after swimming in mice treated with RJ [40]. The study found
that these parameters were improved by RJ intake [40]. However, we should note that this fatigue was
not induced by anticancer therapies such as TKIs. However, there is a report that processed honey and
RJ ameliorated cancer-related fatigue in a double-blinded, randomized clinical trial [33]. Specifically,
the visual analogue fatigue scale and fatigue severity score in the test article group (processed honey
and RJ for four weeks; n = 26) were significantly lower than those in the control group (pure honey for
four weeks; n = 26) [33]. We believe that the present study supports this previous result. However,
the previous study had some limitations; for example, the study population included six different
types of cancer (breast, gastric, esophageal, colon, rectal, and prostate cancer). Although there was
no statistical difference between the composition of the study and control group, the patients had
to be treated with four different methods (hormonal therapy, chemotherapy, chemoradiation, and
radiotherapy). Furthermore, as discussed by the authors, the short duration of intervention (four
weeks) was another limitation [33]. Thus, the present study is the first report on the association
between RJ and cancer-related fatigue in RCC patients treated with TKIs. Fatigue is widely recognized
as a highly common adverse event in TKI-treated patients with metastatic RCC (sunitinib, 55%;
pazopanib, 27%; axitinib, 9%; and sorafenib; 8%) [12]. In addition, it was observed that only 4%
of these patients received pharmacologic treatment for fatigue, whereas 72% of hypertension was
treated [12]. Moreover, there are only a few effective treatment options for fatigue caused by TKIs.
Hence, our observation that RJ may significantly suppress TKI-induced fatigue is an important finding
for TKI-based treatment strategies.
In addition to fatigue, our results demonstrated that RJ suppressed the frequency and severity
of anorexia. To our knowledge, this is the first report about the preventive effect of RJ on anorexia
in RCC patients. In addition, there is no information on the relationship between RJ and anorexia in
patients with malignancies. In general, anorexia in cancer patients is caused by complex interactions
involving various factors, such as nausea, constipation, pain, depression, and hypothyroidism [41].
In addition, it is recommended that anorexia treatment should include drugs that target the following
conditions: nutritional disorders, muscle catabolism, anemia, and fatigue [42]. Furthermore, it was
reported that inflammatory status, oxidative stress, and immunosuppression are important targets for
anorexia treatment. From our results, we cannot describe the interactions induced by RJ to exert the
preventive effects against anorexia. However, we speculate that there are multiple beneficial effects of
RJ on various TKI-induced adverse events including fatigue, digestive symptoms, anemia, and nephro-
and hepato-toxicities that contribute to this finding, although RJ is not significantly associated with
the prevention of these events. Furthermore, RJ has been reported to possess anti-inflammatory
and antioxidative activities, and act as a significant regulator of immune conditions caused by
anticancer therapies [35]. We agree with the opinion that the clinical management of anorexia requires
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a multidisciplinary and multi-pharmacological approach [42]. As useful information for TKI-treatment
management, RJ intake is beneficial to prevent anorexia in cancer patients treated with sunitinib.
Our results showed that RJ had no significant effect on oral mucositis. However, a preliminary
study designed as a randomized, single-blinded (physician-blinded) trial showed that prophylactic RJ
use led to a significant reduction in head and neck cancer patients. However, the study population
was small (the RJ and control groups had seven and six patients, respectively) [32]. On the other
hand, other investigators also reported that RJ improved symptoms of oral mucositis and shortened
the healing time in 103 patients [31]. However, in these two studies, patients were treated with a
combination of chemotherapy and radiotherapy. We believe that RJ may prevent the oral mucositis
caused by chemotherapy and/or radiotherapy, but not by TKIs.
Our results showed that there was no significant relationship between RJ consumption and the
blood test results. Several in vivo studies demonstrated RJ administration led to the protection of
various organ functions [35]. For example, RJ strongly suppressed clinical and pathological aggravation
of the liver, kidneys, and testis in experimental animals treated with cisplatin [29,30,37]. On the
other hand, in a human trial, the serum levels of creatinine and urea were significantly increased
during the first and second cycle of cisplatin-based chemotherapy in 32 cancer patients, but the
increase in kidney function-related parameters was suppressed by RJ administration. However,
the nephroprotective activity was not statistically significant [34]. Our results are similar to those
reported in this study, and we assume that differences such as species, dosage, and period of RJ
treatment as well as physiological characteristics of the kidneys are causes for the different observations
in animal models and cancer patients.
Our study design has several limitations that restrict the conclusions about the preventive effects of
RJ on AEs caused by TKIs in patients with RCC. First, the trial had a relatively small number of patients
in each group. However, we emphasize that this trial is a preliminary study on the RJ consumption by
patients with malignancy treated with TKIs. In addition, the number of patients in the present study
appears to be relatively similar to that reported in previous clinical trials on RJ administration [32,33].
Second, the RJ capsules were provided by a company that sells supplements made from honey.
To ensure that the study is not biased, we performed this trial as a double-blinded, randomized study,
and the administration, data collection, and analysis were done by a third party approved by the
Human Ethics Review Committee. Therefore, our results were not affected by the company and we
did not receive any financial support for the publication of this manuscript. Finally, our study design
cannot identify the active substance causing the beneficial functions of RJ. Although RJ contains mostly
sugars, lipids, amino acids, and vitamins, 10-hydroxy-2-decenoic acid (10-HDA), royalisin, and apisin
are known as major components with pharmacological activities [43–45]. We assume that some of
these RJ-specific components may cause the observed effects. Further detailed analyses are necessary
to identify the active ingredients.
In conclusion, our results demonstrated that prophylactic RJ intake is effective for the prevention
and suppression of sunitinib-induced fatigue and anorexia. In addition, RJ did not affect treatment
safety and compliance. Specifically, we found that the risk of TKI dose reduction or discontinuation
was significantly lower in the RJ group than in the placebo group. Sunitinib remains a recommended
standard agent used singly or in combination with immune therapy, low molecular weight heparin,
and vaccines for the treatment of metastatic RCC [6,7]. Therefore, we believe that our results are
important to improve the treatment strategies for RCC. On the other hand, we emphasize that further
detailed clinical studies with more participants are needed to determine whether RJ intake prevents
TKI-induced AEs in cancer patients.
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Abstract: Background: Gac (Momordica cochinchinensis Spreng) seeds have long been used in
traditional medicine as a remedy for numerous conditions due to a range of bioactive compounds.
This study investigated the solvent extraction of compounds that could be responsible for antioxidant
activity and anticancer potential. Methods: Defatted Gac seed kernel powder was extracted
with different solvents: 100% water, 50% methanol:water, 70% ethanol:water, water saturated
butanol, 100% methanol, and 100% ethanol. Trypsin inhibitors, saponins, phenolics, and antioxidant
activity using the 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS),
the 2,2-diphenyl-1-picrylhydrazyl (DPPH) and the ferric reducing antioxidant power (FRAP) assays;
and anticancer potential against two melanoma cancer cell lines (MM418C1 and D24) were analysed
to determine the best extraction solvents. Results: Water was best for extracting trypsin inhibitors
(581.4 ± 18.5 mg trypsin/mg) and reducing the viability of MM418C1 and D24 melanoma cells
(75.5 ± 1.3 and 66.9 ± 2.2%, respectively); the anticancer potential against the MM418C1 cells was
highly correlated with trypsin inhibitors (r = 0.92, p < 0.05), but there was no correlation between
anticancer potential and antioxidant activity. The water saturated butanol had the highest saponins
(71.8 ± 4.31 mg aescin equivalents/g), phenolic compounds (20.4 ± 0.86 mg gallic acid equivalents/g),
and antioxidant activity, but these measures were not related to anticancer potential. Conclusions:
Water yielded a Gac seed extract, rich in trypsin inhibitors, which had high anticancer potential
against two melanoma cell lines.
Keywords: Momordica cochinchinensis; Gac; seeds; saponins; trypsin inhibitors; phenolics; anticancer;
antioxidant; extraction; freeze dried extract
1. Introduction
Momordica cochinchinensis Spreng, commonly called Gac, is a plant species of the family
Cucurbitaceae, which is also known as red melon, baby jackfruit, spiny bitter gourd, sweet gourd,
and cochinchin gourd. It is native to Southeast Asia and is commonly grown as a food crop in Vietnam,
Thailand, Laos, Myanmar, and Cambodia [1,2]. From the food and commercial perspectives, the most
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commonly used part of the mature fruit is the red flesh surrounding the seeds, called the aril, which is
traditionally used as a colourant in rice or, more recently, as a material that is processed into functional
food ingredients or supplements [3].
The seeds are not eaten; they are removed from the aril and are mostly considered as waste [3,4].
However, in traditional medicine, Gac seeds are purported to have an array of therapeutic effects
on a variety of conditions, such as fluxes, liver and spleen disorders, haemorrhoids, wounds,
bruises, swelling, and pus [2,5]. In modern research, several constituents have been identified,
which could be involved in the putative medicinal properties of Gac seeds, including trypsin inhibitors
(e.g., MCoTI-I, MCoTI-II and MCoTI-III) [6–8], saponins (e.g., Momordica Saponin I and Momordica
Saponin II) [9,10], and phenolic compounds (e.g., gallic acid and p-hydroxybenzoic acid) [11].
Gac seed extracts have been linked with many medicinal properties, such as gastroprotective [12–14],
anti-inflammatory [15,16], anticancer [17], and antitumor [18] activities. Most of these properties
are linked to the seed’s saponins [12,13,15,16]. Furthermore, karounidiol, a triterpenoid compound,
likely a saponin, present in Gac seeds [19], possess cytotoxic activity against human cancer cell
lines [20]. Protease inhibitors, like the trypsin inhibitors in Gac seeds [7,8,21], have diverse biochemical
functions [4,22], including acting as anticancer agents by inhibiting the growth of transformed
cells [23–26]. Some trypsin inhibitors, such as those from Cajanus cajan and Phaseolus limensis,
possess antioxidant, anti-inflammatory, and anti-bacterial activity [27].
There is limited information on how to best recover the bioactive compounds from Gac seeds,
particularly to optimise anticancer potential. Efficient extraction and preservation methods are
important for their immediate and long-term use. For any given plant bioactive, extractable
yield depends on the extraction solvent, the chemical nature of the targeted component, and the
characteristics of the extraction procedure. When other factors are kept constant, the extraction
solvent plays a key role in obtaining the desired quality and quantity of the target constituents [28,29].
The choice of solvent is mainly based on the chemical properties of the targeted compounds, such as
their polarity or hydrophobicity.
Due to the hydrophilic or amphiphilic nature of the trypsin inhibitors, phenolics, and saponins
in Gac seeds, aqueous solvents and the low alcohols are likely to be the best extraction solvents for
these bioactive compounds. They are also the safest and the most environmentally-friendly solvents
for the extraction of bioactive compounds from plant materials [30,31]. For drying after solvent
extractions, numerous methods have been developed; however, freeze drying is considered to be
superior for preserving the medicinal qualities of botanical extracts and it is therefore widely used [32].
Additionally, to make it easier for the extraction of trypsin inhibitors [33] and to avoid interference
of sticky oil during the freeze-drying procedure, the Gac seeds need to be defatted before they are
extracted with solvents.
Thus, this study aimed to investigate the effectiveness of different solvents (water, alcohols,
and mixtures) to extract the bioactive compounds of interest (trypsin inhibitors, saponins, and phenolics)
from defatted Gac seed kernel powder. The relationships between the extracted compounds and the
antioxidant activity and the anticancer potential of the extracts were also investigated.
2. Materials and Methods
2.1. Materials
2.1.1. Solvents, Reagents, and Chemicals
Solvents (ethanol, methanol and butanol) and chemicals (vanillin, sulphuric acid and potassium
persulfate) were purchased from Merck (Bayswater, VIC, Australia). Folin-ciocalteu’s phenol
reagent, anhydrous sodium carbonate, sodium nitrile, ferric chloride, gallic acid, catechin,
2,4,6-tris(2-pyridyl)-s-triazine, (±)-6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (trolox),
aescin, 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)
diammonium salt (ABTS), trypsin (type I) from bovine pancreas, benzyl-DL-arginine-para-nitroanilide
34
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(BAPNA), Tris, and dimethylsulfoxide (DMSO) were purchased from Sigma-Aldrich Co. (Castle Hill,
NSW, Australia). Sodium acetate trihydrate was purchased from Government Stores Department
(Sydney, NSW, Australia). Aluminium chloride was a product of J. T. Baker Chem. Co. (Thermo Fisher
Scientific, North Ryde, NSW, Australia). Acetic acid was a product of BDH Laboratory Supplies
(Bio-Strategy, Tingalpa, QLD, Australia). Sodium hydroxide was a product of Ajax FineChem
(Thermo Fisher Scientific, North Ryde, NSW, Australia) and hydrochloride acid a product of Lab-Scan
Ltd. (Bacto, Mt Pritchard, NSW, Australia).
Human melanoma MM418C1 (mutated BRAF oncogene), referred to as C1 melanoma cells,
and D24 (wild type BRAF oncogene) and human keratinocyte (HaCat) cell lines were provided by the
School of Health and Biomedical Sciences, RMIT University (Bundoora, VIC, Australia). RPMI-1640
media, streptomycin, and penicillin were Gibco products (Thermo Fisher Scientific, North Ryde, NSW,
Australia). Fetal bovine serum (FBS) was from Serana (Melbourne, VIC, Australia).
2.1.2. Gac Seeds
Gac seeds, from accession VS7 as classified by Wimalasiri et al. [1], were collected from 450 kg
of fresh Gac fruit. These fruits were bought at Gac fruit fields in Dong Nai province, Ho Chi Minh
City, Vietnam (Latitude: 10.757410; Longitude: 106.673439). After their separation from the fresh fruit,
the seeds were vacuum dried at 40 ◦C for 24 h to reduce moisture and increase the crispness of the
shell, which facilitated shell removal. The dried seeds were de-coated to get the kernels, which were
then packaged in vacuum-sealed aluminium bags and stored at −18 ◦C until used.
Preparation of Defatted Gac Seed Kernel Powder
Defatted Gac seed kernel powder was prepared as described by Le et al. [34]. Briefly, the Gac
seed kernels were ground in an electric grinder (100 g ST-02A Mulry Disintegrator, Taiwan Machinary,
Sydney, NSW, Australia) to a powder that could pass through a sieve of 1.4 mm. The powder was then
freeze-dried using a Dynavac FD3 Freeze Dryer (Dynapumps, Seven Hills, NSW, Australia) for 48 h,
at −45 ◦C under vacuum at a pressure loading of 10−2 mbar (1 Pa), to reduce the moisture content to
1.21 ± 0.02%. The powder was then defatted using three 30-min extractions with hexane at a powder
to hexane ratio of 1:5 w/v. The resulting slurry was suction filtered and the residue (defatted meal)
was air-dried for 12 h and stored in a desiccator at ambient room temperature until used. The moisture
content of the defatted powder, measured using a Shimadzu MOC63u moisture analyser (Rydalmere,
NSW, Australia), was 8.61 ± 0.15%.
2.2. Methods
2.2.1. Extraction
Based on a previous study [34], six solvents (deionised water, 100% methanol, 50% methanol in
water, 100% ethanol, 70% ethanol in water, and 90% n-butanol in water), were used for the extraction
of bioactive compounds from the defatted and dried Gac seed kernel powder. Twenty grams of
the powder were added to 400 mL of each solvent and the suspension was kept under constant
magnetic stirring for 30 min at 40 ± 1 ◦C. Following extraction, the mixtures were filtered through
two layers of cheese cloth and then through a Whatman No. 1 filter paper (Thermo Fisher Scientific,
North Ryde, NSW, Australia), and the clear filtrates were collected in 500 mL evaporating flasks.
Triplicate extractions were done for each solvent.
2.2.2. Freeze Drying Extracts
The filtrates collected from the extractions were freeze-dried into powders as summarized in
Figure 1. First, the liquid extracts were concentrated using a rotary evaporator (Buchi Rotavapor B480,
Buchi Australia, Noble Park, VIC, Australia) at 40 ◦C under vacuum until thick but not completely
dried in the 500 mL evaporating flasks. Then, to transfer the extracts into pre-weighed 100 mL
35
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evaporating flasks, three different solvents were used. For each of the butanol, methanol, and 50%
methanol extracts, 50 mL of 50% methanol in water was used, for each of the ethanol and 70% ethanol
extracts, 50 mL of 50% ethanol in water was used, and for the water extract, 30 mL of water was
used. The suspensions were mixed well, and the evaporation resumed until around 20 mL of the
concentrated extracts were left. The concentrates were then frozen using liquid nitrogen before freeze
drying with a BenchTop Pro freeze dryer (Scitek, Lane Cove, NSW, Australia) at −60 ◦C and 30 mbar
for 48 h. The flasks with residue were placed in a desiccator and quickly weighed. The difference in
weight between the flasks with residue and the empty flasks was taken to be the mass recovered for
each extract. These freeze dried (FD) crude extracts were then stored in air-tight containers at −20 ◦C
for use within 3 months.
Figure 1. Procedure for producing freeze dried (FD) crude extracts from defatted Gac seed kernel powder.
2.2.3. Determination of Extractable Yield
To determine the extractable yield, 10 mL of each filtered liquid extract, resulting from Section 2.2.1,
was transferred into a tared flat-bottomed glass vial and then dried at 105 ◦C with a vacuum pressure of
60 kPa for 24 h in a vacuum oven (Thermoline, Wetherill Park, NSW, Australia) until a constant weight
was achieved. These vials were cooled in a desiccator for 30 min and weighed. The extractable yield
was calculated, in g dried extract per 100 g of dried defatted Gac seed kernel powder, using Equation (1),
where EY was the extractable yield, DE (g) was the mass of dried extract after the vacuum oven drying,
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40 was the ratio of the 10 mL used for the vacuum oven drying to the 400 mL originally used for the
extract, and DS (g) was the mass of dried defatted Gac seed kernel powder used for the extraction.




2.2.4. Determination of Dry Mass Yield
Dry mass yield was defined as the amount (g) of FD crude extract, produced as described in
Section 2.2.2, per 100 g of dried defatted Gac seed kernel powder. Equation (2) was used to calculate
the dry mass yield (DM), in which FD (g) was the weight of the FD crude extract, DS (g) was the mass
of dried defatted Gac seed kernel powder used for the extraction, and V was the volume of the filtrate
collected after extraction.
DM (g/100 g) =
FD × V/(V − 10)
DS
× 100 (2)
2.2.5. Determination of Trypsin Inhibitor Activity (TIA)
The TIA assay was performed as described by Makkar et al. [35] except that the absorbance was
measured at 385 nm, as suggested by Stauffer [36], instead of at 410 nm.
Reagent Preparation
Substrate solution: A substrate solution of 92 mM BAPNA was prepared as follows. First, 40.0 mg
BAPNA was dissolved in 1.00 mL DMSO and diluted to 100 mL with 0.05 M Tris-buffer (pH 8.2)
containing 0.02 M CaCl2 pre-warmed to 37 ◦C. This solution was prepared daily and kept at 37 ◦C
while in use.
Trypsin solution: 20.0 mg of trypsin (type I) from bovine pancreas was dissolved in 1 mM HCl to make
1 L and stored at 4 ◦C for use within a week. In the analytical procedure with 92 mM BAPNA, this solution
gave an absorbance value in the range of 0.900 ± 0.010 after subtracting the reagent blank at 385 nm.
Determination of TIA
Each FD crude extract from Section 2.2.2 (Figure 1) was dissolved in water at a concentration to
give an inhibition of Trypsin between 40% and 60% and the assay was setup as shown in Table 1 with
four test tubes prepared for each FD crude extract. All the prepared test tubes were kept in a water
bath at 37 ◦C for 10 min to promote the formation of an enzyme–inhibitor complex and then 5.0 mL of
BAPNA solution, pre-warmed to 37 ◦C, was added into each tube and the tubes were incubated in a
water bath at 37 ◦C for 10 min. One mL of 30% acetic acid solution was added to each tube to stop the
reaction. Then, 2.0 mL of trypsin solution was added into each reagent and sample blank (Table 1).
After thorough mixing, the absorbance of the reaction mixture due to the release of p–nitroaniline was
measured at 385 nm.
Table 1. The trypsin inhibitor activity assay setup.
Component Reagent Blank (a) Standard (b) Sample Blank (c) Sample (d)
Deionised water (mL) 2 2 1 1
Trypsin solution (mL) - 2 - 2
Diluted extract (mL) - - 1 1
BAPNA (mL) 5 5 5 5
Acetic acid (mL) 1 1 1 1
Trypsin solution after
reaction inactivation (mL) 2 - 2 -
BAPNA (benzyl-DL-arginine-para-nitroanilide) was added to start the reaction and acetic acid for inactivation.
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Calculation
The change in absorbance (AI) due to the trypsin inhibitor per mL of diluted extract was
(Ab − Aa) − (Ad − Ac), where the subscripts referred to tubes (a) to (d) in Table 1. Since 1 μg of trypsin
gave an absorbance of 0.0190, the weight of trypsin inhibited per mL of extract was AI/0.019 μg.
From this value, The TIA of the FD crude extracts was calculated using Equation (3) and expressed as
mg of pure trypsin inhibited per mg of FD crude extract.
TIA =
AI





AI: Change in absorbance due to inhibition per 1 mL of extract;
AI = (Ab – Aa) – (Ad – Ac), subscripts as per Table 1;
S: Weight (mg) of the FD crude extract dissolved in 1 mL;
m%: Moisture content of the FD crude extract powder.
2.2.6. Determination of Total Saponin Content (TSC)
The FD crude extracts from Section 2.2.2 were dissolved in water at a concentration of 2 mg/mL
and vortexed before the TSC was determined according to Tan et al. [37] with some modifications.
Briefly, 0.25 mL of each extract was mixed with 0.25 mL of 8% (w/v) vanillin solution and 2.5 mL of
72% (v/v) sulphuric acid. The mixture was vortexed and incubated in a water bath at 60 ◦C for 15 min
and then cooled on ice for 10 min. The absorption of the mixture was measured at 560 nm using a Cary
60 UV-Vis spectrophotometer (Agilent Technologies, Mulgrave, VIC, Australia). Aecsin was used as
a standard and the results were expressed as milligram aecsin equivalents (AE) per gram of the FD
crude extract powder (mg AE/g).
2.2.7. Determination of Total Phenolic Content (TPC)
The FD crude extracts from Section 2.2.2 were dissolved in water at a concentration of 2 mg/mL
and vortexed before the TPC was determined according to the method of Tan et al. [38] with some
modifications. Briefly, 0.5 mL of each extract was mixed with 2.5 mL of 10% (v/v) Folin–Ciocalteu
reagent in water and incubated at room temperature for 2 min to equilibrate. Then, 2 mL of 7.5% (w/v)
sodium carbonate solution in water was added and the mixture was incubated at ambient temperature
for 1 h. The absorption of the reaction mixture was measured at 765 nm using a Cary 60 UV-Vis
spectrophotometer. Gallic acid was used as a standard and the results were expressed as milligram
gallic acid equivalents (GAE) per gram dry weight of the FD crude extract powder (mg GAE/g).
2.2.8. Determination of Antioxidant Capacity
The FD crude extracts from Section 2.2.2 were dissolved in water at the concentration of 2 mg/mL and
mixed before analysing antioxidant capacity using three assays: the 2,2’-azino-bis(3-ethylbenzothiazoline-
6-sulfonic acid) diammonium salt (ABTS), the 2,2-diphenyl-1-picrylhydrazyl (DPPH) and the ferric
reducing antioxidant power (FRAP).
DPPH
The DPPH assay measures the total free radical scavenging capacity of the extracts. The assay
was performed as described by Tan et al. [38]. A stock solution of 0.6 M DPPH in methanol was
prepared and kept at −20 ◦C until use. The working solution was prepared by mixing 10 mL of
stock solution with 45 mL of methanol to obtain an absorbance of 1.1 ± 0.02 units at 515 nm using a
spectrophotometer. Each extract (0.15 mL) was mixed with 2.85 mL of the working solution and the
mixture was allowed to stand for 3 h, after which the absorption was measured at 515 nm using a
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Cary 60 UV-Vis spectrophotometer. Trolox was used as a standard and the results were expressed as
milligram Trolox equivalents (TE) per gram of the FD crude extract powder (mg TE/g).
ABTS
The ABTS assay measures the total free radical scavenging capacity of the extracts. The assay
was performed as described by Tan et al. [38] with slight modifications. Stock solutions of 7.4 mM
ABTS and 2.6 mM potassium persulfate were freshly prepared or kept at 4 ◦C in a dark bottle for use
within a month, respectively. A fresh working solution was prepared for each assay by mixing equal
quantities of the two stock solutions and incubated for 15 h to 16 h in the dark at ambient temperature.
Then, 1 mL of the working solution was diluted with approximately 30 mL of methanol to obtain
an absorbance of 1.1 ± 0.02 units at 734 nm using a Cary 60 UV-Vis spectrophotometer. Each extract
(0.15 mL) was mixed with 2.85 mL of the working solution and the mixture was incubated for 2 h in the
dark at ambient temperature. The absorption of the reaction mixture was measured at 734 nm using a
Cary 60 UV-Vis spectrophotometer. Trolox was used as a standard and the results were expressed as
milligram Trolox equivalents (TE) per gram of the FD crude extract powder (mg TE/g).
FRAP
The FRAP assay measures the ferric reducing power. The assay was performed following the
method of Thaipong et al. [39], based on the increase in absorbance at 593 nm. A fresh FRAP working
solution was initially prepared by mixing 300 mM acetate buffer (pH 3.6), 10 mM iron reagent (TPTZ)
in 40 mM HCl, and 20 mM FeCl3•6H2O in the ratio of 10:1:1 (v/v/v). The fresh working solution
was warmed to 37 ◦C before using. Each extract (0.15 mL) was mixed with 2.85 mL of the working
FRAP solution and the mixture was incubated at ambient temperature in the dark for 30 min before
its absorbance was measured at 593 nm using a Cary 60 UV-Vis spectrophotometer. Trolox was used
as a standard and the antioxidant capacity of each sample, based on its ability to reduce ferric ions,
was expressed as milligram Trolox equivalents (TE) per gram of the FD crude extract powder (mg TE/g).
2.2.9. Determination of Cytotoxicity
Cell Lines and Culture
The human melanoma MM418C1 (C1, wild type BRAF oncogene) and D24 (mutated BRAF
oncogene) cell lines were maintained in RPMI-1640 media supplemented with 10% (v/v) FBS,
1% (v/v) streptomycin and penicillin at 37 ◦C in 5% CO2. HaCat keratinocytes were used as normal
untransformed cells and grown in the same media.
In Vitro Cytotoxicity Assay
All cells were seeded in 96 well plates (Greiner Bio-One, Labfriend, Sydney, NSW, Australia),
5000 cells/well along with 100 μL of fresh media. The FD crude extracts from Section 2.2.2 were
dissolved in RPMI-1640 cell culture media at a concentration of 2 mg/mL and UV-sterilised for 10 min
in a laminar flow hood before use on cells. The cells were allowed to attach for 4 h before being treated
with 10 μL of the extract and incubated for 48 h.
The effect of the extracts on cell growth was determined using the CCK-8 (Cell Counting
Kit-8) assay (Sigma-Aldrich, St Louis, MO, USA). The assay measured cytotoxicity based
on the conversion of a water-soluble tetrazolium salt, 2-(2-methoxy-4-nitrophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt (WST-8), to a water-soluble
formazan dye upon reduction by dehydrogenases in the presence of an electron carrier [40].
To determine cell viability, 10 μL of CCK-8 solution was added to each well of the 96-well
plate containing treated and control samples. The plates were incubated at 37 ◦C for 2 h and the
absorbance was measured spectrophotometrically at 450 nm using a CLARIOstar® High Performance
Monochromator Multimode Microplate Reader (BMG LABTECH, Mornington, NSW, Australia) and
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the results were analysed using the MARS data analysis software (version 3.00R2, BMG LABTECH,
Mornington, NSW, Australia). The data were presented as a proportional viability (%) by comparing
the treated cells with the untreated cells (control) using Equation (4):
Cell viability =
At − Ab
Ac − Ab × 100 (4)
where At was the absorbance value of the treated cells, Ab was the absorbance of CCK-8 only, and Ac
was the negative control which included cells and CCK-8 only. Two types of controls were used:
the media control consisted of cultured cells in 10% (v/v) FBS containing medium alone and the vehicle
control consisted of cells in 10% (v/v) FBS containing medium, to which 10 μL of RPMI-1640 media
without FBS was added. However, as both controls did not cause cytotoxicity, the media control was
used to calculate cell viability.
Cell morphology was analysed at 48 h using a Nikon Eclipse TS100 (Nikon, Tokyo, Japan) phase
contrast inverted microscope and the images were captured using a Nikon DS-Fi1digital camera.
2.2.10. Statistical Analyses
Extractions were performed in triplicate and means ± standard deviation (SD) were assessed
with the one-way Analysis of Variance (ANOVA) and Tukey’s Post Hoc Multiple Comparisons test
using the IBM SPSS Statistics 24 program (IBM Corp., Armonk, NY, USA). Differences in means were
considered statistically significant at p < 0.05. Correlations and their significance were determined
using the Microsoft Excel 2016 (Microsoft Corp., Seattle, WA, USA) and Principle Component Analysis
(Minitab 17.1.0, Sydney, NSW, Australia).
3. Results
3.1. Effect of Solvent on the Extractable Yield and the Dry Mass Yield
Extractable yield and dry mass yield were calculated for each extract. The extractable yields
ranged from 4.4 g/100 g for the ethanol extract to 15.5 g/100 g for the aqueous extract while the dry
mass yield ranged from 3.7 g/100 g for the ethanol extract to 13.1 g/100 g for the aqueous extract
(Table 2). For both the extractable yield and the dry mass yield, the values were substantially higher
for the aqueous extracts than for the organic solvents, whether they were mixed with water or not.
Furthermore, the extractable yield (before drying) was higher than the dry mass yield (after freeze
drying) for all extracts. The observed loss during the drying process was highest for the 70% ethanol
extract (−31%) followed by the methanol extract (−28%) and the butanol extract (−20%). The aqueous
and ethanol extracts had the same loss (−15%), while the lowest lost was for the 50% methanol extract
(−11%).
Table 2. Effect of solvent on the extractable yield (EY) and the dry mass yield (DM).






Water 15.5 ± 0.1 a 13.1 ± 0.1 b 400 ± 3 355 ± 0 15.3 ± 0.1 d
50% Methanol 10.2 ± 0.0 c 9.1 ± 0.3 d 400 ± 3 348 ± 3 10.9 ± 0.2 f
70% Ethanol 10.2 ± 0.0 c 7.1 ± 0.4 e 400 ± 3 340 ± 5 30.6 ± 0.3 a
90% Butanol 6.9 ± 0.1 e 5.5 ± 0.1 f 400 ± 3 350 ± 0 19.9 ± 0.1 c
Methanol 6.7 ± 0.2 e 4.8 ± 0.2 g 400 ± 3 330 ± 0 27.8 ± 0.2 b
Ethanol 4.4 ± 0.0 g 3.7 ± 0.0 h 400 ± 3 345 ± 0 14.9 ± 0.0 e
The values were the means ± SD of three replicate extractions for each solvent. All the values for EY and DM were
compared to each other, the values for yield loss were compared separately and the values not sharing the same
superscript letter for EY and DM, and separately for yield loss, were significantly different at p < 0.05.
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3.2. Effect of Solvents on the Content of Bioactive Compounds
3.2.1. Trypsin Inhibitors
The yield of trypsin inhibitors was measured as the trypsin inhibitor activity (TIA) of the FD
crude extracts (Figure 2). The water extract had the highest TIA (581.4 mg/mg) and the yield decreased
relative to the concentration of water in the water and low alcohol mixtures: −40% for the 50%
methanol (≈50% water) extract, −54% for the 70% ethanol (≈30% water) extract and −97% for the
water-saturated butanol (≈10% water) extract. The 100% methanol and 100% ethanol extracts had
much lower TIA values than the water extract, −96% and −95%, respectively (Figure 2). Therefore,




e d d 
Figure 2. Effect of solvent on the trypsin inhibitor activity (TIA) of the FD crude extracts. The values
are the means ± SD of three replicate extractions for each solvent. Columns not sharing the same letter
are significantly different at p < 0.05.
3.2.2. Saponins
The yield of saponins was measured as the total saponin content (TSC) of the FD crude extracts
(Figure 3). The highest TSC was found in the butanol and methanol extracts, which were 24% higher
than the TSC in the 50% methanol and 70% ethanol extracts, 48% higher than the ethanol extract,
and 53% higher than the water extract. Therefore, butanol and methanol were the best solvents for






Figure 3. Effect of solvent on the total saponin content (TSC) extraction from Gac seed. The values
were the means ± SD of three replicate extractions for each solvent. Columns not sharing the same
letter were significantly different at p < 0.05.
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3.2.3. Phenolics
The yield of phenolics was measured as the total phenolic content (TPC) of the FD crude extracts
(Figure 4). The highest TPC was found in the butanol extract; the TPC in this extract was 13% higher
than the water extract, 29% higher than the 50% methanol and 70% ethanol extracts, 35% higher than
the methanol extract, and 63% higher than the ethanol extract. Therefore, butanol extracted the highest






Figure 4. Effect of solvent on the total phenolic content (TPC) of the FD Gac seed crude extracts.
The values were the means ± SD of three replicate extractions for each solvent. Columns not sharing
the same letter were significantly different at p < 0.05. GAE, Gallic acid equivalents.
3.3. Effect of Solvents on Antioxidant Activity
The antioxidant activity of the extracts was measured using three assays: DPPH, ABTS, and FRAP.
The butanol extract gave the highest values for ABTS and DPPH assays and the ethanol extract gave the
highest value for FRAP assay (Figure 5). These two extracts produced significantly higher antioxidant















Figure 5. Effect of solvent on the antioxidant capacity of the FD crude extracts. The values were
the means ± SD of three replicate extractions for each solvent. Columns not sharing the same
superscript letter were significantly different at p < 0.05. * indicated the highest antioxidant activity.
TE, Trolox equivalents.
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3.4. Effect of Extraction Solvent on Cancer Cell Viability
The FD crude extracts were tested for cell toxicity using two melanoma cell lines (D24 and C1) and
a normal keratinocyte line (HaCat). The water extract was the most cytotoxic towards both cancer cell
lines compared to the other extracts (Figure 6); the extract decreased the cell viability by 67% for D24
and 75% for C1 melanoma cells. The 70% ethanol and 50% methanol extracts also showed cytotoxic
activity towards the C1 melanoma cells, decreasing their viability by 69% and 46%, respectively,
while the butanol, methanol, and ethanol extracts had no effect. Besides the water extract, no other FD
crude extract had any effect on the viability of the D24 melanoma cells.
In contrast, all the FD crude extracts decreased the cell viability for the normal keratinocytes
(HaCat). Except for the ethanol extract, which only decreased the HaCat cell viability by 24%, all the
extracts reduced the viability by between 64% (water) and 75% (methanol).
abcd 
abcd 
Figure 6. Effect of the FD crude extracts prepared with the different solvents on the cell viability of
normal (HaCat) and melanoma (D24 and C1) cell lines after 48 h treatment. The values were the
means ± SD of three replicate extractions for each solvent. Columns not sharing the same letter were
significantly different at p < 0.05.
These results were consistent with the cellular changes observed using a phase contrast
microscope. As seen in Figure 7, the control untreated HaCat keratinocytes were firmly attached with
flattened oblong shapes (Figure 7A), the D24 melanoma cells were lightly attached with advanced
elongations (Figure 7B), and the C1 melanoma cells were firmly attached and tightly packed with
elongated processes (Figure 7C). In comparison to the untreated cells (Figure 7A–C), exposure of
the cells to the various Gac seed extracts induced typical changes of cell death, such as cytoplasmic
condensation, detached cells (red arrows in Figure 7), and cell disruption, to form apoptotic bodies
(blue arrows in Figure 7).
The cellular changes observed with the water extract (Figure 7D–F) were consistent with the
viability results (Figure 6) in that signs of morphological changes were seen for all three cell types.
The 50% methanol and 70% ethanol extracts also caused substantial morphological changes to the C1
melanoma cells (Figure 7I,L) and HaCat cells (Figure 7G,J). The butanol and methanol extracts also
caused substantial morphological changes to the HaCat cells (Figure 7M,P). In contrast, the ethanol
extract had the least effect on the morphology of all three cells (Figure 7S–U) akin to controls.
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Figure 7. Morphological effects of different extraction solvents of Gac seed on HaCat (control) and
melanoma D24 and C1 cell lines observed under a phase contrast microscope after 48 h treatment.
Cytotoxicity is indicated by red arrows pointed to condensation and detached cells; blue arrows pointed
to apoptotic bodies. Magnification: 100×.
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The most sensitive cells were HaCat keratinocytes, while the least sensitive were the D24
melanoma cells, which had the least morphological changes when treated with all the solvent extracts,
except for the water extract (Figure 7).
3.5. Correlations between Extract Yields, Bioactive Compounds, Antioxidant Activity, and Cancer Cell Viability
across the FD Crude Extracts
TIA of the extracts was strongly and positively correlated with the extractable yield and the dry
mass yield (Table 3, Figure 8). Essentially, the more material extracted, the higher the TIA, with the
water extract having the highest values for both. TIA and extracted yields were also negatively
correlated with the FRAP antioxidant activity and the viability of the C1 melanoma cells (Table 3,
Figure 8). For example, almost 85% (r2) of the variability in the C1 cell viability could be explained
by variability in the TIA. In contrast, the C1 cell viability was positively correlated with the FRAP
antioxidant activity. Therefore, the negative effect of the water extract on the C1 cell viability may be
related to its high TIA but not FRAP activity.
Table 3. Coefficient of correlations (r) between yields, bioactive compounds, antioxidant activity,
and cell viability across the Gac seed crude extracts.
Yield Bioactive Compound Antioxidant Activity Cell Viability
EY DMY TIA TSC TPC ABTS DPPH FRAP HaCat D24 C1
EY 1.00
DMY 0.98 † 1.00
TIA 0.96 ‡ 0.97 ‡ 1.00
TSC −0.42 −0.50 −0.61 1.00
TPC 0.51 0.49 0.31 0.36 1.00
ABTS 0.48 0.43 0.29 0.44 0.97 † 1.00
DPPH −0.52 −0.58 −0.66 0.81 § 0.37 0.46 1.00
FRAP −0.93 ‡ −0.89 § −0.88 § 0.19 −0.48 −0.50 0.44 1.00
HaCat −0.42 −0.35 −0.22 −0.63 −0.73 −0.78 −0.28 0.63 1.00
D24 −0.79 −0.80 −0.77 0.65 −0.28 −0.13 0.69 0.56 −0.01 1.00
C1 −0.88 § −0.83 § −0.92 § 0.53 −0.23 −0.26 0.50 0.83 § 0.18 0.61 1.00
† p < 0.001, ‡ p < 0.01, § p < 0.05, EY: Extraction yield; DMY: Dry mass yield; TIA: Trypsin inhibitor activity;
TSC: Total saponin content; TPC: Total phenolic content; ABTS: 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic
acid) assay; DPPH: 2,2-diphenyl-1-picrylhydrazyl assay; FRAP: ferric reducing antioxidant power assay.
Figure 8. Correlations between extraction yields (red lines), bioactive compounds (blue lines),
antioxidant activity (green lines), and cell viability (black lines) from Gac seed crude extracts.
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There were positive correlations between the TSC with DPPH antioxidant activity, and TPC with
ABTS antioxidant activity (Table 3, Figure 8). However, there were no significant correlations between
these bioactive compounds and any other variables, including the effects of the extracts on cytotoxicity
for both C1 and D24 cancer cells (Table 3, Figure 8). Furthermore, there were no other significant
correlations between any of the other measured parameters.
4. Discussion
Gac seeds have long been used in traditional medicine as a remedy for numerous conditions.
Several bioactive constituents have been identified in Gac seeds, such as trypsin inhibitors, saponins,
and phenolics. In this study, the extraction of these bioactive constituents with different solvents was
investigated and their relationships with antioxidant activity and anticancer potential were explored.
The results revealed that the water extract had the highest anticancer potential, which may be related
to its high content of trypsin inhibitors but not to its antioxidant activity.
The water extract from defatted Gac seeds had the highest anticancer potential, reducing the
growth of the melanoma cells compared to the control. This is consistent with the finding that
a water extract from Gac seeds was the best extract for supressing the migration and invasion of
a breast cancer cell line [18]. Water extracts from Gac aril have also been shown to suppress the
viability of colon, liver [17], and melanoma [41] cancer cell lines. Compared to the previous study [17],
where the Gac aril water extract at 1.24 mg/mL inhibited colon and liver cancer cells by 38 and 45%,
respectively, in the present study, the water extract at the much lower concentration of 0.2 mg/mL
had a significantly higher anticancer activity of 67% and 75% for the D24 and C1 melanoma cells,
respectively. This suggests that water is not only safe and inexpensive, but it is also a highly efficient
solvent for extracting compounds with anticancer potential from Gac, especially Gac seeds. The use of
water as the extraction solvent also means that the methodology is widely accessible to more people,
particularly in rural and underdeveloped countries that do not have access to organic solvents and
processing facilities.
The water extract also had the highest TIA value, which was likely due to the presence of trypsin
inhibitor proteins because Gac seeds are known to contain trypsin inhibitor peptides that are soluble
in buffered aqueous solvents [31,33,42]. The strong inverse correlation between TIA and the viability
of the C1 melanoma cells also suggests that trypsin inhibitors were involved in the water extract’s
anticancer potential against these cells. The known Gac seed trypsin inhibitors have a low molecular
weight of 3–4 kDa with a compact cyclic conformation [6,21], which can make it easy for them to
penetrate into cancer cells and illicit cytotoxicity [43]. However, this is also consistent with the known
anticancer potential of bigger proteins from Gac aril (35 kDa) [17] and other seeds, such as soybeans [44],
which has been studied extensively [26,45–47].
However, although the water extract was the only extract to decrease the viability of the D24
melanoma cells, an inverse correlation between TIA and the viability of the D24 cells was not seen
(p = 0.07) mainly because the 50% methanol and the 70% ethanol extracts had no activity against this
cell line while they had activity against the C1 melanoma cell line. This could be due to the D24 cells,
which have a mutated BRAF oncogene, being more resistant [48] to the presence of trypsin inhibitors,
and therefore, they could only be killed when the trypsin inhibitors reach a high enough concentration,
for example, in the water extract compared to the lower concentrations in the other extracts. However,
it could also be that the D24 cells, and maybe also the C1 cells, were affected by other water soluble
constituents of the Gac seeds, for example cyclotides which do not have trypsin inhibition activity [6].
For example, although many Gac seed trypsin inhibitors are cyclotides, MCoCC-1, a 3.3 kDa cyclotide
unique to Gac seeds, which does not have trypsin inhibitor activity, has been shown to exhibit high
cytotoxicity against the human melanoma MM96L cell line [6]; cell survival was decreased 43% in
the presence of 2 μM MCoCC-1. The TIA is a measure of trypsin inhibitors, which may be cyclotides
because they are found in Gac seeds [21], but other cyclotides are also present in Gac seeds that are
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purported to have anticancer potential [6,22]; however, these may not have antitrypsin activity and
therefore would not be measured by the TIA.
The higher antioxidant activity of the butanol extract was likely due to its high content of
saponin and phenolic compounds; this solvent had the highest TSC and TPC values among the
extracts. There were strong positive correlations between saponins with DPPH antioxidant activity
and phenolics with ABTS antioxidant activity, but neither saponins nor phenolic compounds were
related to the FRAP antioxidant activity. Therefore, the extracted Gac seed saponins and phenolic
compounds acted as antioxidants through the mechanism of scavenging the free radicals produced
by DPPH and ABTS [39] rather than the reduction of oxidised intermediates in the FRAP chain
reaction or through chelation [39]. A similar correlation was also reported by Chan et al. [49] for
saponins and phenolic compounds extracted from defatted kenaf seeds. In that study, butanol was
the most effective solvent for the extraction of saponins and phenolics. This solvent was non-polar
enough to dissolve the saponin aglycones [50] and the phenolic rings [11], yet polar enough to also
interact with the carbohydrate end of the saponin molecules and the carboxyl groups of gallic acid
and p-hydroxybenzoic acid, which are reported to be present in Gac seeds [11]. Because butanol
is classified by the FDA as a Class 3 solvent [51] with no known human hazards and approved for
pharmaceutical applications, the use of it as an extraction solvent is regarded as less toxic and of low
risk to human health.
Despite the high saponins, phenolics, and antioxidant activity of the butanol extract, it did
not exhibit any anticancer potential against the two melanoma cell lines. This observation was not
consistent with previous findings, which showed that one of the triterpenoid compounds found
in Gac seed oil, karounidiol [20], had anticancer potential [19] and tumor inhibition effects [52].
This compound, likely a saponin, may not have been at a high enough concentration in the present
extracts because the Gac seed kernels were defatted before they were extracted with the various
solvents, which was consistent with a study by Le et al. [53], who found that Gac seed saponins were
mainly associated with the fat component of the seeds.
5. Conclusions
Gac seeds, which are mostly considered as a waste product, could be a potentially useful source
of anticancer candidates due to their cytotoxic activity against specific melanoma cells. The utilisation
of Gac seeds to produce an anticancer product could reduce the waste burden on the environment
and add value to the Gac fruit, which is cultivated in an increasing number of countries. This study
found that water is suitable for the recovery of trypsin inhibitors and the preparation of an extract
with significant anticancer potential. Butanol was found to be suitable to produce an extract enriched
in saponins and phenolic compounds and with a high antioxidant activity. However, further studies
are needed to fully understand what specific compounds are involved in the bioactivity of Gac seeds
and their mechanism of action in order to better define their potential applications in the nutraceutical
and pharmaceutical industries.
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Abstract: Numerous studies support the potent anticancer activity of resveratrol and its regulation
of key oncogenic signaling pathways. Additionally, the activation of sirtuin 1, a deacetylase,
by resveratrol has been known for many years, making resveratrol perhaps one of the earliest
nutraceuticals with associated epigenetic activity. Such epigenetic regulation by resveratrol, and the
mechanism thereof, has attracted much attention in the past decade. Focusing on methylation and
acetylation, the two classical epigenetic regulations, we showcase the potential of resveratrol as an
effective anticancer agent by virtue of its ability to induce differential epigenetic changes. We discuss
the de-repression of tumor suppressors such as BRCA-1, nuclear factor erythroid 2-related factor 2
(NRF2) and Ras Associated Domain family-1α (RASSF-1α) by methylation, PAX1 by acetylation and
the phosphatase and tensin homologue (PTEN) by both methylation and acetylation, in addition to the
epigenetic regulation of oncogenic NF-κB and STAT3 signaling by resveratrol. Further, we evaluate
the literature supporting the potentiation of HDAC inhibitors and the inhibition of DNMTs by
resveratrol in different human cancers. This discussion underlines a robust epigenetic activity of
resveratrol that warrants further evaluation, particularly in clinical settings.
Keywords: resveratrol; epigenetic; methylation; acetylation
1. Introduction
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) (Figure 1) is a naturally occurring polyphenol
found in peanuts and the skin of grapes and berries. It is a phytoalexin produced in response to
injury, ultraviolet radiation or a pathogen attack. The initial interest in resveratrol was because
of its antioxidant properties [1], which led to the recognition of its chemopreventive ability [2].
Resveratrol was also found to generate reactive oxygen species, leading to effective anticancer
activity through a prooxidant mechanism [3,4] which also happens to be a hallmark of several other
polyphenols [5–7]. It is now believed that resveratrol exhibits both antioxidant and prooxidant
properties [8–10], which depend largely on the tumor microenvironment and the presence of transition
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metal ions, particularly copper ions. Besides its anticancer properties, resveratrol has also been
investigated to explain the ‘French paradox’ [11], a phenomenon of the relatively low incidence of
coronary heart diseases in the French population despite a diet rich in saturated fats, perhaps due to
the consumption of red wine with high resveratrol content.
Figure 1. Chemical structure of resveratrol.
The realization of the potent anticancer properties of resveratrol was followed by numerous
investigations into the various signaling pathways that it affects, leading to the observed effects [12–17].
In recent years, the focus of cancer research has shifted to stem cells, epithelial-to-mesenchymal
transition (EMT) and epigenetic regulation, even in the context of lead compounds such as resveratrol
that have a natural origin. Accordingly, a number of studies have documented the ability of resveratrol
to affect stem cell populations [18,19] and EMT [20,21]. This article focuses on epigenetic regulation by
resveratrol, which is increasingly being proposed as contributing to its anticancer properties.
2. Epigenetic Regulation by Resveratrol
Even though ‘epigenetics’ was originally intended to define heritable changes in phenotypes
that were independent of changes in the DNA sequence, the meaning of this word has now
considerably broadened to describe the alterations in human chromatin that influence DNA-templated
processes [22,23]. Epigenetic changes do not result in any changes in the DNA sequence, but can still
have lasting effects on gene expression. Epigenetic changes involve at least four known modifications
of DNA and sixteen classes of histone modifications [22–24].
A number of studies have recognized the effects of nutraceuticals, including polyphenol
resveratrol, on the epigenetic machinery in humans [25–35]. Resveratrol can modulate epigenetic
patterns by altering the levels of S-adenosylmethionine and S-adenosylhomocysteine or by directing
the enzymes that catalyze DNA methylation and histone modifications [27]. It also activates the
deacetylase sirtuin and regulates oncogenic and tumor suppressor micro-RNAs [36]. Methylation and
acetylation are two classical epigenetic modifications, and these will be the subject of our discussion in
this article as we showcase the epigenetic basis of the anticancer action of resveratrol.
3. Methylation
The DNA methylation of gene promoters has a profound effect on their eventual expression and
function. Differential DNA methylation can lead to a disease condition in healthy phenotypes. This is
particularly true for cancer wherein the differential DNA methylation of the promoters of oncogenes
and tumor suppressor genes helps maintain a delicate balance. The increased (hyper) methylation
of promoter CpG islands causes gene silencing, while the decreased (hypo) methylation of promoter
CpG islands leads to the expression of the gene.
3.1. Breast Cancer
Breast cancer is a widely studied cancer when it comes to epigenetic regulation, particularly
differential methylation, by resveratrol. Studies have been conducted to elucidate the genome-wide
methylation patterns after resveratrol treatment, and there have also been efforts to understand the
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epigenetic basis of the de-repression of tumor suppressors by resveratrol. The subsection to follow
will focus on this activity of resveratrol.
3.1.1. Genome-Wide Analyses
A study on the genome-wide methylation-modifying effects of resveratrol, which involved
exposing MCF10CA1h and MCF10CA1a cells to resveratrol for 9 days followed by Illumina 450K
array analysis, revealed a profound effect of resveratrol on genome-wide DNA methylation with
approximately 75% differentially methylated genes being hypermethylated [37]. This study evaluated
the epigenetic activity of not only resveratrol but also pterostilbene, an analog of resveratrol.
While treatment with resveratrol was done at a dose of 15 μM, pterostilbene treatment was at a
7 μM dose. The compounds targeted genes that are over-expressed in tumors because of DNA
hypomethylation. Since increased DNA methylation results in the silencing of genes, it makes sense
that the resveratrol-induced hypermethylated genes have predominantly oncogenic functions [37],
such as the Notch signaling pathway. However, in another study that also looked at genome-wide
DNA methylation after resveratrol treatment (in this case, 24 h and 48 h treatment), only about
12.5% of CpG loci were found to be differentially methylated by resveratrol [38]. This study used
MDA-MB-231 breast cancer cells and the concentration of resveratrol was 100 μM. Additionally, this
study predominantly found DNA hypomethylation by resveratrol. It is possible that the differences
in genome-wide DNA methylation (75% vs. 12.5%) in these two studies might be reflective of the
different experimental setups, in particular, the time-durations of the resveratrol treatment as well as
the doses used, with longer treatment leading to substantially more methylation.
3.1.2. Effects on Tumor Suppressors
Tumor suppressor genes are typically inactivated at the onset of tumorigenesis and, therefore,
their reactivation by anticancer therapy is a mechanism through which tumor progression can be
controlled. Several studies have documented the epigenetic reactivation of the tumor suppressor genes
by resveratrol in breast cancer (Figure 2), as discussed below.
Figure 2. Activation of tumor suppressor genes by resveratrol through promoter DNA hypomethylation.
The CpG islands in the DNA promoter regions of the tumor suppressor genes are hypermethylated
resulting in their silencing. De-methylation of these CpG islands by resveratrol results in the activation of
transcription and the eventual expression of tumor suppressor genes such as the phosphatase and tensin
homologue (PTEN), BRCA-1 and nuclear factor erythroid 2-related factor 2 (NRF2).
Phosphatase and tensin homologue (PTEN) is a well-characterized tumor suppressor in breast
cancer [39]. In one of the earlier studies describing an effect of resveratrol on promoter DNA
methylation, it was reported that resveratrol was highly efficient in reducing PTEN promoter DNA
methylation in MCF7 breast cancer cells [40]. Since reduced DNA methylation leads to gene expression,
this action of resveratrol induced the expression of PTEN which could explain its anticancer effects.
Further, it was reported that the epigenetic effects were complex as not only PTEN was induced but
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the cell cycle regulator p21 was up-regulated as well, in addition to the down-regulation of DNMT
(DNA methyltransferase). This is interesting because DNA methyltransferases increase methylation.
Thus, it appears that resveratrol is able to reduce DNA methylation possibly through two different
ways—by reducing methylation and by inducing de-methylation.
BRCA-1 (breast cancer type 1) is another tumor suppressor gene. Its expression is known to
be regulated by epigenetic mechanisms. In a study that demonstrated the effects of resveratrol on
BRCA-1 methylation [41], it was shown that exposure of breast cancer cells MCF7 to tumor promoter
TCDD (2,3,7,8 tetrachlorodibenzo-p-dioxin) resulted in the hypermethylation of BRCA-1 promoter CpG
island concomitant with an increased association of trimethylated histone H3K9 and DNMTs, namely
DNMT1, DNMT3a and DNMT3b, with BRCA-1 promoter. Resveratrol, at physiologically relevant
doses, was able to repress these TCDD effects. In a follow-up study, the research group evaluated the
effects of TCDD alone, and in combination with resveratrol, on pregnant Sprague–Dawley rats [42].
It was found that, similar to in vitro observations in MCF7 cells, gestational exposure to TCDD led
to the reduced DNA CpG island methylation of BRCA-1 promoter in the mammary tissues of the
offspring, which was preceded by the occupation of BRCA-1 promoter by DNMT-1. Also, confirming
a possible therapeutic role, resveratrol was found to partially attenuate TCDD effects [42].
Nuclear factor erythroid 2-related factor 2 (NRF2) is also a tumor suppressor that is
epigenetically regulated by resveratrol. In a study that looked at the effects of resveratrol on E2
(17β-estradiol)-induced carcinogenesis [43], resveratrol alone up-regulated NRF2 in mammary tissues
of rats, and attenuated the repressive effects of E2 on NRF2. E2 suppressed NRF2 through DNA
methylation, an activity that was inhibited by resveratrol, thus providing further evidence in support
of its regulation of promoter DNA methylation in breast cancer.
3.1.3. DNMTs as Mediators of Resveratrol Effects in Breast Cancer
There is much evidence supporting an inhibitory effect of resveratrol against DNMTs [40,41,44–46].
However, most of the evidence comes from in vitro studies. To validate these findings, a pilot study was
conducted that enrolled 39 women with increased breast cancer risk [47]. The subjects were divided into
three groups—placebo and those receiving 5 or 50 mg resveratrol. Resveratrol was administered twice
daily for twelve weeks and the focus was on the DNA methylation of four cancer-related genes—p16, Ras
Associated Domain family-1α (RASSF-1α), Adenomatous Polyposis Coli (APC) and Cyclin D2 (CCND2).
An inverse relationship between serum resveratrol levels and RASSF-1α methylation was observed, i.e.,
when resveratrol levels increased, the methylation of RASSF-1α decreased, thus leading to the expression of
this tumor suppressor gene. In another study by this group [48], an in vivo effect of resveratrol on DNMT
expression was examined in normal vs. tumor tissues. The model evaluated was ACI rats, an inbred line
derived from the August and Copenhagen strains. An interesting observation was that resveratrol affected
DNMT3b, but not DNMT1. Two different doses of resveratrol were tested and while DNMT3b differed in
normal vs. tumor tissues of rats treated with low resveratrol, a high resveratrol dose resulted in decreased
DNMT3b in tumor tissues with increased DNMT3b in the normal tissues [48]. This observation is a little
different from the one performed in vitro in immortalized breast cancer epithelial cells, MCF10A [49],
where resveratrol, at a non-cytotoxic dose, only induced subtle changes in the DNA methylation of eight
pre-determined genes. However, the involvement of DNMT3b in resveratrol activity was also identified in
a genome-wide DNA methylation study in breast cancer cells [37].
Further confirming the importance of targeting DNMTs in breast cancer patients, the elevated
expression of DNMT transcripts was reported in a study that evaluated breast cancer tissues from
40 breast cancer patients and compared those with tissues from 10 paired normal breast tissues [50].
This study further confirmed the down-regulation of DNMT transcripts in vitro in breast cancer cells.
3.2. Glioma
Glioblastoma multiforme was the other malignancy where evidence of the effect of
resveratrol on methylation was initially presented. It was shown that resveratrol could sensitize
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resistant glioblastoma T98G cells to temozolomide, inhibiting temozolomide IC-50 with
increased apoptosis [51]. Interestingly, temozolomide-resistant cells have increased MGMT
(O(6)-methylguanine-DNA-methyltransferase) activity and the protein expression of MGMT is
an important determinant of temozolomide-resistance [51]. These results are suggestive of yet another
DNA methylation-suppressing activity of resveratrol. In a recent report, inhibition of Wnt signaling
has been identified as the mechanism by which resveratrol induces cell death in T98G cells [52].
Epigenetic regulation has been identified as one of the bases of perturbed Wnt signaling [53] and it is
plausible that Wnt signaling might be another piece in the puzzle.
3.3. Lung Cancer
Lung cancer, the majority of which is non-small cell lung cancer (NSCLC), is the leading cause of
cancer-related deaths in the United States, as well as worldwide. A number of studies have described
the inhibitory effects of resveratrol against various lung cancer models [54–56], albeit, a majority of
the studies have focused on NSCLC with little information on the other lung cancer types. In recent
years, efforts have been made towards the personalized management of lung cancer [57], with a
focus on epigenetics in such personalized therapy [58]. Further, it has recently been demonstrated
that resveratrol can epigenetically regulate the expression of zinc finger protein36 (ZFP36) through
differential DNA methylation [59]. Specifically, resveratrol reduced the methylation of ZFP36, resulting
in its up-regulation in A549 NSCLC cells. A role of ZFP36 in human malignancies is increasingly being
realized, making it an attractive target for therapy [60]. Thus, its epigenetic targeting by resveratrol
further underlines the anticancer potential of resveratrol, particularly in lung cancer.
4. Acetylation
Even before the realization of the methylation potential of resveratrol, it has been known to
modulate acetylation within the cellular microenvironment. A quarter century back, resveratrol was
reported to be an activator of sirtuin-1 (SIRT1), the NAD-dependent deacetylase, marking its influence
on acetylation, and thereby epigenetic regulation [61]. While the activity of resveratrol against Class
III HDACs sirtuins is well characterized, it has been suggested that perhaps resveratrol possesses
a pan-HDAC inhibitory property and can inhibit HDACs representing class I, class II as well as
class IV [62]. Recently, resveratrol has been identified as an inhibitor of bromodomains [63] and the
bromodomain and extraterminal (BET) family [64]. Bromodomains affect epigenetic machinery by
recognizing lysine acetylation on histones, thereby functioning as epigenetic readers. The interactions
of resveratrol with bromodomains open yet another mechanism of epigenetic regulation by resveratrol
which is not yet fully explored. The next few subsections discuss the reported effects of resveratrol on
the acetylation of different genes in various human cancers.
4.1. Breast Cancer
Acetylation and its impact on breast cancer progression is well appreciated. It is because
of this knowledge that HDAC inhibitors still remain an attractive therapeutic strategy against
breast cancers [65–67]. It is not only the HDAC inhibitors but also the inhibitors of HATs (histone
acetyltransferases) that are being evaluated [68], which provides a good example of how dynamic
the process of acetylation and deacetylation is, and how an imbalance can lead to tumor onset and
progression. In a study [69] that is indicative of an intricate connection between methylation and
acetylation, the two classical epigenetic modifications, it was reported that lysine acetylation within the
signal transducer and activator of transcription 3 (STAT3) can impact the interaction of DNMT1 with
STAT3 and is accompanied by the demethylation and, thereby, the re-expression of tumor suppressor
genes. This study used resveratrol as an acetylation inhibitor and the observations in triple negative
breast cancer (TNBC) were further confirmed in melanoma. TNBCs are characterized by the absence
of the estrogen receptor (ER) and progesterone receptor (PR), as well as human epidermal growth
factor receptor 2 (HER2), and it has been reported that the absence of the ERα gene in tumor cells is
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often a result of methylation [70]. With the observation that STAT3 is acetylated and, therefore, highly
expressed in TNBCs, it was evaluated whether inhibiting STAT3 acetylation could reactivate ERα [69].
The TNBC cell line MDA-MB-468 was used as the model and it was observed that treatment with
resveratrol significantly reduced STAT3 acetylation as well as ERα gene promoter DNA methylation
(Figure 3). This resulted in the increased expression of ERα and the sensitization of otherwise resistant
cells to the ER-targeted therapy, tamoxifen. Further, growth of in vivo tumors in mice was not
significantly reduced by tamoxifen alone, as expected, but by the combinational treatment comprising
resveratrol and tamoxifen, thus validating the in vitro findings [69]. As further evidence of the effect
of resveratrol on acetylation in breast cancer, in MCF-7 breast cancer cells, resveratrol has been shown
to induce H3 acetylation [71]. Thus, there seems to be evidence suggesting a modulatory effect of
resveratrol on protein as well as histone acetylation.
Figure 3. Epigenetic regulation in triple negative breast cancers (TNBCs). TNBCs are characterized by
activated STAT3 signaling, involving acetylated STAT3. ERα signaling in TNBCs is silenced through
promoter DNA hypermethylation which might be related to STAT3 acetylation but the mechanisms
remain unclear (and are therefore shown with a dotted line). Resveratrol is an effective inhibitor of
STAT3 acetylation as well as ERα promoter DNA methylation. Restoration of ER-signaling makes
TNBC cells sensitive to the ER-targeting therapy, tamoxifen.
4.2. Cervical Cancer
In cervical cancer models, paired box gene1 (PAX1) is a tumor suppressor whose expression is
repressed during tumorigenesis by DNA hypermethylation. In a study that evaluated the effect of
nutraceuticals, including resveratrol, on the inhibition of cervical cancer through the reactivation of
PAX1, it was reported that resveratrol was capable of reactivating PAX1 expression in Caski cells [72].
However, surprisingly, the reactivation of PAX1 was not found to be due to the effect of resveratrol on
the DNA methylation of PAX1 promoter. Rather, it possibly involved the acetylation modulating ability
of resveratrol through its regulation of HDAC activity. Similar to an effect of resveratrol on histone
H3 acetylation in breast cancer cells above, resveratrol has been reported to induce H3 acetylation in HeLa
cervical cancer cells as well [71]. Such an effect of resveratrol on H3 acetylation assumes significance given
the proposed role of histone H3 acetylation as a prognostic marker for cervical cancer patients [73].
4.3. Colon Cancer
NF-κB signaling is known to be important to the progression of colon cancer [74], especially in
resistance to cisplatin [75]. An increase in the protein acetylation of the NF-κB p65 subunit leads to
the activation of the NF-κB pathway and its nuclear accumulation. Therefore, the inhibition of the
acetylation of p65 can potentially be an effective strategy to check the growth of colon cancer as well
as to overcome resistance to cisplatin. In an in vitro study performed in HK2 cells, resveratrol was
found to decrease the protein acetylation of the p65 subunit, thus reversing the cell viability-inducing
activity of cisplatin [76]. Such down-regulation of NF-κB protein acetylation by resveratrol in colorectal
cells was confirmed in another study [77] and this resulted in reduced tumor invasion and metastasis
because of the down regulation of NF-κB-regulated factors, such as MMP-9 and CXCR4.
56
Medicines 2019, 6, 24
4.4. Leukemia and Lymphoma
In leukemia, resveratrol can potentiate the activity of HDAC inhibitors [78], while in a Hodgkin
lymphoma represented by L-428 cells, resveratrol can effectively induce apoptosis as well as cell
cycle arrest [79]. As the mechanism, it was observed that resveratrol induced the tumor suppressor
p53 through an increase in the p53 K373-acetylation (Table 1). Additionally, resveratrol treatment was
found to induce the lysine acetylation of FOXO3a [79]. In leukemia U937 cells, resveratrol potentiates
reactive oxygen species production by retinoic acid, particularly the production of superoxide anions,
primarily through the up-regulation of the gp91-phox gene that is part of the membrane-bound
cytochrome b558 [80]. As a mechanism, it was elucidated that resveratrol promoted acetylation within
the promoter region of the gp91-phox gene, particularly the Lys-9 residues and Lys-14 residues of
histone H3 within the chromatin surrounding the gene promoter.
Table 1. Epigenetic effects of resveratrol on tumor suppressors: mechanisms of their re-activation.
Tumor Suppressor Cancer Type Effect of Resveratrol Reference
BRCA-1 Breast
Reduced promotor DNA methylation in vitro [36]
Reduced promotor DNA methylation in vivo [37]
NRF2 Breast Reduced promotor DNA methylation [38]
p53 Lymphoma Induced acetylation [73]
Prostate [75]
PAX1 Cervical Regulation of histone acetylation [66]
PTEN
Breast Reduced promoter DNA methylation [35]
Prostate Acetylation and activation [77]
RASSF-1α Breast Reduced DNA methylation [42]
4.5. Prostate Cancer
In prostate cancer, metastasis-associated protein 1 (MTA1) is oncogenic with its expression
correlating with tumor progression. It is itself involved in the transcriptional repression of target
genes through the post-translational modifications of histones as well as non-histones by virtue of it
being a part of the nucleosome remodeling deacetylation corepressor complex, the ‘NuRD complex’.
Resveratrol was shown to down-regulate MTA1, leading to acetylation and the activation of the
tumor suppressor p53 through the destabilization of the corepressor complex [81]. The NuRD
complex plays a role in maintaining chromatin conformation, which it achieves through the
deacetylation of histone proteins [82]. HDAC1 and HDA2 are components of the NuRD complex,
with the MTA1-HDAC1 subunit responsible for the deacetylation of histones by NuRD. With a
direct regulation of MTA1, and the observation that HDAC1 was decreased in resveratrol-treated
MTA1 immunoprecipitates, it is evident that resveratrol has a profound effect on histone acetylation.
Further, the effects of resveratrol were similar to those of the HDAC inhibitor SAHA, thus underlying
the acetylation-affecting epigenetic activity of resveratrol. The results were further confirmed in vivo
in a follow-up study [83], and it was shown that the MTA1-mediated tumor progression was, in part,
due to PTEN inactivation and that resveratrol could acetylate and reactivate PTEN [84] (Table 1).
Signaling through the androgen receptor (AR) is important in prostate cancer, even in the
advanced castrate-resistant prostate cancers. In a study that specifically looked at the regulation of AR
signaling by resveratrol, it was observed that treatment with 10 μM resveratrol for just 3 h inhibited
the acetylation of AR and affected the binding of AR to the enhancer region of prostate-specific antigen
(PSA) [85]. At a slightly longer treatment of 24 h, resveratrol inhibited the nuclear accumulation of AR
as well. Given the important role that AR plays in prostate cancer, such epigenetic regulation of its
activity and the effect on down-stream signaling by resveratrol is an encouraging finding that gives
hope for its possible use as a therapy against prostate cancer.
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5. Conclusions and Perspectives
While various cellular signaling pathways and genes (oncogenes as well as tumor suppressor
genes) are still being evaluated as therapeutic targets of anticancer agents such as resveratrol, in recent
years, attention has also turned to epigenetic regulation. In fact, epigenetic regulation of classical
signaling pathways is increasingly being realized. For example, two of the very well characterized
signaling pathways, NF-κB and STAT3, are epigenetically regulated by resveratrol [69,76,77,86].
This represents a fundamental evolution in our understanding with regards to the intricate regulation
of oncogenic pathways. Our discussion on the topic, as presented in this article, detailed many studies
that provided evidence supporting the epigenetic activity of resveratrol. However, resveratrol does
not regulate gene expression only through epigenetic mechanisms. For example, in a study in acute
lymphoblastic leukemia [87] that looked at the possible effect of resveratrol on the methylation of MDR1
(multidrug resistance gene 1), no evidence of the differential DNA methylation of MDR1 promoter by
resveratrol was found. While resveratrol had a visible suppressive effect on MDR1, there did not seem
to be any epigenetic perspective. This is a perfect reminder that not all regulation of gene expression
and function by resveratrol has an epigenetic basis. Additionally, regulation through microRNAs
(miRNAs) is within the realm of epigenetic regulation, but we decided to cover just the classical
epigenetic mechanisms with regards to methylation and acetylation so as to keep the discussion
more focused. Finally, the bioavailability of resveratrol still remains a concern, but that should not
deter us from fully elucidating its mechanism of action and its potential as a viable anticancer lead.
Several groups are working hard on improving the bioavailability through novel approaches and
once they achieve success, resveratrol should be ready for further evaluations in clinical settings as an
anticancer agent with multifaceted epigenetic activity.
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Abstract: It is estimated that over 60% of the approved drugs and new drug developments for cancer
and infectious diseases are from natural origin. The use of natural compounds as a potential source of
antitumor agents has been deeply studied in many cancer models, both in vitro and in vivo. Most of
the Western medicine studies are based on the use of highly selective pure compounds with strong
specificity for their targets such as colchicine or taxol. Nevertheless, approximately 60% of fairly
specific drugs in their initial research fail because of toxicity or ineffectiveness in late-stage preclinical
studies. Moreover, cancer is a multifaceted disease that in most cases deserves a polypharmacological
therapeutic approach. Complex plant-derived mixtures such as natural extracts are difficult to
characterize and hardly exhibit high pharmacological potency. However, in some cases, these may
provide an advantage due to their multitargeted mode of action and potential synergistic behavior.
The polypharmacology approach appears to be a plausible explanation for the multigargeted
mechanism of complex natural extracts on different proteins within the same signalling pathway
and in several biochemical pathways at once. This review focuses on the different aspects of natural
extracts in the context of anticancer activity drug development, with special attention to synergy
studies and xenohormesis.
Keywords: cancer; natural compound; synergy; xenohormesis; polypharmacology
1. Introduction
Cancer is not a single disease, but a complex clinical situation in which multiple molecular
pathways and cellular processes are compromised. Each cancer type has its own molecular fingerprint
and, at least one of the cancer hallmarks described in [1], is altered. However, in spite of this
heterogeneous situation, all cancers have a common behavior based on uncontrolled proliferation
and invasion. This invasive phenotype is the real clinical problem and, in most cases, still remains
unresolved, causing morbidity and mortality.
Anticancer research and drug discovery are continuously increasing the therapeutic arsenal,
and relevant advances have been made towards individualized treatments [2–5]. New antibody-based
drugs, called biological treatments [6,7], have improved treatments and prognosis in some cancer
types such as breast, lung, liver cancers and lymphoma. New specific inhibitor families have also been
developed, especially against proliferation related kinases. These drugs are called “inibs” [8,9]. In this
sense, there is a tendency to look for highly specific drugs within the low micromolar range to solve
very specific, almost individual cases. In vitro and in silico approaches have propelled the development
of these specific drugs, and our bibliography is full of these examples [10–13]. These specific drugs
follow the classic pharmacological dogma “one drug-one target”, but in spite of their undeniable value,
they lack some relevant aspects that will be discussed in the following sections.
Medicines 2019, 6, 6; doi:10.3390/medicines6010006 www.mdpi.com/journal/medicines63
Medicines 2019, 6, 6
On the contrary, the molecular promiscuity of some molecules, especially those from natural
origin [14,15], allow them to exert a potential multitarget mechanism of action. These compounds
are able to interact with different targets, modifying different pathways or different steps of the same
signaling cascade. In addition, promiscuity is not always due to a single compound but a mixture
of compounds, as occurs in some complex natural extracts. In these cases, each compound is able
to interact with one or multiple targets, increasing the pharmacological promiscuity of the whole
drug. In addition, natural extracts or their main components can be combined with conventional
chemotherapy, reducing the development of resistance to antitumor drugs and toxic effects [16].
This review will be focused on discussing the advantages and drawbacks of the use of natural
extracts when compared with classical individual targeting strategy. Xenohormesis, multitargeting,
synergy and drug resistance will be the main points that will be addressed.
2. Natural Compounds, Hormesis and Xenohormesis
Chemistry and analytical advances have allowed the synthesis and characterization of millions of
new molecules for drug discovery. In some cases, synthesis was structurally guided using in silico or
structural approaches, in others, combinatorial libraries were built based on a molecular scaffold or
leads. This approach has allowed the development of new drugs not only for cancer treatment but
also for other diseases. However, all these drugs have been human-designed and lack natural origin.
On the contrary, natural extracts and their compounds have been selected for by millions of years of
evolution as complex sources of medicinal agents. This is the basis of xenohormesis hypothesis [17,18].
They present very diverse chemical structures, from the simplest phenolic acids in plants to the most
complex marine compounds [19–21]. Glycosylation, methylation and other esterifications and the
presence of other moieties, increase the number and diversity of natural compounds. This constitutes
a countless and invaluable source of new drugs. From a biomedical point of view, hormesis is
an adaptive response in which the exposure to a low dose of an environmental factor or chemical
compound, that is harmful at high concentrations, has a beneficial and/or adaptive effect on a cell or
organism. Sometimes this response is mediated by some compounds that, when incorporated in the
heterotroph diet, induce biological responses leading to pharmacological effects. This final effect is
called xenohormesis, as the final benefit is obtained by the heterotroph organism, not for the plant that
originally adapted to the stressful condition [17,18]. Xenohormesis is a way of cross-species interaction
and communication.
Although hormesis is an essential concept in evolution, xenohormesis has also
allowed the expansion and fixation of evolutionary advances in non-autotrophs organisms.
Nowadays, xenohormesis gives us a chance to obtain benefits from natural compounds and obtain
new drugs selected by nature all through the evolution process. These compounds can be used
directly for anticancer drug discovery, and also as new leads in novel developments using the classical
structurally guided or in silico approaches. This is one of the main advantages of natural extracts
and their compounds. They can be used as any other drugs, but with the benefit of being selected by
natural evolution.
3. Combined Therapies, Multitargeting and Synergy
Based on the classic pharmacological dogma “one drug-one target”, monotherapy has been the
traditional approach, not only to treat diseases, but also to find new active drugs against a chosen
target. However, presently there is evidence pointing out that combined therapies are much more
efficient than single-drug-based treatments. In this sense, combinational therapy is extended to treat
not only cancer but also other diseases, such as AIDS, bacterial infections, hypertension, metabolic or
rheumatic disorders [22].
Combined drug therapy design is a hard and challenging task. Individual and combined
actions must be characterized and it sometimes requires new preclinical and clinical trials.
In addition, these multiple comparisons are sometimes difficult to incorporate into those studies.
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Combined therapies are normally based on co-administration of two or more drugs. These combined
drugs can be based on the combination of pure compounds, or can be achieved by using drugs based
on mixtures of natural extracts.
Combined therapies are based on targeting different molecular signatures of the disease. On the
one hand, multitargeting makes drug screening more complicated as complex assays must be
developed to test all possibilities. On the other hand, multitargeting creates the opportunity to
obtain synergic interactions between the combined therapy elements and drug resistance development,
as detailed in further sections. There is a plethora of combined chemotherapy treatments covering most
of the different cancer phenotypes. In fact, most of the recommended treatment regimens include two
or more drugs, but as mentioned above, combined therapy use is not exclusive to cancer treatments,
it is also extended to other disciplines such as antimicrobial and antihypertensive diseases.
Synergy is therefore the most relevant characteristic of combined therapies, including natural
extracts. The first impetus for synergy research came from pharmaceutical legislation which demands
the verification that every compound of a combined pharmaceutical preparation contributes to the
claimed complete efficacy [22]. In terms of pharmacology, synergy is the ability of some mixtures
to be more potent than the sum of their individual components. This definition is exportable to
other disciplines and is based on the complementary as well as additive mechanism of action.
Accordingly, synergy is not an absolute factor and the pharmacological interaction between the
components of a mixture can be more or less synergic. This aspect is the main difference between
additive and synergic behavior and is sometimes forgotten by researchers and clinicians.
Another aspect to be analyzed is that a single mixture is able to perform in a different way
depending on the proportion of its components. According to this, different proportions of the same
compounds could provide different results in terms of synergy, not only in an absolute way, but also in
terms of being more or less synergic [23]. In this sense, an ideal proportion which provides the highest
synergy results is always mathematically possible.
There are several ways to develop synergy studies, but in all cases, a previous and detailed
design is required to obtain conclusive results. Most synergy studies fail because of a deficient design,
both in qualitative and quantitative ways. There are several exhaustive and relevant reviews on
synergy [22,24–26], so this review will not go deeper into how to study it. However, some aspects
about study design deserve a comment:
• Drug selection: The right selection of the drugs for synergy studies is the first step to succeed.
There are multiple available drugs for a single disease, but not all are suitable for a synergy
study. Drugs must be selected considering different molecular targets. If not, antagonism or
other undesired pharmacological interactions can be obtained. These different molecular targets
can be located in different molecules, in distinguished epitopes of the same molecule or even in
molecules of different pathways.
• Synergy study method: As mentioned above, there are several methods to study synergy between
drugs. Quantitative methods such as Combination Index (CI) [27] or Fractional Inhibitory
Concentration Index (FICI) [14] calculation are preferred as they obtain better conclusions.
• Biological assay: According to the selected method for synergy studies, a robust and reliable
biological assay must be selected that allows testing a high number of samples with a large
variability in composition. Survival or viability tests are diverse and allow high throughput
screening approaches [28]. They are commonly used for anticancer compound research, but also
for most of the other areas of drug discovery in which synergy is topical, such as antimicrobial
drug discovery.
• Sample testing: Once the test is selected, an adequate design of the plates is also crucial.
Checkboard plate design is probably the best approach for pairwise combinations using
multi-wells plates. This strategy can be used not only for pairwise combinations but also for
3-drug combinations as shown in Figure 1.
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Figure 1. Checkboard plate design can be used not only for single plate experiments but also for more
complex studies using three different compounds. In these cases, the concentration of each compound
increases in one of the three dimensions (x, y and z axis) as indicated in the figure.
Following these recommendations, the final results will not only be scientifically relevant, but also
comparable to other single drug or combined therapies. This will allow researchers and clinicians to
obtain better conclusions and contribute to the development of new therapeutic approaches.
4. Examples of Synergy Studies
References to synergic interactions between drugs in cancer research are abundant in the
bibliography. However, focusing on natural extract synergy studies, three main groups of examples
can be classified. The first group includes studies covering complex extracts whose components
present synergistic interactions among them. The second group includes examples of synergy between
different extracts and natural compounds of different origin. Finally, the third group comprises
examples of anticancer approved drugs combined with natural compounds or extracts. Some of the
most relevant examples of each category are listed below and shown in Table 1.
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Table 1. Examples of synergic interactions among compounds or compounds and approved drugs in
cancer research. Main examples included in this manuscript are shown in this table, organized in rows.
First and second columns indicate the name of the components among which synergy is obtained.
Third and fourth and fifth columns show the cellular models in which synergy studies were performed
(including their origin), the main effect and the bibliographic reference.
Extract/Compound Synergy Experimental Model (Cell Line) Effect References
Pomegranate extract Among their compounds
Oral cancer (KB, CAL27), colon
cancer (HT-29, HCT116, SW480,










Grape extract Among their compounds and withAra-C and tazofurin Leukemia (HL-60)
Antiproliferative and
apoptotic [31]
Grape extract Among their compounds Colon cancer (HCT116) Antiproliferative andapoptotic [32]
Rosemary extract Among their compounds Colon cancer (HT-29) Antiproliferative [33]
Ginger extract Among their compounds Prostate cancer (PC-3) Antiproliferative [34]
Graviola flavonoids Among their compounds Prostate cancer (PC-3) Antiproliferative [35]
Turmeric extract With rosemary compounds Breast cancer (MDA-MB-453,MDA-MB-468, and MCF7)
Antiproliferative, G1 cell
cycle arrest [36]
Tea extract With capsicum compounds Cervical cancer (HeLa) and breastcancer (4T1) Antiproliferative [37]
Tea extract With soy compounds Mice in vivo model Metabolic effect [38]
Tea extract With soy compounds Prostate cancer (LnCAP)xenotrasplants Antiproliferative [39]
Tea extract With others tea extracts Review Antioxidant,antimicrobial and antitumoral [40]





Carothenoids With other phytochemicals Prostate cancer LNCaP , PC-3 andDU-145) and breast cancer (MCF-7) Antiproliferative [43]
Genistein





xenograft, COL-357 and L3.6pl)
colon cancer (HT29), hepatic cancer
(HepG2, Hep3B, SK-Hep-1,
HEpG2 xenograft), cervical cancer
(HeLa) ovarian cancer (OAW-42),








ovarian cancer (2008 and C13) and










line and xenograft) and ovarian
cancer (SKOC3, CAOV3 and C200)
Antiproliferative [44]
Quercetin With doxorubicin, cisplatin, arsenictrioxide and temozolomide
Neuroblastoma and Edwing’s
sarcoma cell lines, laryngeal cancer
(Hep2), leukemia (U937 and HL-60)
and astrocytoma
Antiproliferative [44]
Resveratrol With Cisplatin and doxorubicin Acute leukemia (ML-2/DX30,AML-2/DX100 and AML-2/DX300) Antiproliferative [44]
Pomegranate polyphenolic extracts have demonstrated numerous biological activities such as
antioxidant, cardiovascular preventive and antitumoral activities [45–48]. These extracts are enriched
in ellagitannins such as ellagic acid, punicalagin and punicalin. Synergy studies between pomegranate
polyphenols have been performed in colon cancer cells [29], prostate [30] and other cellular models [49].
Grape fruit is also a well-known source of active compounds, including resveratrol as the most
representative one. As with pomegranate, grape extracts present abundant biological activities [31,50].
In regards to cancer and synergy studies, grape polyphenols have shown synergy between them,
especially on colon cancer cell models [32]. Rosemary terpenes have also shown antitumoral synergic
activity on colon cancer cells [33]. Ginger compounds [34], graviola flavonoids and acetogenin’s action
on prostate cancer [35] are examples of synergic interactions between different compounds included
those that are present in the same extract.
In addition to single complex natural extracts, some studies have tested the synergic interactions
between different extracts and/or different natural compounds, even mixing a complex natural
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extract with an individual natural compound. On the one hand, turmeric extracts have showed
synergic activity with rosemary extracts as well as their representative compounds, carnosic acid
and curcumin [36]. Tea natural compounds, mainly catechins, synergistically interact with capsicum
compounds [37], soy phytochemicals [38,39] and between different tea extracts [40]. On the other hand,
individual compounds such as resveratrol, quercetin and ellagic acid also interact synergistically
in human leukemia cells [41,42]. Carotenoids and other phytochemicals also presented similar
behavior [43]. Finally, natural compounds and extracts synergistically interact with clinically used
anticancer drugs as occurs between many polyphenols and anticancer drugs such as cisplatin,
doxorubicin, 5-fluoracil and others as reviewed in Reference [44].
5. Drawbacks of Using Natural Compounds
Pure natural compounds have demonstrated the same validity as synthetic or semisynthetic drugs
in drug discovery. They are single compounds with a well-known chemical structure. They can be
obtained from natural resources, in most cases using synthetic or semisynthetic approaches [51,52].
However, natural extracts, regardless of vegetal, microorganism or animal origin, are usually complex
mixtures. Two main consequences are derived from natural extract’s complexity. First, these mixtures
must be chemically characterized as much as possible. The improvement of analytical techniques
such as liquid and gas chromatography coupled to mass detection, magnetic resonance and other
approaches have permitted the characterization of very complex extracts [23,53–55]. The second
consequence is that natural extract reproducibility is sometimes difficult due to the biological
diversity of samples. This depends on origin, climate conditions, storage and extraction procedures.
However, as occurred in other disciplines, this drawback can be avoided by controlling crop conditions,
origin and extract production.
Natural compound bioavailability is also a drawback that deserves attention. Natural compounds
have very different structures and, therefore, their bioavailability depend on the individual
compound [56–58]. On the one hand, some natural compounds are quickly and fully absorbed,
reaching the plasma in their native form so providing significant plasmatic concentrations. On the
other hand, other natural compounds have scarce absorption, high metabolized rates and a fast
excretion process. In all these cases, plasmatic concentration are low and biological activities are
difficult to infer. Some strategies have been developed to improve natural compound bioavailability.
Such as the use of different forms of encapsulation [59]; as nanoparticles [60,61], emulsion [62] or
liposomes [63]. These approaches have been used especially to increase the solubility of highly
hydrophobic compounds and extracts, and to improve the bioavailability of hydrophilic compounds
with low stability or poor absorption [64,65]. However, in the end, natural compounds are not quite as
different to other drugs that also present bioavailability limitations, and each case must be studied
independently taking in account its solubility and the ADME processes.
Drug resistance is probably the most important problem of cancer treatments. There are many
drug resistance mechanisms [66,67] and no drug is free to develop a resistant phenotype. Once again,
natural compounds and extracts are not different to other drugs, and resistance phenomena may also
take place. Combined therapies minimize the risk of drug resistance, as tumor cells that develops
resistance against one of the drugs may be affected by other drugs or compounds present in the
same mixture. In this sense, natural pure compounds perform as any other drug and can be used in
combination to reduce resistance, but natural extracts are mixtures that may act as a combined therapy
itself, contributing to a decrease in drug-resistant phenotypes.
6. Concluding Remarks
The current state of the art shows that combined therapies using natural extracts or combination
of natural compounds and polypharmacology are quite promising. This is due to both the
synergic interactions between their components and the reduction of drug resistant phenotype risk.
Natural extracts are naturally occurring mixtures that have been selected by hormesis processes
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that can be beneficial to humans according to xenohormesis theory. They are indeed real combined
therapies that, if well selected and characterized, can be used for new anticancer drugs development.
In this sense, the design of high-quality synergy studies is crucial and a supplementary effort in this
sense is worthy.
But not everything may be considered an advantage when using natural extracts, they share some
drawbacks with conventional anticancer drugs. Poor bioavailability and drug resistance mechanisms
are as common among natural extracts as with conventional drugs. However, the polypharmacological
properties of natural extracts makes resistance more difficult and, as occurred with other conventional
drugs, bioavailability problems can be addressed using different approaches such as encapsulation.
The most important disadvantage of natural extracts is their complexity and reproducibility,
but as mentioned above, technical advances and quality controls during processing can overcome
this problem.
In conclusion, natural extracts are a promising source of new anticancer drugs, but also suppose
a challenging issue. As in the past, natural extracts will continue to be used as sources to develop new
anticancer agents. These compounds have been selected on an evolutionary basis that may suppose an
advantage for their performance.
Nevertheless, the same criteria for safety, efficacy and quality that are required for their synthetic
counterparts must be expected. Strong efforts must be applied in extract characterization and in
synergy studies. Despite these challenges, natural extracts are an irreplaceable source of new anticancer
compounds that undoubtedly will allow the development of new anticancer therapies in the future.
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Abstract: The human microbiome plays many roles in inflammation, drug metabolism, and even
the development of cancer that we are only beginning to understand. Colorectal cancer has been
a focus for study in this field as its pathogenesis and its response to treatment have both been linked
to the functioning of microbiota. This literature review evaluates the animal and human studies
that have explored this relationship. By manipulating the microbiome with interventions such as
probiotic administration, we may be able to reduce colorectal cancer risk and improve the safety and
effectiveness of cancer therapy even though additional clinical research is still necessary.
Keywords: probiotics; synbiotics; microbiome; microbiota; colorectal cancer
1. Introduction
Globally, colorectal cancer is the third most commonly diagnosed type of cancer in men and
the second most common in women [1]. In the United States, there are an estimated 135,430 new
cases of colorectal cancer annually with an estimated 50,260 deaths due to the disease each year [2].
Colorectal cancer mortality has been improving over time in the United States by about 2.5% to
3% per year since 1990 [3] and while survival rates remain poor in advanced disease, early-stage
colon cancer, this can potentially be cured with an estimated 74% five-year survival rate for patients
with stage I disease [4]. As survival improves, it becomes more and more important to mitigate the
adverse effects of colon cancer treatment. Surgery, chemotherapy, immune therapy, and radiation
therapy all carry the possibility of significant treatment-related morbidity and mortality. In particular,
adverse events affecting the gastrointestinal tract—such as nausea, diarrhea, colitis, and gastrointestinal
bleeding—can diminish a patient’s quality of life, preclude additional treatment, and sometimes even
become life-threatening.
One promising avenue of study in the prevention and treatment of colorectal cancer is with
the human microbiota. This refers to the 10 to 100 trillion symbiotic microbial cells harbored by
each individual largely located in the gut where they are involved with metabolizing food remnants,
intestinal and digestive secretions, and exfoliated colonocytes. The human microbiome, in turn,
refers to the genes contained by these cells [5]. The microbiota serves a myriad of roles in the body
with both positive and negative effects on human health and several large ongoing projects exist to
explore this complex interplay [6,7]. Complicating this research is the fact that the microbiome is
extremely diverse between individuals. The entire human genome consists of approximately 22,000
genes. This is compared to the human gut microbiome, which contains 3.3 million non-redundant
genes that vary between individuals [5].
In the context of this diversity, there is debate over what makes up a “healthy” human microbiome.
When the total DNA content of microbes inhabiting humans is analyzed, only one third of their
constituent genes are found in a majority of healthy individuals [8]. Early research into the human
microbiome had focused on identifying a core set of microbial taxa that were universally present in
healthy people who lacked overt disease phenotypes on the assumption that certain specific microbes
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were essential to health. However, this proved to be an oversimplification as the variety of microbial
species between individuals meant that characterizing an ideal set of specific microbes was not
practical. An alternative hypothesis is that a healthy microbiome represents a “functional core”—a set
of metabolic and other molecular functions performed by the microbiome that are not necessarily
performed by the same organism in every individual.
As research into the microbiome progresses, we find that it affects health in ways we wouldn’t
expect. For instance, disruptions in the relative proportions of gut microbial populations may affect
weight gain and insulin resistance contributing to type II diabetes mellitus [9]. These discoveries
extend to the complex relationship between gut microflora, cancer development, and the effectiveness
of cancer treatments. The composition of the microbiome has been correlated with colon cancer
development in mouse [10,11] and human studies [12]. There is evidence that the effectiveness of
various chemotherapy [13–15] and immune therapy [16,17] regimens depend on the composition of
the microbiome.
Manipulating the microbiome using probiotics to improve the safety and GI side effect profile of
cancer treatment has also been explored with a few studies evaluating the possible clinical benefit of
probiotics with surgery [18], radiation therapy [19], and chemotherapy [20]. Probiotics are attractive
as a potential complement to treatment because they are inexpensive and associated with few, if
any, major adverse effects. Available evidence also suggests that probiotics may have a significant
clinical impact. For instance, in one study of 168 patients evaluated after colorectal surgery for cancer,
those receiving probiotics had a significantly decreased rate of all postoperative major complications
when compared to the placebo arm (28.6% vs. 48.8%, p = 0.010) [21]. However, prospective studies
evaluating the clinical effect of probiotics in cancer patients are currently few in number and more
evidence is needed to determine the situations in which probiotics are beneficial.
In addition, the composition of the gut microbiome is heavily dependent on diet. In one
mouse study, switching from a low-fat, plant polysaccharide-rich diet to a high-fat, high-sugar
“Western” diet had major effects on the microbiome within one day with measurable changes in
microbiome metabolic pathways and gene expression [22]. Of particular interest are prebiotics,
which are non-digestible food ingredients that benefit the host by stimulating the growth or activity of
commensal bacteria in the gut [23]. These have been shown to significantly change the microbiome
composition. Administration of fructo-oligosaccharides, for instance, significantly increases the
number of bifidobacteria found on fecal analysis and it decreases the amount of Bacteroides, Fusobacteria,
and Clostridium [24]. Furthermore, prebiotics such as long and short chain oligosaccharides undergo
fermentation in the colon by anaerobic bacteria, which metabolize them to short chain fatty acids
(SCFAs) such as acetate, propionate, and butyrate. An increased concentration of SCFAs in the colon
seems to have several beneficial effects including improved barrier function, increased intestinal mucus
synthesis, stimulation of immunosuppressive cytokines such as interleukin 10 (IL-10), and reduced
levels of pro-inflammatory mediators. Furthermore, increased SCFAs seem to result in the preferential
growth of protective bacteria over pathogenic strains [25]. Synbiotics—combinations of pre-biotics
and probiotics—have been shown to have similar beneficial regulatory effects.
2. Correlation between the Microbiome and Overall Gastrointestinal Health
We know from a number of studies that the microbiome plays an integral role in gastrointestinal
health and function and that manipulation of the microbiome—using probiotics, for instance—can have
beneficial effects (Figure 1). Commensal microorganisms exhibit mechanisms that appear to decrease
inflammation. They combat pathogenic bacteria by producing bactericidal substances and competing
with pathogens and toxins for adherence to the intestinal epithelium. Many regulate immune responses
by enhancing innate immunity and modulating signaling pathways and others regulate intestinal
epithelial homeostasis by promoting intestinal epithelial cell survival, enhancing barrier function,
and stimulating cell protective responses [26]. Clinically, there have been a number of studies
and meta-analyses showing a benefit of probiotics in a range of gastrointestinal diseases including
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pouchitis [27], infectious diarrhea [28,29], and chronic constipation [30]. Most of these studies have
been small with methodological limitations. Due to differences in study composition, probiotic doses,
and biological activity between various commercial probiotic preparations, results from any given
study cannot be applied universally to all probiotic substances. Currently, no probiotic strategy
represents standard of care or primary treatment for these GI issues. Nevertheless, given their potential
benefit and anti-inflammatory properties, it stands to reason that probiotics may also have a beneficial
effect in the prevention and treatment of cancer particularly with regard to preventing or alleviating
the adverse effects of traditional cancer therapies.
Figure 1. Proposed functions of gut commensal bacteria that may be beneficial in the prevention and
treatment of colorectal cancer.
3. Correlation between the Microbiome and the Development of Colorectal Cancer
Recent research has shown that the composition of the microbiome in patients who have developed
colorectal cancer is significantly different from the microbiome of patients who have not. A Japanese
study that analyzed the micro-genome using terminal restriction fragment length polymorphism
and next-generation sequencing analyses noted that several bacterial genera (Actinomyces, Atopobium,
Fusobacterium, and Haemophilus) as well as several individual species (including Bacteroides fragilis and
Streptococcus gordonii) were significantly associated with patients with known colorectal carcinoma
but not in control patients without the disease [31]. Another study noted that microbiota close to
the tumor tissue did not differ significantly when compared to the microbiota close to the normal
mucosa in the same individual, which suggests that the microbiome does not change secondary
to neoplasia but instead that colorectal cancer-distinctive microbiota may be present in the early
stages of carcinogenesis [32]. We also know that dysbiosis—an imbalance or maladaptation of the
microbiota—affects certain pathways that theoretically can lead to tumorigenesis [12] (Figure 2).
Dysbiosis in the GI tract can lead to disruption of homeostasis of the immune system and mucosal barrier
with subsequent inflammation resulting in increased mucosal barrier permeability and a continuous
state of inflammation. This, in turn, can activate cytokines and growth factors such as tumor growth
factor beta (TNF-β), tumor necrosis factor (TNF), IL-6, and vascular endothelial growth factor (VEGF),
which can potentially lead to the growth and survival of dysplastic cells [33]. Dysbiosis with bacterial
biofilm formation can also lead to increased bile acid metabolism, cell proliferation via Toll-like receptors,
and other mechanisms that may, in turn, contribute to malignant transformation [34].
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Figure 2. Overview of proposed mechanisms linking dysbiosis of the gut microbiome to tumorigenesis.
1 Short chain fatty acids. 2 Tumor growth factor beta. 3 Tumor necrosis factor. 4 Vascular endothelial
growth factor.
Research into two types of bacteria called Bacteroides fragilis and Fusobacterium nucleatum provides
models for how specific changes in the microbiome can contribute to tumorigenesis. A 2009 study
examined enterotoxigenic B. fragilis (ETBF) and a cause of acute inflammatory diarrheal disease that
also asymptomatically colonizes 20% to 35% of adults [35]. Both EBTF and nontoxigenic B. fragilis
chronically colonized multiple intestinal neoplasia (Min) mice in the study, but only EBTF was shown
to cause colitis and a strong induction of colonic tumors. It was found that ETBF activates the signal
transducer and activates transcription-3 (Stat3) in the colon, which leads to colitis characterized by
a T helper type 17 (TH17) immune response. Antibody blockade of IL-17 and receptor of IL-23—key
cytokines in the TH17 response—was shown to inhibit the ETBF-induced colitis, subsequent colonic
hyperplasia, and tumor formation.
Fusobacterium, particularly F. nucleatum, was shown to be over-represented in the genetic analysis
of colorectal cancer tissue in two separate 2012 studies [36,37]. Prior to that, the species was
linked to periodontitis and appendicitis but not to cancer. It was known that F. nucleatum could
elicit a pro-inflammatory response, but it was initially unclear whether the bacteria contributed to
tumorigenesis or if it was simply an opportunistic infection at the immunocompromised tumor site.
Later on, mouse studies confirmed that F. nucleatum did, in fact, contribute to colorectal tumorigenesis
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and contribute to the stimulation of tumor cell growth by activating β-catenin signaling and inducing
oncogenic gene expression by the FadA adhesion virulence factor [38].
Further studies on mouse models give us the strongest evidence that previously explored
connections between dysbiosis and the development of malignancy are causative and not merely
correlative. One study published in 2013 noted that tumor-bearing mice showed a different microbiome
profile compared to non-tumor-bearing mice. When gut microbiota from tumor-bearing mice were
introduced to and allowed to colonize germfree mice, the previously germfree mice were noted to have
significantly increased tumorigenesis compared to mice that were colonized with microbiota from
tumor-free mice. Furthermore, manipulation of the gut microbiome with antibiotics in these higher-risk
mice resulted in a dramatic decrease in the number and size of tumors [11]. Another study in 2015
came to a similar conclusion by showing that isogenetic mice in a controlled environment exhibited
different susceptibility to colorectal cancer depending on their distinct gut microflora profile [39].
4. Correlation between the Microbiome and Cancer Treatment Effectiveness
A major challenge in cancer therapy research is determining why certain patients will respond to
a particular treatment while other patients with similar epidemiologic and clinical characteristics will not.
A recent study has suggested that a patient’s microbiome may play a much bigger role in response
to systemic cancer therapy than previously realized. One recent in vitro study showed that exposing
5-FU-resistant colorectal cancer cells to Lactobacillus plantarum selectively inhibited characteristics of the
cells including the expression of certain cancer-specific markers (CD44, 133, 166, and ALDH1). Treating the
cells with combined Lactobacillus plantarum and 5-FU led to caspase-induced apoptosis and demonstrated
further potential anticancer effects by inactivating the cells’ Wnt/β-catenin signaling pathway [40]. In live
subjects, mouse models have shown that disrupting the microbiota may decrease the effectiveness of
systemic cancer therapies. One study evaluated mice that previously had received chronic treatment
with antibiotics or were raised in a sterile environment. They were inoculated with subcutaneous
tumors and given treatment with either an experimental immunotherapy (CpG-oligonucleotide) or
platinum chemotherapy. Antibiotic-treated and germ-free mice had less cytokine production and very
little tumor cell death after treatment with immunotherapy when compared to controls. When treated
with platinum chemotherapy, the immune cells of antibiotic-treated and germ-free mice produced fewer
of the enzymes necessary for generating reactive oxygen species [14]. A separate mouse study evaluated
the relation between cyclophosphamide and microbiota. Cyclophosphamide was shown to induce certain
Gram-positive bacteria to translocate from the small intestine to secondary lymphoid organs, which,
in turn, stimulated a subset of helper and memory T-cells. Tumor-bearing mice that were antibiotic-treated
or germ-free that did not have these specific bacteria showed reduced T-cell stimulation and a reduced
tumor response after treatment with cyclophosphamide [41].
Other studies in mice have looked more specifically into how immunotherapy is affected by
microbiota. The CTLA-4 blockade, for instance, appears to be dependent on T-cell responses specific
for Bacteroides thetaiotaomicron or Bacteroides fragilis. In a 2015 study, it was found that tumors in
antibiotic-treated or germ-free mice did not respond to treatment with a CTLA-4 blockade but that
this lack of response could be overcome by gavage with B. fragilis. Interestingly, the CTLA-4 blockade
was also found to be effective if B. fragilis polysaccharides were administered or if B. fragilis-specific
T cells were transferred to the subject, which implies that the treatment’s effectiveness was tied
to the bacteria’s stimulatory effect on the immune system and not to the continued presence of
the bacteria itself. Furthermore, fecal microbial transplant from humans to mice showed that the
treatment of melanoma patients with anti-CTLA-4 antibodies favored the outgrowth of B. fragilis with
anticancer properties by affecting IL-12-dependent T-helper 1 (TH1) immune responses to cancer [16].
A similar study done the same year compared melanoma growth in two groups of mice raised in
two different facilities and known to harbor different populations of commensal bacteria. The groups
showed differences in spontaneous antitumor immunity and tumor growth that disappeared after
the mice from the two groups were housed together. Fecal transfer from mice in the population
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with less tumor growth to mice in the other population resulted in slower tumor growth as well
as enhanced tumor infiltration with CD8 positive immune cells. Furthermore, anti-PD-L1 therapy
was shown to be more effective in the lower-risk population of mice. Ribosomal RNA sequencing
identified Bifidobacterium as being associated with antitumor effects. The researchers noted that oral
administration of Bifidobacterium alone improved tumor control by the same amount as anti-PD-L1
therapy and that combining the two treatments “nearly abolished tumor outgrowth” in the mice [17].
While the results of these studies certainly cannot be directly applied to humans, they suggest that
the effectiveness of many cancer therapies likely rely, at least in part, on the function of the microbiome.
It is further speculated that this may mean the use of certain antibiotics may dampen the effect of
certain anti-cancer therapies [15]. Research in human models including a prospective cohort study
evaluating whether microbiota composition is correlated with the effectiveness of chemotherapy in
colorectal cancer is ongoing [13].
5. Manipulation of the Microbiome as a Component of Cancer Treatment
If the microbiome plays such an important role in the development and treatment of colorectal
cancer, does that mean we can alter the microbiome to benefit patients? Current research has
approached this question in several different ways (Table 1). Specifically—can manipulating the
microbiome be used as a means to help prevent cancer from developing? Can it help prevent or
alleviate the adverse effects of therapy for patients who have already been diagnosed? In addition,
can it help improve the oncological outcomes such as overall survival?
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5.1. Cancer Prevention
There have been a number of studies in both mouse and human models exploring whether
manipulation of the microbiome can prevent cancer development. In colorectal cancer specifically,
probiotics are reported to have several cancer-preventative mechanisms that have been shown to
operate via intraluminal and systemic effects as well as directly on the intestinal mucosa [49]. In these
studies, probiotics have been shown to competitively exclude pathogenic intestinal flora [50,51],
alter intestinal microflora enzyme activity [52], reduce carcinogenic secondary bile acids [53],
bind carcinogens and mutagens, and increase short chain fatty acid production. Probiotics have
also been shown to decrease DNA damage [54] at the level of the intestinal mucosa and help maintain
an intestinal barrier function [55].
Several studies have looked into the role of probiotics in the prevention of colon cancer and
have shown that they appear to have an inhibitory effect on the development of tumors and
precancerous lesions even though the effect is not entirely consistent across studies [56]. In one
randomized, double-blind, placebo-controlled trial, patients with colon cancer and polypectomized
patients were administered a synbiotic consisting of oligofructose-enriched inulin, Lactobacillus
rhamnosus GG, and Bifidobacterium lactis Bb12 [57]. Biomarker testing, toxicity assays, and colorectal
tissue biopsy samples were checked over the 12-week course of the study with favorable results.
Synbiotic administration was associated with reduced colorectal proliferation, reduced capacity of
fecal water to induce necrosis in colonic cells, and an improved epithelial barrier function. Colon cancer
patients were also noted to have increased the production of interferon gamma and assays performed
on colon biopsy samples in polypectomized patients showed decreased exposure to genotoxins.
Currently, there is very limited human data directly evaluating colorectal cancer risk in relation to
specific characteristics or manipulation of the microbiome. A 2005 trial evaluated colorectal tumor
recurrence in 398 men and women with a history of removing at least two prior colorectal tumors who
were divided into groups receiving a dietary fiber supplement, Lactobacillus casei, both, or neither [43].
While there was no significant difference in the development of new colorectal tumors between
the groups, the occurrence rate of tumors with moderate or higher-grade atypia was significantly
lower in the group receiving L. casei. In addition, a large Italian prospective cohort trial showed that
self-reported yogurt intake had an inverse association with colorectal cancer risk (HR 0.65 [95% CI,
0.48–0.89] between the highest and lowest tertile) after accounting for potential confounding factors
such as BMI, smoking, and physical activity [44]. While these studies are a long way from showing
any clinical role for probiotics in colorectal cancer prevention, they suggest that further study may
hold promise.
5.2. Alleviating Adverse Effects
Given that previous studies have shown a symptomatic benefit in benign gastrointestinal
conditions such as pouchitis and infectious diarrhea, it stands to reason that probiotics may be
beneficial in mitigating the adverse gastrointestinal effects of cancer treatment. Mouse studies
have supported this hypothesis. For instance, one 2015 study showed that mice treated with
intraperitoneally-injected 5-FU developed diarrhea, but their symptoms were improved when given
a probiotic suspension. These mice demonstrated the repairing of damage in the jejunal villi as well as
reduced mRNA expression of TNF-alpha, IL-1 beta, and IL-6 in intestinal tissue [57]. In another study,
mice given with the probiotic mixture VSL#3 had reduced the severity of weight loss and diarrhea
after administration of irinotecan as well as reduced apoptosis in the small and large intestine on
histological examination [58].
Probiotics also seem to help alleviate non-GI adverse effects as well. A separate study looked
at the effect of administering L. casei and L. rhamnosus strains to mice receiving cyclophosphamide.
Mice receiving probiotics demonstrated increased immature myeloid progenitors in bone marrow
with early recovery of neutrophils in the peripheral blood, improved phagocytic cell recruitment to
infectious sites, and increased resistance to opportunistic infection with Candida albicans [59].
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There is limited human data evaluating whether probiotics can help improve tolerance to
chemotherapy. In one randomized control trial, colorectal cancer patients starting treatment with
irinotecan were concurrently given either placebo or a probiotic containing 10 different strains of bacteria.
Unfortunately, the trial was discontinued prematurely due to slow accrual with only 46 out of 220
planned patients enrolled. While the study did show a trend toward reduced frequency of severe diarrhea
and use of antidiarrheal drugs in the group receiving probiotics, the study was very limited due to its
size [20]. A 2007 clinical trial evaluated 150 patients randomly assigned to receive one of two 5-FU-based
chemotherapy regimens (Mayo regimen versus simplified de Gramont regimen) and further randomized
to receive or not receive Lactobacillus rhamnosus GG with fiber as a supplement during chemotherapy [45].
In total, 26% of the patients received pelvic radiation therapy. Patients receiving Lactobacillus had a lower
incidence of grade 3 or grade 4 diarrhea (22% vs. 37%, p = 0.027), less abdominal discomfort, and had
fewer hospitalizations and chemotherapy dose reductions due to bowel toxicity. However, the study was
limited due to lack of blinding and placebo control.
Probiotics have also been studied in the setting of radiation therapy and surgery for the treatment
of cancer. In a 2009 meta-analysis of four studies evaluating probiotics in the treatment of radiation
enteritis, some of the individual studies showed a significant effect, but the meta-analysis did not
demonstrate an overall benefit when all trials were taken into account [46]. Nevertheless, research has
shown that intestinal bacteria contribute to radiation-induced injury and repair [60]. Given the
variation of probiotic strains and doses between studies, it would be premature to rule out probiotics
as a possible treatment in the current state of research.
Results have been mixed in trials evaluating probiotics as an adjunctive treatment to surgery
as well. In one study of 168 patients evaluated after colorectal surgery for cancer, those receiving
a four-probiotic regimen had a significantly decreased rate of all postoperative major complications
when compared to the placebo arm (28.6% vs. 48.8%, p = 0.010) [21]. However, a separate randomized
trial evaluating 73 patients who received a prebiotic, a synbiotic, or a standard bowel prep prior to
resection for colorectal cancer found no difference in the systemic inflammatory marker response and
no effect on post-operative course or complication rates [18].
5.3. Cancer Outcomes
Data evaluating probiotics as a potential means to prevent cancer or to alleviate the adverse
effects of cancer treatment is limited, but data evaluating whether probiotics affect cancer treatment
outcomes is even scarcer. Currently, there does not appear to be any published randomized control
trials in the literature evaluating whether manipulation of microbiota in patients receiving treatment
for colorectal cancer can affect outcomes such as the objective response rate or progression-free survival.
Two randomized control trials, however, did evaluate the effect of probiotics on cancer outcomes in
bladder cancer. The first, which is a 1995 trial, evaluated 138 patients with primary bladder tumors
treated with transurethral resection of the bladder tumor (TURBT). Afterwards, the patients were
treated with either an oral preparation of Lactobacillus casei or placebo. Patients receiving probiotics
had a significant decrease in cancer recurrence with a corrected cumulative recurrence-free rate at one
year of 79.2% versus 54.9% with placebo (p = 0.01) [59]. A later trial in 2008 evaluated 207 patients with
superficial bladder cancer. Patients were treated with TURBT followed by transurethral epirubicin
with one group of 100 patients receiving an oral Lactobacillus casei preparation once daily for one year.
Three-year recurrence free survival was significantly higher in the group receiving probiotics (74.6%
vs. 59.9%, p = 0.02). However, overall survival did not differ between the two groups [48]. While it is
difficult to draw generalized conclusions from these trials, they do suggest that further clinical study
would be reasonable especially given the relative safety [61] of administering probiotics.
6. Discussion
We currently have only a very primitive understanding of the microbiome and how it functions in
the human body. There is an ongoing debate over even the fundamentals of the microbiome. We know
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that it is vital to human health, but we are far from being able to define what a “healthy” human
microbiome looks like. We know that certain functions such as regulation of the immune system
and gut mucosal barrier are beneficial, but it stands to reason that there are a vast number of critical
microbiome functions that have not yet been discovered.
Luckily, we do not need a perfect understanding before translating knowledge of the microbiome
into clinical interventions. Studies so far have suggested that restoring function to the microbiome
can have beneficial effects in the prevention of cancer and in improving the effectiveness and safety
of cancer treatment. As we have seen, administration of certain Lactobacillus and Bifidobacterium
strains is associated with biochemical and histologic changes that may decrease the risk of developing
malignancy [50,51]. Other Lactobacillus [40], Bifidobacterium [17], and Bacteroides [16] strains seem to
play critical roles in the effectiveness of certain cytotoxic and immune therapies. Nonetheless, the bulk
of research in these topics has been in animal models. Data from human research, particularly in
clinical trials evaluating whether probiotics or synbiotics can alleviate the adverse effects of various
cancer therapies, has so far shown mixed results.
These mixed results are not necessarily unexpected given the early state of clinical research
into probiotics, colorectal cancer, and the microbiome. Colorectal cancer provides many different
populations, cancer treatment modalities, and patient outcomes to study, which means a probiotic
regimen showing a benefit in one cohort will not necessarily show a benefit in all colorectal cancer
patients. Several of the clinical trials evaluating probiotics in cancer patients suffer from major
limitations ranging from lack of blinding and a placebo control group [56] to inadequate patient
accrual [20]. While some of these studies suggest that probiotic therapy is helpful, it will take further
clinical research with larger, more diverse patient populations to determine if there is true benefit.
In addition, while some individual probiotic formulations have been studied across multiple
clinical trials, there is no strong evidence favoring one formulation over another. Certain bacterial
species seem to provide specific helpful functions, but translating this knowledge into clinically
beneficial therapies will likely prove difficult. For instance, as previously noted in mouse studies,
commensal Bifidobacterium seems to be important in the effectiveness of anti-PD-L1 therapy [17]. If this
were experimentally proven in humans as well, many questions would remain. Would we be able to
overcome a Bifidobacterium “deficiency” through the administration of oral probiotics or synbiotics?
If so, is there a minimum dosage in colony forming units (CFUs) that would need to be administered for
the treatment to be effective? Could other, non-Bifidobacterium strains of commensal bacteria perform
equivalent functions that amplify the effectiveness of anti-PD-L1 treatments?
Additionally, what is the benefit, if any, of administering multiple strains of probiotics in a single
formulation? There are innumerable interactions between individual bacterial strains in the gut
microbiota and certain microbiome compositions appear to make individuals more or less susceptible
to colonization with certain pathogenic bacteria [62]. It stands to reason that multiple types of bacteria
with anti-tumor effects may synergize when administered together. In fact, many of the clinical trials
reviewed in this article examined probiotic formulations instead of probiotics consisting of a single
strain. Presumably using probiotic strains with different beneficial mechanisms of action may elicit
a better outcome than any one alone and there may be other mechanisms by which commensal bacteria
cooperate with each other. However, it is also entirely possible that the opposite is true and giving
certain probiotics in combination will cause them to limit each other’s effectiveness.
Ultimately, in order to realize the promise of microbiome-related therapies, research will need to
focus on developing defined probiotic therapy regimens with specific strains and doses that may result
in a reproducible clinical benefit. Even then, we will need additional research to determine whether
a synergistic effect between probiotics and anti-cancer drugs will translate into improved oncologic
outcomes such as progression-free or overall survival.
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7. Conclusions
Studies evaluating the gut microbiome have shown promising connections between it and the
pathogenesis and treatment of colorectal cancer. Further translational research and clinical trials in
human subjects are warranted to investigate the possibility of manipulating the microbiome to improve
outcomes in colorectal cancer.
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Abstract: Green tea and green tea polyphenols (GTPs) are reported to inhibit carcinogenesis and
malignant behavior in several diseases. Various in vivo and in vitro studies have shown that GTPs
suppress the incidence and development of bladder cancer. However, at present, opinions concerning
the anticancer effects and preventive role of green tea are conflicting. In addition, the detailed
molecular mechanisms underlying the anticancer effects of green tea in bladder cancer remain
unclear, as these effects are regulated by several cancer-related factors. A detailed understanding of
the pathological roles and regulatory mechanisms at the molecular level is necessary for advancing
treatment strategies based on green tea consumption for patients with bladder cancer. In this review,
we discuss the anticancer effects of GTPs on the basis of data presented in in vitro studies in bladder
cancer cell lines and in vivo studies using animal models, as well as new treatment strategies for
patients with bladder cancer, based on green tea consumption. Finally, on the basis of the accumulated
data and the main findings, we discuss the potential usefulness of green tea as an antibladder cancer
agent and the future direction of green tea-based treatment strategies for these patients.
Keywords: animal model; treatment; bladder cancer; epidemiology; green tea
1. Introduction
Green tea is obtained from the leaves of the plant Camellia sinensis, and it is one of the most
popular beverages worldwide, particularly in Asia. Green tea is recognized to have health-promoting
effects that are attributed to green tea polyphenols (GTPs), such as epicatechin, epigallocatechin,
epicatechin-3-gallate (ECG), and epigallocatechin-3-gallate (EGCG) [1]. In addition, its antioxidant,
anti-inflammatory, and antibacterial properties have been reported to provide various benefits to
its consumers [2]. Several investigators have reported that the addition of GTPs to drinking water
can prevent carcinogenesis and the development of various types of malignancies [3–5]. In addition,
laboratory-based evidence of the anticancer effects of GTPs has been increasing [4,6]. On the other
hand, other studies have shown that green tea consumption does not decrease the risk for various
types of cancers, including brain cancer and breast cancer [7,8]. In addition, a meta-analysis of
published case-control and cohort studies showed that green tea consumption is not associated with
risk of pancreatic cancer [9]. Furthermore, no significant association between green tea consumption
and colon cancer risk was observed (summary RR: 0.99; 95% CI: 0.79, 1.24) in prospective cohort
studies [10]. Additionally, it has been reported that green tea consumption might be associated with an
increased risk of upper aerodigestive tract cancer [11]. Taken together, the anticancer effects of green
tea consumption and GTPs remain controversial. With regard to bladder cancer, various in vivo and
in vitro studies have provided inconsistent results.
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Below, we first present a general discussion on the relationship between green tea consumption
and cancer risk on the basis of data from epidemiological studies, the mechanisms underlying these
anticancer effects, the safety and adverse effects of GTPs, and trials of treatment strategies based on
green tea consumption. Then, we present a detailed review of these topics with a focus on bladder
cancer. Previously, excellent reviews of studies, particularly epidemiological investigations, on the
relationship between green tea consumption and bladder cancer risk have been published [12,13].
Therefore, in the present review, we paid attention to the molecular mechanisms underlying the
anticancer effects, findings from studies involving animal models, and novel treatment strategies
based on green tea consumption for patients with bladder cancer, as these topics have been less well
addressed in previous reviews.
2. Anticancer Effects of Green Tea Polyphenols
GTPs exhibit anticancer effects via the regulation of different cancer-related processes and factors,
including DNA methylation, histone modification, micro-RNA, and proteins [5,14–17]. They also play
an important role via the regulation of apoptosis, growth, invasion, and angiogenesis in various types
of malignancies [13,15,18,19]. A recent study showed that GTPs can influence the pathological roles
of not only cancer cells, but also cancer stem cells [17]. These findings have led to a hypothesis that
GTPs have strong anticancer effects in vivo and in vitro. In the next section, findings that support this
hypothesis are discussed.
2.1. Anticancer Effects Shown in Epidemiological Studies
When discussing the anticancer effects of GTPs, it is necessary to focus on the different phases in
the natural evolution of malignant cells. Briefly, green tea extracts are thought to be useful for primary
prevention (prevention and delay of cancer onset) and tertiary prevention (prevention of recurrence
and metastasis) [17]. With regard to primary prevention, several epidemiological studies have shown
that the average age at cancer onset in individuals with high levels of green tea consumption was
significantly higher than that in individuals with low levels of green tea consumption [17,20,21].
These studies have also shown that the consumption of more than 10 cups of green tea was associated
with a reduced incidence of lung, colorectum, liver, and stomach cancer [17,20,21]. Furthermore,
several reports have shown that GTPs were effective in preventing transformation from a premalignant
status to frank malignancy [14,22].
With regard to tertiary cancer prevention, on the other hand, one study reported that the
recurrence rate for stage I and stage II breast cancer was significantly lower for patients consuming
≥5 cups of green tea daily (16.7%) than in those consuming ≤4 cups (24.3%; p < 0.005) [23]. However,
these preventive effects were not observed for stage III breast cancer recurrence. Another report stated
that the hazard ratio for stage I breast cancer recurrence showed a statistically significant decrease
(hazard ratio, 0.43; 95% confidential interval, 0.22–0.84) [24]. Similar preventive effects on cancer
recurrence have also been reported for other cancers. For example, a study showed that the recurrence
rate for colorectal cancer was significantly lower in an experimental group (daily consumption of green
tea plus tablets of green tea extracts (GTEs) than in a control group (31.0% vs. 15.0%; p < 0.05) [25].
In addition, GTEs reportedly showed inhibitory effects on metastasis in various types of malignancies.
For example, lung metastasis from melanoma was inhibited by GTEs in an animal experiment [26].
2.2. Mechanisms Underlying the Anticancer Effects of Green Tea
Various cancer-related molecules have been reported to be modulated by GTPs. In fact,
many studies have reported that GTPs inhibited cell growth and induced apoptosis in various
types of malignancies [19,27,28]. In addition, these polyphenols modulate the functions of various
cancer-related signaling molecules. For example, the function and expression of vascular endothelial
growth factor (VEGF), which is a strong stimulator of angiogenesis, are mediated by GTPs in oral
cancer and esophageal squamous cell carcinoma [14,29]. Furthermore, in these malignancies, cyclin
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D1, which is a cell cycle regulator, and caspase-3, which is an important determinant for apoptosis,
are associated with GTPs [14,29].
EGCG has also been reported to affect the pathological behavior of stem cells in several cancers.
For example, they inhibited the proliferation and induced the apoptosis of lung cancer stem cells [30]
and suppressed tumor spheroid formation by colorectal cancer stem cells [16].
Numerous previous reports have presented detailed information on the mechanisms underlying
the general anticancer effects of green tea; thus, we present the details only for bladder cancer.
2.3. Cancer Treatment Strategies Based on Green Tea Consumption
While GTPs inhibit tumor growth in human lung cancer cell lines, their inhibitory effects were
approximately 250-fold less effective than those of doxorubicin (Adriamycin) [31]. Therefore, it has
been suggested that GTPs are more suitable for use in cancer prevention than as cancer treatment [17].
In fact, chemoprevention by oral administration of green tea catechins was investigated in volunteers
with high-grade prostate intraepithelial neoplasia, a precancerous change [22]. Furthermore, EGCG
administration was reported to be useful as an adjuvant therapy after complete tumor resection [32].
Various GTPs can also increase the sensitivity of anticancer agents and prevent drug resistance [33,34].
In fact, new cancer treatment strategies using a combination of GTPs and anticancer agents, such as
cisplatin, paclitaxel, and tamoxifen, have been recommended for several types of malignancies [35,36].
The molecular mechanisms underlying these synergistic effects are partially clear. For example,
in osteosarcoma, SOX overlapping transcript variant 7 is known to contribute to an improvement in the
clinical efficacy of combination therapy with EGCG and doxorubicin via inhibition of both autophagy
and stemness [37]. In addition to anticancer agents, various natural compounds have also been shown
to exhibit anticancer effects when combined with GTPs. For example, in a xenograft model of human
leukemia, the oral intake of green tea and intraperitoneal injection of quercetin, which is a polyphenol
present in fruits and vegetables, induced apoptosis and suppressed tumor growth [38]. Furthermore,
another study reported that EGCG and quercetin enhanced the anticancer effects of doxorubicin via
regulation of cell cycle arrest and apoptosis in prostate cancer [39].
As mentioned above, the anticancer effects of GTPs are relatively weak, and a higher concentration
of GTPs near cancer cells is considered to improve their anticancer effects. Polymeric micelles are used
as the drug-delivery systems in various treatments. In recent years, several anticancer drug-loaded
micellar nanocomplexes based on GTE-derivatives have been developed [40,41]. A micellar
nanocomplex based on the self-assembly of EGCG and doxorubicin inhibited tumor growth in a
xenograft model of human liver cancer [41]; similar results were reported for a micellar nanocomplex
prepared by complexation of oligomerized EGCG with trastuzumab (Herceptin) in a mouse model of
breast cancer [40]. These findings indicate that more detailed in vivo studies and clinical trials of such
combined therapies are important for development of new treatment strategies of bladder cancer.
3. Bladder Cancer and Green Tea
Bladder cancer is a common malignancy in 43 countries around the globe, although the incidence
among men, women, and both sexes has decreased in 11, 10, and 12 countries, respectively [42].
Bladder cancer imposes a substantial psychological, physical, and economic burden, and its prognosis
is poor, despite various multidisciplinary therapeutic approaches, particularly in cases with muscle
invasion and/or metastasis [43]. Therefore, more detailed information will be useful for devising
preventive and treatment strategies.
Many studies have focused on the clinical benefits of food choices in terms of chemoprevention,
treatment, and survival in bladder cancer [44]. Furthermore, complementary and alternative medicine
(CAM), defined as a diverse medical and healthcare system, is recognized as a strategy commonly
used by patients with malignancies, including bladder cancer [45]. Green tea consumption and GTPs
intake are suggested as CAM strategies [46].
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3.1. Epidemiological Studies on Bladder Cancer
3.1.1. Case-Control and Cohort Studies
As mentioned above, no consensus has been derived from the findings of epidemiological studies
on green tea consumption, and the effects thereof on carcinogenesis and tumor development and
growth remain controversial. Similarly, with regard to bladder cancer, opinions about the relationship
between green tea consumption and cancer risk are conflicting. For example, it was reported that
the risk of bladder cancer in individuals with high green tea consumption (≥0.14 servings/day) was
lower than that in individuals who never consumed the beverage (odds ratio, 0.60; 95% confidential
interval, 0.45–0.79; p < 0.001) [47]. However, to our knowledge, this is the only study supporting the
hypothesis that a high level of green tea consumption suppresses the risk of bladder cancer. On the
other hand, surprisingly, another study reported that the risk of bladder cancer was significantly higher
for individuals who consumed five to nine cups of green tea daily than in those who did not consume
green tea (odds ratio, 2.67; 95% confidential interval, 0.49–2.84) [48]. However, the same study also
showed that bladder cancer risk was similar for individuals who consumed ≥10 cups daily than for
those who did not consume green tea (odds ratio, 1.18; 95% confidential interval, 1.44–4.94) [48]. Table 1
summarizes the findings of previous studies on the relationship between green tea consumption and
bladder cancer risk.
Table 1. Previous reports on the relationship between green tea consumption and bladder cancer risk.











Waikens et al. Cases/controls = 271/522 Chyou et al.
/1996 (Men) /1993 Never 1.0
/USA Q1 1.0 /USA Ever 1.34 0.79–2.27
/[49] Q2 1.1 0.6−1.9 /[50]
Q3 1.1 0.6–2.3
(Women) Nagano et al.
Q1 1.0 /2000 0–1 cup 1.0
Q2 0.8 0.3–2.1 /Japan 2–4 1.07 0.61–2.00
Q2 0.9 0.3–2.6 /[51] ≥5 1.07 0.58–2.08
Wakai et al. 124/744 Kurahashi et al.
/2004 < 1.0 /2009 (Men)
/Japan 1–4 1.40 0.74–2.62 /Japan <1 cup 1.0
/[47] 5–9 2.67 1.44–4.94 /[52] 1–2 1.18 0.73–1.91
≥10 1.18 0.49–2.84 3–4 0.71 0.43–1.18
≥5 0.90 0.56–1.45
Hemelt et al. 381/371 (Women)
/2010 0 1.00 <3 1.0
/China <Daily 0.83 0.54–1.27 3–4 1.22 0.49–3.00
/[53] Daily 1.02 0.71–1.48 ≥5 2.29 1.06–4.92
<4 1.23 0.76–1.97
≥4 0.83 0.53–1.28
Wang et al. 1007/1299
/2013 Never 1.0
/USA 0.1–0.13 0.82 0.61–1.11
/[49] ≥0.14 0.60 0.45–0.79
ref: reference. OR: odds ratio. RR: relative ratio. CI: confidential interval.
As shown in Table 1, four of the seven studies were performed in Asian countries. In addition,
among the three studies performed in the USA, the subjects were of Japanese ancestry in one and
in another were Japanese individuals living in the USA [47,49,50]. Case-control and cohort studies
have not been performed in Central and South America, Europe, or Africa. This does not mean that
researchers and residents in these countries are not interested in the anticancer effects of tea extracts,
including catechins, in bladder cancer. In fact, to clarify the relationship between fluid intake and the
risk of urothelial cancer, a multicenter cohort study was designed for 233 and 236 subjects from 23
centers in 10 European countries [54]. The findings of that study revealed that the intake of tea and
herbal tea was not associated with the risk of urothelial cancer. However, the effects of green tea per se
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were not investigated. Moreover, information concerning the anticancer effects of green tea in white
and black individuals is scarce.
With regard to epidemiological studies, we should also pay attention to the fact that various
units are used to measure green tea consumption, such as frequency/day, cups/day, and mL/day.
In addition, the volume per cup differs among countries and regions. For example, the volume of
representative cups used for consuming green tea in Japan (120–140 mL) is less than that in Western
countries. This information is important when considering the clinical usefulness of green tea. It would
be useful if more detailed information about the amount of green tea consumed were included in such
reports in future.
3.1.2. Meta-Analyses
There have been several reports of meta-analyses of the relationship between green tea
consumption and bladder cancer risk. In this review, we have focused on meta-analyses published in
English, because we could not verify the content of publications in other languages. A summary of
these meta-analyses is presented in Table 2.











Qin et al./2012/[55] 2 3 0.97 0.73–1.21
Wang et al./2013/[13] 2 2 0.81 0.68–0.98
Wu et al./2013/[56] 3 2 1.03 0.82–1.31
Zhang et al./2015/[57] 0 3 1.02 0.95–1.11
Weng et al./2017/[58] 4 3 0.95 0.73–1.24
Only one meta-analysis showed a negative correlation between green tea consumption and
bladder cancer risk [13], while the remaining four showed no association between green tea
consumption and the risk. A meta-analysis of three cohort studies and three hospital-based case-control
studies showed that green tea consumption was not related to a decreased risk of bladder cancer (odds
ratio, 0.97; 95% confidential interval, 0.73–1.21) [55]; in addition, another meta-analysis of two cohort
studies and three case-control studies showed that there was no significant relationship (relative risk,
1.03; 95% confidential interval, 0.82–1.31) between green tea consumption and bladder cancer risk [56].
Yet, another dose–response meta-analysis of 25 case-control studies and seven prospective cohort
studies showed no significant association between green tea consumption and bladder cancer risk [58].
On other hand, it should be noted that the number of studies included in these meta-analyses
was relatively small. Although the meta-analysis by Weng et al. assessed the relationship between the
consumption of various types of tea (black tea, oolong tea, herbal tea, etc.) and bladder cancer risk in
32 studies (25 case-control studies and seven cohort studies), it included only seven studies involving
green tea consumption [58]. Another limitation of these meta-analyses is that they did not include
papers published in languages other than English. We found a meta-analysis of five studies showing
that increased consumption of green tea may have a protective effect on bladder cancer (odds ratio,
0.76; 95% confidential interval, 0.66–0.95); however, only three of those five studies were verifiable [59].
Considering that green tea is a major beverage for Asians, the majority of whom are not native English
speakers, we believe that the publication of English versions of studies published in Asian languages
is important.
3.2. Mechanisms Underlying the Anticancer Effects of Green Tea in Bladder Cancer
Although it remains unclear how GTPs regulate malignant aggressiveness, various cancer-related
mechanisms and molecules are known to play important roles in the anticancer effects of green tea.
In addition, green tea and its extracts have been suggested to affect multiple pathological activities and
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signaling pathways [60]. Therefore, we evaluated the relationships between GTP and cancer-related
functions, including cell survival, cell death, migration, and the cell cycle, in bladder cancer cell lines
(Table 3).
Table 3. Relationships between green tea polyphenol treatment and various cancer-related functions in
in vitro studies of bladder cancer cell lines.
Cell Line Type Dosage/Concentration Author/Year/Reference
Growth inhibition
AY-27 EGCG >100 μM Kemberling et al./2003/[61]
NBT-II EGCG 10, 20, or 40 μM/L Chen et al./2004/[62]
J82 EGCG 70–87 μM Rieger et al./2007/[63]
UM-UC-3 EGCG 70–87 μM Rieger et al./2007/[63]








KK47 EGCG 70–87 μM Rieger et al./2007/[63]
TCCSUP EGCG 70–87 μM10–80 μg/mL
Rieger et al./2007/[63];
Philips et al./2009/[65]
TSGH-8301 EGCG 25–100 μM Chen et al./2011/[66]
MBT-2 EGCG 12.5–50 μM Hsieh et al./2011/[67]
RT4 EGCG 60–80 μg/mL Philips et al./2009/[65]
SW780 EGCG 10–80 μg/mL Philips et al./2009/[65]
Apoptosis induction
NBT-II EGCG 10 μM/L Chen et al./2004/[62]
T24 EGCG 10–80 μg/mL Qin et al./2007/[64]
TCCSUP EGCG 40 μg/mL Philips et al./2009/[65]
TSGH-8301 EGCG 75 μM Chen et al./2011/[66]
MBT-2 EGCG 50 μM Hsieh et al./2011/[67]
SW780 EGCG 50–200 μM Luo et al./2017/[27]
Migration inhibition
UM-UC-3 EGCG 5 μM Rieger et al./2007/[63]
EJ EGCG 5 μM Rieger et al./2007/[63]
TCCSUP EGCG 5 μM Rieger et al./2007/[63]
SW780 EGCG 25–50 μM Luo et al./2017/[27]
Cell cycle arrest
NBT-II EGCG 10, 20, or 40 μM/L Chen et al./2004/[62]
EGCG: epigallocatechin-3-gallate. GTP: green tea polyphenol.
3.2.1. Cancer Cell Proliferation and Cell Death
In vitro studies have shown that EGCG suppressed cancer cell proliferation and growth in various
types of bladder cancer cell lines. Interestingly, one study showed that a high concentration (60 μg/mL)
of ECG and ECGC significantly suppressed the proliferation of bladder cancer cell lines (RT4, SW780,
TCCSUP, and T24) [65]. However, the same study also showed that a low concentration (10 μg/mL)
of ECG could suppress proliferation in SW780, but not in RT4 and T24 [65]. Thus, we speculate that
the inhibitory effects of green tea polyphenols on bladder cancer cell proliferation are regulated by
complex mechanisms.
In addition to its effects on cancer cell proliferation, EGCG induced apoptosis in various types of
bladder cancer cell lines, regardless of the malignant potential and species (Table 3). A study showed
that EGCG played an important role in not only the induction of apoptosis, but also the inhibition of
growth in a bladder cancer cell line (NBT-II) [62]. However, another study showed that EGCG affected
only the apoptosis of bladder cancer cells (SW780), but not cell proliferation or migration [27].
Autophagy is a highly conservative catabolic process used by eukaryotic cells for the degradation
of damaged or superfluous proteins and organelles [66]. Although autophagy plays important roles
92
Medicines 2018, 5, 87
in cell signaling and cellular homeostasis, including physiological cytoprotective or prosurvival
mechanisms, completely uncontrolled or excessive autophagy has been associated with cell death [68].
Autophagy is also recognized as an important factor for understanding the pathological characteristics
and for planning treatment strategies for many types of cancers [69,70]. This process is stimulated
by various stimuli, including nutrients [71,72]. In fact, in bladder cancer cells, autophagy plays an
important role in pathological processes and signaling pathways via external stimuli, including natural
products [73,74]. With regard to the relationship between autophagy and GTPs, an in vitro study
showed that the latter inhibited epirubicin-induced autophagy [75].
Thus, GTPs, especially EGCG, play important roles in cell survival, and affect cell proliferation
and cell death in various types of bladder cancer cell lines. On the other hand, as shown in Table 3,
the dosage and concentration of EGCG used in in vitro studies varied greatly. Further studies are
necessary to judge the optimal dosage and concentration to ascertain the relationship between GTP
and bladder cancer cell survival.
3.2.2. Other Cancer-Related Mechanisms
Cancer cell migration and invasion are two key processes for cancer cell dissemination and
metastasis in almost all solid tumors, including bladder cancer. As shown in Table 3, in vitro studies
have used scratch assays and migration assays to show that EGCG suppressed cell migration and
invasion. However, information pertaining to cell migration and invasion is scarce relative to that
related to cell survival and death. On the other hand, the concentrations of EGCG that inhibited
bladder cancer cell migration were typically lower than those that affected tumor growth and apoptosis
(Table 3). More detailed investigations are needed to clarify this issue.
A previous study showed that EGCG caused cell cycle arrest in rat transitional cell cancer [62].
Another study suggested that tea polyphenols can deregulate the cell cycle in bladder cancer cells [46].
Oxidative stress is defined as an imbalance between the cellular production of reactive oxygen species
(ROS) and antioxidants; excessive production of ROS causes DNA damage and promotes the activities
of oncogenes and/or inhibits tumor suppressor genes [76]. Oxidative stress plays important roles in
the aggressiveness of bladder cancer [77]. A previous study has shown that GTPs can protect against
oxidative stress in the event of bladder cell death, although this effect was not detected in one of the
bladder cancer cell lines (T24) [78].
On the other hand, as shown in Table 3, EGCG has been most widely used for in vitro studies
aiming to clarify the relationship between GTPs and various cancer-related functions. Furthermore,
other reports have shown that EGCG is the most important component in terms of the health benefits
and anticancer effects of green tea [79,80]. Therefore, ECGC has been the focus of discussion in terms
of both potential preventative and of therapeutic approaches for bladder cancer.
3.2.3. Cancer-Related Potential Molecular Targets of Green Tea Polyphenols
Next, we evaluate reports on the relationships between GTPs and cancer-related signaling
molecules in bladder cancer cell lines (Table 4).
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Table 4. Potential molecular targets of green tea polyphenols in bladder cancer cell lines.
Molecules Cell Line Author/Year/Reference
Bcl-2 family T24 Qin et al./2007/61; Gu et al./2017/[68]
TSGH-8301 Chen et al./2011/[66]
MBT-2 Hsieh et al./2011/[67]
SW780 Luo et al./2017/[27]
BIU87 Gu et al./2017/[68]
Caspase family TSGH-8301 Chen et al./2011/[66]
MBT-2 Hsieh et al./2011/[67]
SW780 Luo et al./2017/[27]
Cyclin D1 NBT-II Chen et al./2004/[62]
Cyclin-dependent kinase 4/6 NBT-II Chen et al./2004/[62]
Heat shock protein 27 TSGH-8301 Chen et al./2011/[65]
JNK/Bcl-2/Beclin-1 T24, BIU87 Gu et al./2017/[75]
Matrix metalloproteinase-9 SW780 Luo et al./2017/[27]
N-cadherin UM-UC-3 Rieger et al./2007/[63]
Nuclear factor-kappa B TCCSUP Philips et al./2009/[65]
SW780 Luo et al./2017/[27]
Phosphatidylinositol 3-kinase UM-UC-3 Rieger et al./2007/[63]
/Akt signaling T24 Qin et al./2007/[64]
TSGH-8301 Chen et al./2011/[66]
Retinoblastoma protein NBT-II Chen et al./2004/[62]
Wnt signaling TCCSUP Philips et al./2009/[65]
As shown in Table 4, GTPs can regulate the expression and activity of various types of
cancer-related molecules. Among them, the bcl-2 and caspase families are well-known important
regulators of apoptosis in many types of cancer cells, including bladder cancer cells [81–83]. In addition,
phosphatidylinositol 3-kinase (PI3K)/Akt signaling is one of the most important mediators for
the regulation of pathological activities such as cell proliferation, apoptosis, and progression in
malignancies, including bladder cancer [82,84,85]. Furthermore, a JNK/Bcl-2/Beclin-1-mediated
mechanism is associated with autophagy and apoptosis in bladder cancer cells [68]. As a mechanism
underlying the pro-apoptotic function, the regulation of nuclear factor-kappa B and matrix
metalloproteinase (MMP)-9 has been suggested [27]. Various apoptosis-related molecules have
been associated with GTP-induced cell death in bladder cancer cells. Surprisingly, however,
there has been no study of the relationship between GTPs and p53 status and function in bladder
cancer, even though significant mechanistic associations have been reported in other types of
malignancies [86,87]. Therefore, the effects of GTPs on bladder cancer cell proliferation and death
require further investigation.
MMP-9 and N-cadherin, which play crucial roles in cancer cell migration and invasion in bladder
cancer [88,89], are reportedly modulated by GTPs in bladder cancer cell lines [27,63]. However, there is
little information on the effect of GTPs on E-cadherin, which is the best known and classical member
of the cadherin family, in bladder cancer. Similarly, the influence of GTPs on MMP-2, which is a strong
stimulator of cell invasion and migration, remains unclear. However, there has been a report that
a mixture of lysin, proline, arginine, ascorbic acid, and GTEs inhibited cancer cell invasion via the
regulation of MMP-2 and MMP-9 production in a bladder cancer cell line (T24) [90].
In a bladder cancer cell line established from Wistar rats (NBT-II), EGCG caused growth
inhibition and cell cycle arrest via the downregulation of cyclin D1, cyclin-dependent kinase 4/6,
and retinoblastoma protein in terms of regulation of cell cycle progression [62]. As mentioned above,
several investigators have reported that GTPs play an important role in cell cycle regulation in bladder
cancer cells [46,62]. However, more detailed information on the molecular mechanisms is necessary to
understand the antibladder cancer effects of green tea.
Proteomic analysis has shown that EGCG affects the expression levels of heat shock protein
27 in the TSGH-8301 cell line [66]. Interestingly, a recent study showed that heat shock protein 27
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expression was significantly associated with clinicopathological features, including the stage and
grade, of bladder cancer in 132 patients [91]. The same study also showed no association with clinical
outcomes, such as tumor recurrence, progression, and patient survival. Detailed mechanistic links
between GTPs and heat shock protein 27 in other diseases, including cancers, have been reported,
and knowledge of changes in heat shock protein 27 activities by green tea are important for the
evaluation of cancer-related signal pathways and development of new therapeutic strategies [92]. With
regard to bladder cancer, more detailed investigations of GTP-induced anticancer effects of heat shock
protein 27 are therefore necessary.
In summary, various types of cancer-related molecules are modulated by GTPs. These molecules
usually play multiple roles in the malignant behavior of most cancers, including bladder cancer.
For example, MMP-9 plays an important role in apoptosis and cell migration, while Wnt signaling
plays an important role in cell proliferation, cell cycle regulation, apoptosis, and migration in bladder
cancer [93,94]. We propose that identification of detailed molecular mechanisms of anticancer cell
effects by GTPs is essential for targeting the key signaling molecules.
3.2.4. Correlation with Genetic Polymorphisms
A previous report has showed that, although the frequency of green tea consumption was not
significantly associated with breast cancer risk in all women or in women with the low-activity
genotype of the angiotensin-converting enzyme (ACE), a significant decrease in cancer risk with an
increase in the frequency of green tea consumption was found in women bearing the high-activity
genotype of ACE [95]. Furthermore, the same study group showed that methylenetetrahydrofolate
reductase and thymidylate synthase genotypes affected the association between green tea consumption
and breast cancer risk [24]. In recent years, several studies on various malignancies have
shown the relationship between the anticancer effects of GTPs and genetic polymorphisms [96,97].
With regard to bladder cancer, a study reported that genotype was significantly associated with tea
consumption-associated changes in bladder cancer risk [47]. Tea consumption did not decrease the risk
of bladder cancer for rs7571337 AA-genotype carriers, whereas it decreased the risk for carriers of the
rs7571337 AG+GG genotypes [47]. Unfortunately, the study evaluated the effects of a mix of green tea,
black tea, decaffeinated tea, and other herbal teas, rather than those of green tea alone [47]. In another
study, lymph node metastasis from urothelial cancer was associated with the methylation status
of DACT1, which is controlled by polymorphisms in the gene encoding methylenetetrahydrofolate
reductase (MTHFR) [98]. Similarly, MTHFR 677T polymorphisms were reported to be associated with
hypomethylation of insulin-like growth factor-2, the proportion of which was significantly associated
with lymph node metastasis [99]. However, such DNA methylation was not significantly associated
with green tea consumption [98,99].
In summary, the anticancer effects of GTPs according to genetic polymorphisms in patients with
bladder cancer require further studies, with an emphasis on the prevention of carcinogenesis and
tumor progression in multiple population groups. Of note, most previous studies were conducted in
Asian subjects.
3.3. Anticancer Effects of Green Tea in Animal Models
Various in vivo studies using animal models have shown that GTEs may be useful therapeutic
agents for patients with bladder cancer (Table 5).
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Table 5. Anticancer effects of green tea in animal models of bladder cancer.



















Inhibited the growth of
transitional carcinoma cells
Rieger et al./2007/[63] EGCG Drinking Xenograft model Over 50% decrease in the meanfinal tumor volume
Sagara et al./2010/[102] GTE Drinking Mouse; Chemicallyinduced
Inhibited tumor growth and
invasion via regulation of
angiogenesis
Chen et al./2011/[66] ECGC Gavage Mouse; xenograftmodel
Inhibited tumor growth in a
dose-dependent manner







more effective than free EGCG in
inhibiting tumor growth
Henriques et
al./2014/[103] Whole green tea Drinking
Mouse; Chemically
induced
Influenced inflammation in the
urothelium, but not
carcinogenesis
Matsuo et al./2017/[104] GTE Drinking Mouse; Chemicallyinduced
Inhibited tumor growth and
angiogenesis via human-antigen
R-related pathways
ref: reference. GTEs: green tea extracts. ECGC: epigallocatechin-3-gallate.
While one study reported that GTPs inhibited tumor growth and invasion via regulation of
angiogenesis in a mouse model of chemically (N-butyl-N-(4-hydroxybutyl)-nitrosamine; BBN) induced
bladder cancer [102], another reported that green tea infusion did not affect the development of
bladder cancer after chemical induction in a mouse model [103]. However, the latter study used whole
green tea, not GTEs. In another study, GTP intake suppressed the expression of cyclooxygenase-2,
hemeoxygenase-1, and human antigen-R (HuR), and this suppression of cancer-related molecules led to
the inhibition of cancer cell proliferation and angiogenesis in a mouse model of BBN-induced bladder
cancer [104]. Interestingly, the study also found that VEGF-A expression was not directly affected by
green tea intake, although it was regulated by green tea intake via HuR regulation [104]. Therefore,
green tea intake is speculated to regulate various malignant behaviors through complex mechanisms.
Some rat models of bladder cancer also showed the anticancer effects of green tea. In a study
of Fisher 344 rats implanted with urothelial cancer cells (AY-27), 18 of 28 (64%) rats who received
intravesical EGCG instillation were free of tumors, whereas all 12 control rats developed tumors [61].
These findings indicated that intravesical EGCG instillation significantly (p = 0.001) suppressed the
growth of urothelial cell carcinoma in rats [61]. Another study involving a rat model of bladder cancer
induced by the intake of drinking water containing BBN showed that the number and volume of
tumors were significantly fewer in rats treated with powdered green tea than in control rats that
received no such treatment [101]. The same authors also showed dose-dependent anticancer effects
of green tea powder intake in a similar rat model of bladder cancer [100]. On the other hand, it has
been reported that green tea infusion influences urothelial inflammation, but not carcinogenesis, in a
mouse model of BBN-induced bladder cancer [103]. However, in that study, mice treated with BBN
only showed no cancer cells.
Taken together, the anticancer effects of GTPs were confirmed in various animal models, and these
results support the need for preclinical studies and clinical trials of the use of GTPs in the prevention
of recurrence and progression in patients with bladder cancer.
3.4. Bladder Cancer Treatment and Prevention Strategies Based on Green Tea Consumption
Epirubicin is an effective anticancer agent for bladder cancer. Epirubicin reportedly induces
this cytoprotective autophagy in bladder cancer cell lines [67]. Interestingly, GTPs inhibited
epirubicin-induced autophagy and promoted apoptosis in the same study [67]. Accordingly, it was
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suggested that GTPs can be used in combination with epirubicin for enhanced epirubicin-based
bladder cancer therapy.
Discrepancies in findings regarding the anticancer effects of green tea between epidemiological
studies and in vitro studies can be attributed to differences in the concentration of the GTPs used
among studies. The concentration of GTPs used in in vivo studies is routinely lower than that used
in in vitro studies [105]. In one study, patients with prostate cancer received polyphenon E, which is
derived from a hot water extract of green tea leaves (Camellia sinensis) and contains 85–95% catechins,
including EGCG, for 3–6 weeks before surgery. However, GTP levels in the prostatectomy tissue were
low to undetectable [106]. In addition, in a phase II randomized double-blind trial of bladder cancer,
polyphenon E or placebo was administered prior to transurethral resection or radical cystectomy,
following which tissue EGCG levels were compared between the experimental and placebo groups;
there was no significant difference between the two groups [107]. On the basis of these findings,
several investigators have shown interest in new technologies and methods that can achieve higher
concentrations of GTPs in cancer tissues.
Nanoparticles are recognized as useful drug carriers. The use of EGCG–gold nanoparticles
was found to be more effective than the use of free EGCG for treatment in an animal model of
bladder cancer [67]. Moreover, EGCG–gold nanoparticles administered orally, intraperitoneally, and
intratumorally suppressed tumor growth in C3H/He mice injected with murine bladder cancer cells
(MBT-2). The anticancer effects were greater with intraperitoneal and intratumoral administration than
with oral administration [67]. Another study showed that Mg(II)-catechin nanocomposite particles
had anticancer effects in vitro and in vivo in a rat model of in situ bladder cancer [108]. In that
study, Mg(II)-catechin nanocomposite particles that delivered siRNA targeting oncogene eukaryotic
translation initiation factor 5A2, showed enhanced antitumor activity [108].
Various new treatment and prevention strategies based on GTPs have been developed in in vitro
studies and animal experiments. Some of them have been confirmed to be effective in vivo in bladder
cancer animal models. Therefore, there is now a need for translational studies of such in vitro and
animal experiments in humans.
3.5. Safety
In general, GTPs are considered to be safe because they are natural compounds. GTPs were found
to have no toxic effects on normal cells in the gallbladder [28]. Furthermore, 24-h treatment with 20
μg/mL and 40 μg/mL of EGCG increased the frequency of apoptotic cells in colon cancer cell lines
(COLO205), while no significant changes were observed in normal colon epithelial cells (NCM460) [19].
Although green tea and its extracts have a relatively high level of safety for normal cells, it should
be noted that “natural” does not always imply safety. In fact, a review on the toxicological effects
of green tea showed that various side effects occurred in animal models, healthy volunteers, and
patients, with hepatotoxicity, gastrointestinal disorders, and nervous system stimulation being the
most important effects, although green tea and its main components are not recognized as major
teratogenic, mutagenic, or carcinogenic substances [2]. The study also recommended that green tea
should be used with caution in pregnancy, while breast feeding, and in susceptible individuals, as data
in these contexts are limited [2].
In normal urothelial cells (UROtsa cell line), GTEs, including ECG and EGCG, were found to
inhibit growth in a dose-dependent manner [62]. Another report mentioned that bladder cancer cells
(SW780 cell line) were much more sensitive to EGCG than normal bladder epithelial cells (SV-HUC-1
cell line) [27]. In that study, 24-h treatment with EGCG at 100 mM induced cell proliferation inhibition of
more than 70% in SW780 cells and of only 7.8% in SV-HUC-1 cells [27]. In addition to anticancer effects,
preventive effects against oxidative stress in normal bladder cancer cells have been reported [78].
We previously discussed the anticancer effects of GTPs in a mouse model of BBN-induced
bladder cancer [102,104]. When normal urothelial cells in mice treated with GTPs were examined
by hematoxylin–eosin staining, abnormal morphological changes were not detected. However,
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more detailed analyses are necessary to confirm the safety and biological effects of GTPs on normal
urothelial cells.
4. Future Direction
The anticancer effects of green tea in bladder cancer have been analyzed using comprehensive
methods in epidemiological studies, in vitro studies using bladder cancer cell lines, animal models,
and in vivo studies using human tissues. However, some limitations need to be overcome in order to
understand the effects of green tea more accurately. Prospective randomized clinical trials with large
study populations are yet to be performed to determine the anticancer effects of green tea in Western
countries, including the USA, since epidemiological studies have provided some evidence that can
serve as a foundation for such trials. On the other hand, such trials are difficult to design because the
frequency and amount of green tea consumption in these countries are quite low.
As mentioned above, a combination of conventional chemotherapy and GTPs can be effective in
several cancers, including bladder cancer [35,36,67]. In recent years, green tea has come to be known as
a radiation sensitizer in prostate cancer [109]. However, there is little information on green tea-induced
changes in terms of the anticancer effects of radiotherapy for bladder cancer. At present, immune
checkpoint inhibitors are the major therapeutic agents used for patients with advanced/metastatic
bladder cancer [110,111], and the usefulness of green tea as a sensitizer of immune checkpoint inhibitors
has not yet been investigated. Therefore, more information on the efficacy and safety of combination
therapy involving cytotoxic anticancer methods and green tea consumption or GTP intake in bladder
cancer is warranted.
Clarification of the extent of the anticancer effects of green tea is difficult, because other bladder
cancer-related external factors, such as smoking, exposure to chemical agents, and family history,
also play a role [112–115]. In addition, the influence of other beverages, such as coffee, black tea,
and oolong tea, and the total fluid intake should be investigated. Furthermore, GTP has complex
molecular interactions that could contribute to its potential health benefits [80]. We hope that this
review will encourage further investigations of the anticancer effects of green tea that could lead to the
development of new treatment and prevention strategies based on green tea consumption and GTP
intake, which are relatively safe.
5. Conclusions
In this review, we summarized studies on the potential anticancer effects of green tea consumption
and GTP intake in bladder cancer by gathering data from epidemiological, in vivo, and in vitro
studies, which have shown conflicting results. In vitro studies using cancer cell lines indicated
that GTPs suppress malignant behavior via inhibition of cancer cell proliferation, migration, and
invasion and inhibition of apoptosis, and some in vivo studies using animal model also showed similar
results. However, some epidemiological studies showed no significant relationship between green
tea consumption and the risk of bladder cancer. These discrepancies can be attributed to differences
in the race, country, and measurement unit for green tea consumption and/or the influence of other
factors, such as smoking, amount of green tea consumption per day, and the intake of other beverages.
Therefore, more detailed and wider analyses of larger study populations from various countries,
including USA, Europe, and Africa, are necessary to confirm the anticancer effects and usefulness of
green tea as an anticancer agent. The anticancer effects of GTPs alone are considered to be limited,
whereas a combination of GTPs and other strategies, such as chemotherapy, radiotherapy, immune
therapy, and molecular targeted therapy is expected to have some clinical benefit in patients with
cancer, including bladder cancer.
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Abstract: Resveratrol (trans-3,5,4′-trihydroxystilbene, RSV) is a non-flavonoid dietary polyphenol
with antioxidant, anti-inflammatory and anti-cancer properties that is primarily found in red berries.
While RSV displays many beneficial effects in vitro, its actual effects in vivo or in animal models
remain passionately debated. Recent publications suggest that RSV pleiotropic effects could arise
from its capability to regulate the expression and activity of microRNAs, short regulators themselves
capable of regulating up to several hundreds of target genes. In particular, RSV increases microRNA
miR-663 expression in different human cell lines, suggesting that at least some of its multiple beneficial
properties are through the modulation of expression of this microRNA. Indeed, the expression of
microRNA miR-663 is reduced in certain cancers where miR-663 is considered to act as a tumor
suppressor gene, as well as in other pathologies such as cardiovascular disorders. Target of
miR-663 include genes involved in tumor initiation and/or progression as well as genes involved in
pathologies associated with chronic inflammation. Here, we review the direct and indirect effects
of RSV on the expression of miR-663 and its target transcripts, with emphasise on TGFβ1, and their
expected health benefits, and argue that elucidating the molecular effects of different classes of natural
compounds on the expression of microRNAs should help to identify new therapeutic targets and
design new treatments.
Keywords: resveratrol; miR-663; inflammation; cancer; cardiovascular disease
1. Introduction
Recent years have brought an increasing number of publications describing the potentials of
plant natural products to be used for the treatment of human pathologies. Among those molecules,
Resveratrol (trans-3,5,4′-trihydroxystilbene, RSV), which is produced by plants in defense against the
pathogen Botrytis cinerea [1], is in particular found in the skins of black and red berries. RSV presents
strong antioxidant, anti-inflammatory and anti-cancer properties [2,3]. While most of these properties
have been demonstrated using cell cultures, RSV precise molecular effects in vivo have remained
controversial, in particular because the bioactivity of this compound is limited by the fact that it is
rapidly metabolized [4]. Finally, whether resveratrol alone is beneficial to the health, or whether
resveratrol metabolites actually participate in delivering beneficial effects, also remains a matter of
debate (discussed in [5]).
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Pre-clinical studies, however, are presently being conducted to determine the true therapeutic
potentials of RSV in the treatment of cancer and cardiovascular diseases [3–8]. On the one hand,
several promising results have been reported. For example, the potentials of RSV as a phytoestrogen,
an inhibitor of aromatase activity and an adjuvant has been explored in the context of breast cancer [3].
Other studies have been conducted in patients with colorectal, multiple myeloma neuroendocrine
tumors, with variable results [7,8]. Beneficial effects of RSV on patients with neurologic, metabolic,
and cardiovascular pathologies have also been reported [6,9–12]. Thus, in animal models, resveratrol
has been shown to be anti-hypertensive, to modulate the levels of HDLs and LDLs in rats subjected to
high fat diet, to reduce myocardial ischemia and ischemia-reperfusion injury, and to reduce cardiac
hypertrophy; however, several studies have reported no RSV effect in each type of pathologies
(reviewed by [5]).
The biggest challenge finally rests on determining the molecular pathways through which RSV acts
in different pathological contexts, determining the optimal RSV dose, the best mode of RSV delivery,
and how to increase the bioavailability of RSV in different tissues (discussed in [6]). Based on studies
conducted in animal models such as swine, mouse or monkeys, the absorption of regular, low doses
of RSV seems to bear promising potentials for preventive therapeutics [6]. Transferring these results
in human, however, remains particularly challenging, in particular when it comes to measuring RSV
protecting effects in healthy subjects, given in particular the impossibility of conducting long or very
long-term studies, that, beyond considerable cost, carry high risks of bias [6]. Thus, while beneficial
effects have been reported following RSV treatment of patients that were either healthy, obese or
presenting different pathologies associated with the metabolic syndrome, other studies reported a lack
of effects of this molecule (discussed by [6]).
One fact could potentially explain the apparent paradox of a molecule with low biological
availability providing pleiotropic beneficial effects in many different contexts: it is that RSV can
globally change the composition of endogenous microRNA populations [13]. MicroRNAs are small
(19–23-nt in length) non-coding regulatory RNAs that regulate the stability and/or translation of their
target transcripts. MicroRNAs have been progressively implicated in all aspects of cell biology and
homeostasis and established as key players in a number of pathologies, including, but not limited to,
inflammatory, metabolic and cardiovascular diseases, neuropathologies, and cancers [14–26].
2. Resveratrol-Inducible MiR-663 in Health and Disease
MicroRNAs that regulate fundamental functions, such as metabolism, cell proliferation and
differentiation, or development, have generally been very well conserved between invertebrates and
vertebrates during evolution. In contrast, other microRNAs are found in vertebrates only: thus,
miR-155, a microRNA that has been implicated in inflammatory response and inflammation-associated
cancers. Finally, some microRNAs are only found in one or a few species of vertebrates. This is the
case for miR-663 (a.k.a. miR-663a) that appears to be primate-specific. A few years ago, it was shown
that, upon RSV treatment, miR-663 was upregulated both in human THP-1 monocytes, where it targets
transcripts encoding pro-inflammatory JunB and JunD, and in human SW480 colon cancer cells, where
it targets TGFβ1 transcripts [27,28] (Table 1). At first, this suggested that this microRNA by and large
would deliver beneficial effects to the body. Nevertheless, available literature shows that this is not
always the case (see here after), indicating that miR-663 can be harmful as well, depending on the
cellular context.
2.1. MiR-663 in Inflammation
The capability of RSV to modulate a wide range of signaling pathways implicated in both
the mounting and the termination of the immune response have puzzled scientists for a long time.
It is becoming increasingly clear that many of these effects of RSV are through the modification of
the composition of microRNA populations within the cell [13,29]. Namely, microRNAs are global
regulators with the capability to directly regulate tens to hundreds of target transcripts, and many more
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through indirect regulation that results from microRNAs targeting transcripts encoding regulators
such as transcription factors, factors implicated in different signal transduction pathways, such as
kinases or phosphatases, or epigenetic regulators such as methylases or demethylases.
For example, miR-663 has been shown to decrease AP-1 activity, that is critical for the mounting
of the inflammatory response, by directly targeting JunB and JunD transcripts, at least in part through
the downreguation of miR-155 [27]. In addition, RSV impairs the up-regulation of pro-inflammatory
miR-155 at least in part through increasing miR-663 expression [27]. This property of RSV is likely to
have major consequences, for miR-155 is implicated in the mounting of both the innate and adaptative
immune responses [16,30]. A study conducted on 35 hypertensive patients with coronary artery
disease and type 2 diabetes showed that, after ingesting a grape extract containing RSV for one year,
patients presented with peripheral blood mononuclear cells that expressed less pro-inflammatory
IL-1β and TNFα cytokines, less pro-inflammatory miR-155, and more anti-inflammatory miR-663.
Although conducted on a relatively small sample of patients, this study provides a good evidence that
long lasting, low RSV doses have actual beneficial effects on patient health [31]. Incidentally, it further
suggests that RSV might be a better candidate for preventive rather than for curative therapeutics,
at least when it comes to inflammation-related pathologies.
In contrast, in patients with systemic lupus erythematous, miR-663 impairs the proliferation and
migration of bone marrow-derived mesenchymal stem cells, thus shifting the imbalance between
follicular T helper cells and regulatory T cells toward less regulatory T cells and more follicular
T helper cells. As regulatory T cells reduce the capability of B cells to augment autoimmunity, miR-663
activity, by reducing the secretion of TGFβ1 by T cells, worsens lupus development [32]. In addition,
miR-663 activity proved deleterious in rheumatoid arthritis, a disease linked to synovial inflammation,
cartilage erosion and joint destruction. In fibroblast-like synoviocytes from rheumatoid arthritis
patients, increased levels of miR-663 suppressed the expression of Adenomatous polyposis coli (APC) gene,
triggering the activation of the canonical Wnt signaling pathway through accumulation of β-catenin.
This activation increases the production of pro-inflammatory cytokines and, as a consequence of
increased inflammation in joints, disturb the osteoblast–osteoclast axis and increases bone resorption
by osteoclasts [33].
Nuclear factor TDP-43 (trans-activation response element DNA-binding protein 43) is an
RNA-binding protein that shuttles between the nucleus and the cytoplasm. TDP-43 in particular plays
a role in the biogenesis of microRNAs through its interactions with the nuclear Drosha complex, which
generates pre-miRNAs from pri-miRNAs, and the cytoplasmic Dicer complex, which then produces
mature miRNAs from pre-miRNAs [34]. TDP-43 has been shown to be causative in amyotrophic lateral
sclerosis (ALS) and frontotemporal dementia (FTD) [35]. Interestingly, TDP-43 can bind microRNAs
such as let-7b and miR-663. TDP-43 knockdown in cultured cells decreases let-7b levels while increasing
that of miR-663, thus modulating their activities [36]. It is thus possible that the role played by TDP-43
in neurodegenerative pathologies might be linked to its differential effects on microRNA production,
and ultimately depends on whether these microRNAs are beneficial or deleterious in the context.
Finally, radiation-induced bystander effect corresponds to the biological response to radiations of
cells that, while not being located in the path of ionizing rays, receive signals produced by directly
irradiated cells that lead them to amplify or exaggerate the action of low dose radiation. This effect
can significantly increase radiation risk and tissue damage. In particular, TGFβ1 secretion by directly
irradiated Hela cells reduces the expression of miR-663 in both directly irradiated and bystander Hela
cells, which correlates with increased DNA damage and reduced rate of cell survival. At the same time,
TGFβ1 signaling increases the expression of miR-663 in bystander cells, which in turn decreases the
levels of TGFβ1 by targeting TGFβ1 transcripts. By reducing TGFβ1-induced DNA damage, miR-663
increases the survival of bystander cells, thus limiting the propagation of radiation-induced bystander
effects [37]. Hence, the study of the effects of a low irradiation dose provides a further evidence for
miR-663 activity being at the same time beneficial as well as deleterious.
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Therefore, the functions of miR-663 seem to be context-dependent: it may well be that, in a
given setting, the outcome of miR-663 activity might depend on the context, i.e., on the transcriptome
expressed in a given cell, and especially the panel of miR-663 target transcripts that are present. It is
also most probable that miR-663 effects might be dose-dependent, and that it might target different
transcripts as it has previously been shown for several microRNAs. For example, miR-155 targeting of
Quaking transcripts in RAW264.7 macrophages occurred at low concentration only [38], and, in myeloid
cell from patients with acute myeloid leukemia, miR-155 activity increases and decreases the levels
of different set of transcripts depending of the level of miR-155 expression [39]. Of note, RSV has the
capability to change the level of expression of both miR-155 and miR-663 microRNAs, in both cases
with apparent beneficial outcome [26,27]. Many other pathologies have also been associated with high
levels of miR-155. For example, this microRNA has recently been shown to be causative in paralysis
that develops following thoracic abdominal aortic aneurysm repair [40]. On the other hand, increased
expression of chromosome 21-located miR-155 in the brain of individuals with Down’s dementia has
been linked with the presence of hyperphosphorylated tau protein and the reduction of the levels of
several miR-155 targets, including BACH1, CoREST1, BCL6, BIM, BCL10, Cyclin D, and SAPK4 [41].
Therefore, the capability of miR-663 to decrease miR-155 expression [29] and reported capability of
RSV to cerebral ischemia, in particular through its anti-inflammatory effects, [9] suggests that this
compound might be protective when administered ahead of programmed surgery or intervention.
2.2. MiR-663 in Cancer
It is now recognized that microRNAs play a central role in molecular dysfunctions linking
inflammation with cancer [42,43]. While certain microRNAs are generally considered as pro-oncogenic
or oncomiRs and others as tumor-suppressors, it seems that their actual impact on cancers might be
context- and/or dose-dependent. This is in particular the case for miR-155, that is implicated in the
mounting of a robust anti-tumor immunity when expressed at high doses but favors tumorigenesis
when expressed at moderate level [39,42,43]. More generally, changes in microRNA expression either
are causative in the initiation of cancers, or a consequence of the process of tumorigenesis itself.
Remarkably, miR-155 displays mutator activity, in particular due to its targeting of transcripts encoding
the cell-cycle regulator WEE1 [44].
As seen here above for inflammation, miR-663 can either inhibit or favor cell proliferation and/or
migration in different settings. In human MCF7 breast cancer cells, miR-663 targets transcripts
encoding Eukaryotic translation elongation factor 1A2 (eEF1A2), which results in slowing the
proliferation of MCF7 cells. RSV treatment of these cells increased the expression of miR-663 and
miR-744, with a similar output [45]. Breast cancer has a higher incidence in young Lebanese women
as compared with American woman. A comparative profiling study showed that, in Lebanese
breast cancer patients, 21 miRNAs, including miR-663, were specifically deregulated, possibly as
a result of differential methylation of their promoter [46]. Another study showed that miR-663 is
up-regulated in multidrug-resistant MDA-MB-231-derived ADM cell line, and that increased miR-663
expression was associated with the downregulation of Heparin sulfate proteoglycan 2 (HSPG2) and
chemoresistance [47].
MiR-663 was also shown to increase the proliferation of nasopharyngeal carcinoma NPC C666-1
cells by directly targeting the cell cycle negative regulator CDKN2A [48]. Accordingly, miR-663
expression was higher in the serum of nasopharyngeal carcinoma patients, as compared with controls,
and increasing miR-663 levels were correlated with malignant progression and poor prognosis. On the
other hand, miR-663 expression was decreased by chemoradiotherapy [49]. The oncogenic activity of
miR-663 in nasopharyngeal carcinoma was due to its targeting of p21(WAF1/CIP1) that promotes the
cellular G1/S transition [50]. In contrast, in two papillary thyroid carcinoma cell lines, miR-663 behaved
as a tumor-suppressor by targeting TGFβ1, thus inhibiting epithelium-to-mesenchyme transition [51],
similar to what was previously found in SW480 colon cancer cells [28]. Similarly, miR-663 levels were
low in several human gastric cancer cell lines, and transfecting the two human gastric cancer cell lines
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BGC823 and SNU5 with miR-663 suppressed their proliferation and induced a phenotype of mitotic
catastrophe, indicating that miR-663 behaves as a tumor-suppressor in this type of cancer [52]. A study
about the effects of sunitinib treatment of metastatic renal cell carcinoma patients showed that the
resistance that these patients develop eventually is linked to the downregulation of miR-1 and miR-663.
This downregulation was associated with the acquisition of a migratory phenotype, as established
on xenografts. In sunitinib resistant tumor cells, miR-663 targets FRAS1 (Fraser Extracellular Matrix
Complex Subunit 1) and MDGA1 (MAM Domain Containing Glycosylphosphatidylinositol Anchor 1)
transcripts. Restoring miR-1 and miR-663 levels or knocking down MDGA1 decreased renal cancer cell
proliferation and migration [53]. The expression of miR-663 was upregulated in HepG2 hepatocellular
carcinoma cells co-incubated with the endoplasmic reticulum stress inducer tunicamycin. In these
cells, miR-663 inhibited apoptosis induced by endoplasmic reticulum stress by targeting TGFβ1
transcripts [54]. In agreement with this result, miR-663 was one of seven microRNAs whose expression
was specifically changed in patients with hepatitis B virus-related HCC [55]. In pancreatic cancer tissues
and cell lines, the downregulation of miR-663 inversely correlated with the upregulation of transcipts
encoding eEF1A2. eEF1A2 and miR-663 levels were linked with TNM (tumor/node/metastasis) stage
and node metastasis status in the patients. MiR-663 was shown to decrease the proliferation and
invasion potentials of pancreatic cancer cells both in vitro and in vivo by directly targeting eEF1A2 [56].
A study about colorectal cancer, based on 109 biopsy specimens, compared biopsied from patients with
tubulovillous adenomas and high-grade dysplasia versus biopsies from patients with normal mucosa
or hyperplastic polyps. It showed that, among 99 microRNAs whose expression was different between
the two groups, miR-663, miR-1268, miR-320b, miR-1275, and miR-320b were the most upregulated
microRNAs in the biopsies of the first group of patients [49]. MiR-663 was also upregulated in biopsies
from cutaneous tissues with malignant melanoma [57].
Patients with lung cancers present with high level of miR-663 expression, and miR-663 direct or
indirect targeting of TGFβ1, P53, Bax, and Fas transcripts increased the proliferation of A549 lung cancer
cells [58]. Accordingly, miR-663 proved deleterious in non-small cell lung cancer cells by targeting
PUMA/BBC3 (p53 up-regulated modulator of apoptosis/Bcl-2 binding component 3) and BTG2 (B-cell
translocation gene 2) transcripts, thus allowing cancer cells to escape apoptosis and promoting tumor
onset and development [59]. Nevertheless, waltonitone treatment inhibited proliferation and induced
apoptosis of H460 and H3255 lung cancer cell lines at least in part through inducing the targeting of
Bcl-2 by miR-663 [60]. These results provide a further illustration of the ambiguous role miR-663 can
play in a particular type of tumor.
In a study on glioblastomas, the most aggressive brain tumor, the grade of tumors correlated
with the level of PI3KCD activity (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit
delta) but inversely correlated with the level of miR-663 expression. Higher miR-663 levels were
associated with increased patient survival, which was linked with miR-663 targeting transcripts
encoding PI3KCD [61]. MiR-663 was also shown to decrease glioblastoma by targeting transcripts
encoding CXCR4, the receptor of chemokine CXCL12 that is known to be involved in glioblastoma
progression, and miR-663 overexpression prolonged survival of mice with glioblastoma [62]. MiR-663
was downregulated in A172 and U87 glioblastoma cell lines. Transfecting these cells with miR-663
inhibited their proliferation, migration and invasion. These effects were through miR-663 direct
targeting of TGFβ1, as well as transcripts encoding TGFβ1 downstream mediators MMP2 (Matrix
metalloprotease 2) and E-cadherin [63]. On the other hand, miR-663 expression was upregulated in
castration-resistant prostate cancer tissues, and miR-663 overexpression in LNCaP prostate cancer
cells increased their potentials for proliferation, invasion and neuroendocrine differentiation, while
reducing dihydrotestosterone-induced upregulation of prostate-specific antigen expression. In situ
hybridization experiments established that the level of expression of miR-663 correlates with TNM
stage and Gleason score and is a good predictor of cancer recurrence [64]. In a meta-analysis,
STAT3 (Signal Transducers and Activators of Transcription 3), JUN and JUNB transcription factors
were identified as key signatures of a metastatic integrative regulatory network in prostate cancer
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progression. MiR-663, that is overexpressed in these types of cancers, was one of five microRNAs
responsible for the down-regulation of the genes encoding these three transcription factors [65].
MiR-663, along with miR-622 and miR-647, was upregulated in Taxol-resistant ovarian cancer cells,
and the survival of Taxol-resistant patients with lower levels of miR-663 and miR-622 expression was
significantly longer than patients with higher levels of expression of these two microRNAs [66].
As for liquid malignancies, miR-663 was downregulated in K-562 cell line and in the white
blood cells of certain patients with chronic myelogenous leukemia, due to the aberrant methylation
of CpG islands upstream of miR-663 gene. MiR-663 suppressed K-562 cell proliferation at least in
part through the targeting of H-ras transcripts [67]. The promoter of miR-663 was also found to
be hypermethylated in Chinese pediatric acute myeloid leukemia [68]. MiR-663 was one of nine
microRNAs most constantly upregulated in multiple myeloma cell lines. The upregulation of these
microRNAs, including miR-663 and miR-155, was linked with decreased viability, migration and colony
formation of these cell lines. In addition, the higher expression levels of these microRNAs correlated
with better patient survival [69]. Thus, miR-663 behaves as a tumor-suppressor in liquid malignancies,
in agreement with previous results showing that all-trans retinoic acid, a powerful pro-differentiation
agent, induces the differentiation of HL-60 acute myeloid leukemia cells through the up-regulation of
miR-663 [70].
Epigenetic deregulation of miR-663 expression appears to be a rather general feature of liquid
malignancies. Of note, it was recently shown that the regulation of miR-663 expression through
epigenetic modification of its promoter depends of mitochondria-to-nucleus retrograde signaling,
as shown by the downregulation of miR-663 in cells lacking mitochondria, and also that miR-663
mediates mitochondria-to-nucleus retrograde signaling [71]. Mitochondrial impairment through
pharmacological disruption of oxidative phosphorylations, that increases reactive oxygen species,
reduces miR-663 expression. MiR-663 regulates the expression of nuclear-encoded respiratory chain
subunits involved in Complexes I, II, III, and IV, as well as that of Complexes I (NDUFAF1), II (SDHAF2),
III (UQCC2), and IV (SCO1) assembly factor. In particular, miR-663 activity is required for stabilizing
respiratory supercomplexes, and directly regulated UQCC2 expression. Mitochondrial dysfunction
is one of the hallmarks of cancer, and indeed miR-663 ectopic expression decreased tumor weight in
xenografts and decreased cellular invasiveness of MCF7 and MDA-MB-231 breast cancer cell lines [71].
In conclusion, miR-663 can either promote or inhibit tumorigenesis and metastasis depending on
the context and the type of tumors. It remains to be shown whether it could be possible to turn miR-663
from deleterious to beneficial in tumors where its activity correlates with increased tumorigenesis,
rather than trying to inhibit its expression. RSV could be a good candidate compound, given its
established anti-proliferation and anti-tumors effects associated with it capability to modulate the
expression of miR-663 along with that of other microRNAs. Of note, RSV effects in different cancers
may have epigenetic bases, given its capacity to modulate the expression of NAD+-dependent histone
deacetylases (Sirtuins), and particularly to activate Sirt1 and Sirt5 while inhibiting Sirt3 activity [72].
2.3. MiR-663 in Atherosclerosis
Atherosclerosis is a chronic inflammatory disease of the vascular wall, which, if left unchecked,
turns into pathologies such as myocardial infarction and ischemic stroke, that are some the most
prevalent causes of morbidity and lethality in the most developed countries. Atherosclerosis, although
associated with systemic risk factors such as hypercholesterolemia, hypertension, and diabetes
mellitus, most usually initiates in regions exposed to disturbed blood flow (d-flow), while arterial
regions exposed to stable flow (s-flow) remain healthy [73]. It has been established that d-flow
induces, and s-flow prevents endothelial dysfunction and atherosclerosis, respectively, at least in
part through alterations in gene expression associated with changes in the epigenetic landscape [73].
Among these genes, microRNAs have been classified into three categories depending on their effects
on atherogenesis: antiatherogenic mechano-miRs, proatherogenic mechano-miRs, and dual-role
mechano-miRs [73].
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MiR-663 was identified among microRNAs that were upregulated in umbilical vein endothelial
cells (HUVECs) submitted to oscillatory shear stress. In these cells, miR-663 was implicated in monocyte
adhesion but not in apoptosis [74]. It was subsequently shown that, in endothelial cells, miR-663 plays
a role in the upregulation of the gene encoding the transcription factor ATF4 and of its downstream
gene VEGF, as well as in the activation of the ATF4 branch of unfolded protein response by oxidized
phospholipids [75]. It was further shown that high concentrations of uric acid inhibit endothelial cell
migration by upregulating miR-663, that directly targets TGFβ1. Higher miR-663 levels were also found
in the serum of hyperuricemic patients and animals [76]. Nevertheless, miR-663 was shown to inhibit
vascular smooth muscular cell phenotypic switch (the transformation from a contractile, differentiate
phenotype to a synthetic, dedifferentiated phenotype associated with artery injury) by targeting JUNB
and MYH9 (myosin light chain 9 expression) transcripts [77]. MiR-663 was further implicated in the
induction of atherosclerosis by Helicobacter pylori [78].
Table 1. Validated and putative target transcripts of miR-663 that link this microRNA with inflammatory,
neurodegenerative and cardiovascular diseases, as well as with cancer.
Target Transcripts MiR-663 Effects References
Opposite effects on inflammation
JunB, JunD Anti-inflammatory, through reducing AP-1 activity and miR-155 expression [27]
TGFβ1 Worsens lupus erythematous development [32]
APC Pro-inflammatory through the activation of Wnt pathway [33]
Stimulation of cell proliferation and migration
TGFβ1 Increases the survival of non-irradiated bystander cells [37]
HSPG2 Increases chemoresistance of MDA-MB-231/ADM cell line [47]
TGFβ1 Inhibits apoptosis induced by endoplasmic reticulum stress [54]
TGFβ1, P53, Bax, Fas Increases lung cancer cell proliferation [57]
PUMA/BBC3, BTG2 Inhibits apoptosis and promotes tumor development [59]
Inhibition of cell proliferation and migration
eEF1A2 Impairs the proliferation of MCF7 cells [45]
CDKN2A Promotes the proliferation of nasopharyngeal carcinoma C666-1 cells [48]
p21(WAF1/CIP1) Promotes the proliferation of nasopharyngeal carcinoma cells [50]
TGFβ1 Antimetastatic in SW480 colorectal cancer cells [28]
TGFβ1 Inhibits epithelium-to-mesenchyme transition of two thyroid carcinoma cell lines [51]
MDGA1, FRAS1 decreases renal cancer cell proliferation and migration [53]
eEF1A2 Inhibits proliferation and invasion of pancreatic cancer cells [56]
Bcl-2 Implicated in waltonitone treatment-induced inhibition of lung cancer cell line proliferation [60]
PI3KCD Inhibits proliferation and invasiveness of glioblastoma cells [61]
CXCR4 Increases survival of mice with glioblastoma [62]
TGFβ1, MMP2, E-Cadherin Inhibits proliferation and invasiveness of glioblastoma cells [63]
H-ras Inhibits proliferation of K-562 cells [67]
UQCC2 Increases phosphorylative oxidations and decreases tumor development [72]
Prevention of arterial injury
TGFβ1 Inhibits endothelial cell migration under high concentrations of uric acid [76]
JUNB, MYH9 Inhibits vascular smooth muscular cell phenotypic switch [77]
Finally, as previously mentioned, a study conducted on peripheral blood mononuclear cells of
type 2 diabetes and hypertensive patients with coronary showed that one-year supplementation with
a grape extract containing RSV modulates the expression of inflammation-related microRNAs and
cytokines expression [31]. In particular, pro-inflammatory miR-155 was down-regulated, while miR-663
was up-regulated, with correlative downregulation of JUND [31], a validated target of miR-663 [27].
3. Conclusions
The literature analyzed here above clearly demonstrates that it goes for microRNAs as it goes for
coding genes: none of them is just only detrimental, none of them is capable of producing beneficial
effects in all circumstances. Thus, the analysis of molecular effects and functions of this class of
regulators requires a rather expressionist approach, looking for bright effects aside the deleterious
ones. This is in particular the case for miR-663, that, as seen in Table 1, depending on the context and
the type of cells and tumors considered, can be either pro- or anti-inflammatory, or behave either as
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a tumor-suppressor gene or well favor tumorigenesis. Also, while miR-663 has been several times
described as a “bad” microRNA, it nevertheless seems capable to deliver tumor-suppressive effects
and to prevent vascular smooth muscular cell phenotypic switch that is associated with arterial injury.
Although microRNAs can successively, or possibly at the same time, behave as the bad, the
good or the ugly, like the heroes of the classical Western movie with a similar name, one impressive
conclusion that can be drawn from the study of the effects of RSV on miR-663 expression is that this
biological compound has the remarkable propriety to induce the good behavior while inhibiting the
bad and the ugly ones. Thus, it has been previously shown that RSV treatment of SW480 colon cancer
cells leads to both the downregulation of microRNAs known to favor cancer initiation and progression
and the upregulation of microRNAs usually considered as tumor-suppressors, including miR-663 in
this context [28]. In this respect, it should be noted that both, miR-663 and RSV are implicated in the
regulation of the TGFβ1 signaling pathway. This might possibly explain at least in part why RSV
can deliver beneficial effects trough the modulation of miR-663 expression, given that TGFβ1 can be
cytostatic at the early stages of cancer while also favoring epithelium-to-mesenchyme transition at
more advances stages of tumorization, owing to the similar function it plays during development.
In addition, TGFβ1 is also implicated in the regulation of the immune response, and systemic immune
suppression and inhibition of host immunosurveillance favors cancer development [79]. Furthermore,
it has been shown that TGFβ1 up-regulates miR-155 in hepatocellular carcinoma cells, thus promoting
epithelium-to-mesenchyme transition, invasion and metastasis [80], and that miR-155 plays a role
in mediating TGFβ1-induced podocyte injury via nephrin, desmin and caspase-9 [81]. Therefore,
the capability of RSV to modulate, directly or indirectly, the levels of miR-155, miR-663 and TGFβ1
activity, and the fact that the three last molecules display dose-dependent activity and can be either
beneficial or deleterious to the body, depending on the context, may possibly explain the apparent
pleiotropic beneficial effects of RSV, and certainly warrants further studies.
Given that RSV seems to be active while provided at low dose for a sustained period, rather than at
higher doses for a shorter period, it is possible that the wide range of beneficial properties of this plant
polyphenol may rely on its capacity to simultaneously reset the expression of multiple microRNAs
within a range of concentrations where they would work for the health of the organism, rather than
just sharply increasing or decreasing their expression. This might possibly explain RSV apparent lack
of delivering increasingly beneficial effects at increasing doses, a fact that led to suggestion that most
of RSV apparent properties may rather result from experimental artifacts. Beside all its proved or
potential beneficial effects to the health of the individual, RSV may well provide us with a new tool
for the study of dose-dependent activity of microRNAs and other non-coding regulatory RNAs in
the future.
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